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AbSTRACT
Retinoblastoma is the most common intraocular tumor in children. The diagnosis 
is usually established by the ophthalmologist on the basis of fundoscopy and 
US. Together with US, high-resolution MRI has emerged as an important 
imaging modality for pretreatment assessment, i.e. for diagnostic confirmation, 
detection of local tumor extent, detection of associated developmental 
malformation of the brain and detection of associated intracranial primitive 
neuroectodermal tumor (trilateral retinoblastoma). Minimum requirements 
for pretreatment diagnostic evaluation of retinoblastoma or mimicking 
lesions are presented, based on consensus among members of the European 
Retinoblastoma Imaging Collaboration (ERIC). The most appropriate 
techniques for imaging in a child with leukocoria are reviewed. CT is no 
longer recommended. Implementation of a standardized MRI protocol for 
retinoblastoma in clinical practice may benefit children worldwide, especially 
those with hereditary retinoblastoma, since a decreased use of CT reduces the 
exposure to ionizing radiation. 
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INTRODUCTION
Retinoblastoma is the most common intraocular tumor in children. The incidence is 
one in 17,000 births. Mean age at clinical presentation is 2 years in unilateral forms 
(60% of cases) and 1 year in bilateral forms [1, 2]. All bilateral forms, as well as 15% of 
unilateral forms are related to a constitutional (hereditary or de novo) mutation of 
the RB-1 gene, localized on chromosome 13q14 [2]. Usually the patients present with 
leukocoria (white pupil reflection) or a squint. 
Retinoblastoma is curable. If detected while still confined to the globe and if there are 
no metastatic risk factors, the child will nearly always survive following appropriate 
treatment [3,4]. The preservation of visual function depends on ocular preservation, 
initial tumor volume, the anatomical relationships of the tumors to the macula and 
optic disk and the adverse effects of the treatments (cataracts, vitreous hemorrhage) 
[5]. In the presence of metastatic risk factors, adjuvant treatment regimens are usually 
applied to prevent life-threatening relapse [6,7]. 
Diagnosis of retinoblastoma is usually made by fundoscopy (Fig. 1) (under general 
anesthesia) and US. The ophthalmologist usually performs both investigations. In 
almost all cases classic intratumoral calcifications can be detected by US providing high 
confidence rate regarding diagnosis. Various tumor parameters (laterality; number, 
location and size of tumors; tumor seeding to vitreous, subretinal space or anterior 
segment) can be evaluated with these techniques. These are important for grouping 
the retinoblastoma and to guide therapeutic decisions. Further diagnostic imaging 
plays a crucial role in determining the local extent and for detecting associated brain 
abnormalities, i.e. intracranial tumor extension, possible midline intracranial primitive 
neuroectodermal tumor (PNET) and brain malformations in patients with 13q deletion 
syndrome [8–10]. 
PNETs are associated with hereditary retinoblastoma, a combination known as 
trilateral retinoblastoma, which occurs in 5–15% of children in the hereditary subgroup 
[10,11]. Besides the pineal region (pineoblastoma), tumors may also occur in the 
suprasellar or parasellar regions. Trilateral retinoblastoma has been lethal in virtually 
all cases reported in literature; however, early detection and intensive (chemo-)
therapy may be lifesaving for some patients [10,12,13]. 
Conservative treatment strategies (avoidance of enucleation and external beam 
radiation therapy) can be successful in the early stages of retinoblastoma and in 
some patients with advanced intraocular disease [14]. The options for eye-preserving 
therapy have significantly improved during recent years and are mainly based on 
tumor reduction with chemotherapy, and are usually combined with laser coagulation, 
cryotherapy or radioactive plaque. Recently, selective ophthalmic artery infusion of 
a chemotherapeutic agent became available as an additional treatment option for 
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locally advanced disease [15]. As a consequence, more children are treated without 
histopathological confirmation and, what is more important, without assessment 
of risk factors for disease dissemination and prognosis. Therefore, imaging is very 
important in local staging. 
Whereas imaging is increasingly used for diagnosis and as a basis for treatment 
decisions in retinoblastoma, there is a lack of standardization for choosing among 
modalities and for the minimum quality of MRI. The purpose of this report is to 
present a guideline for diagnostic imaging of retinoblastoma including a standardized 
MRI protocol using conventional pulse sequences. The potential role of advanced 
imaging techniques for lesion characterization and detection of tumor extent (such as 
3D T1-weighted sequences, diffusion-weighted imaging, diffusion tensor imaging and 
MR-spectroscopy) is beyond the scope of this guideline.
fig. 1 Fundus photograph shows two tumors. 
The large white mass with prominent feeder 
vessels is located at the macula causing 
reduced visual acuity. A smaller tumor is 
located in the inferolateral part of the retina. 
Image courtesy Annette C. Moll, Amsterdam
Risk factors for metastasis and local recurrence
Retinoblastoma may spread either by hematogenous dissemination or by direct 
extension either through the bulbar wall into the orbit or via the optic nerve and 
its meningeal sheath [16]. Therefore, current risk factors for metastasis and local 
recurrence include invasion of the optic nerve posterior to the lamina cribrosa (in 
particular if there is tumor at the surgical resection margin), anterior eye segment 
(AES), or extensive invasion of the ocular coats (massive choroidal and scleral 
invasion) [17–20]. Pathology remains the gold standard to assess high-risk features 
of retinoblastoma. The rate of postlaminar optic nerve invasion in patients treated by 
primary enucleation has been estimated at 7–8% [21,22]. Choroidal invasion is present in 
23–42% of enucleated eyes, out of which the invasion is massive in about 9–11% [19,23–
25]. The exact incidence of massive choroidal invasion is unknown, especially since the 
definition of “massive” differs among pathologists. Recently, new consensus criteria 
were proposed by a worldwide collaboration of pathologists and pediatric oncologists 
[26]. Tumor invasion into the AES is very rare, being present in approximately 2% of 
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primary enucleated eyes [24,27–30]. Children with histopathological risk factors for 
metastatic disease require adjuvant chemotherapy to reduce the risk of relapse [18–
20,31].
Radiation exposure and second primary malignancies in hereditary retinoblastoma
Unlike survivors of non-hereditary retinoblastoma, survivors of hereditary 
retinoblastoma have an elevated risk of developing second (or even more) 
malignancies with a cumulative mortality rate of 17% [32–34]. In patients with 
hereditary retinoblastoma, the cumulative incidence of a second primary malignancy 
within 40 years of the initial retinoblastoma is 28% [34]. Chemotherapy has been 
reported to increase the risk of leukemia in survivors of retinoblastoma [35]. 
Radiotherapy is associated with an increased risk of soft-tissue sarcomas in survivors 
of hereditary retinoblastoma, with a reported significant association of radiation dose 
with the risk of second primary (or more) cancers [34,36]. Assuming a linear relation 
between radiation dose and stochastic risk, several studies have demonstrated a 
theoretical increased risk of CT-associated radiation-induced fatal cancers in children 
[37]. Although low, this risk is likely to be further increased in patients with hereditary 
retinoblastoma, who are known to be genetically unstable, due to the inherited germ 
cell mutation in the RB-1 tumor-suppressor gene. To minimize the development of 
subsequent cancers, survivors of retinoblastoma are advised to avoid unnecessary 
radiation. Furthermore, children undergoing radiotherapy for retinoblastoma may 
experience abnormalities in the growth and maturation of their craniofacial skeleton, 
resulting in mid-face deformities [38]. For these reasons, external beam radiotherapy 
was dramatically reduced for the conservative treatment options, and the principle of 
minimizing the exposure to ionizing radiation should also be applied to imaging. US 
and MRI should be used instead of CT. The radiation from interventional procedures, 
e.g., selective ophthalmic artery chemotherapy infusion, is also important [39]. The 
radiation dose should be optimized, precisely measured and clearly reported in future 
publications to facilitate balancing risks and benefits both in imaging and therapy.
CHoiCe of iMAGiNG MoDALiTY
US, CT and MRI are the mainstay for imaging of head and neck tumors in children. 
US is particularly useful for examining superficial masses, such as retinoblastoma, 
whereas CT and MRI are used to delineate deeper lesions, particularly those involving 
the skull base and the central nervous system. Nowadays, diagnostic evaluation of 
retinoblastoma consists primarily of US and MRI. Positron emission tomography has 
become an important modality for cancer imaging in general; however, its value in 
retinoblastoma imaging is currently limited [40]. 
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US
The human eye, with its superficial position and its fluid-filled structures, is ideally 
suited for US. Ocular US is usually performed by the ophthalmologist while the child is 
under general anesthesia, but can also quite easily be performed without sedation. In 
retinoblastoma, US demonstrates an irregular mass, more echogenic than the vitreous 
body, with fine calcifications (highly reflective foci mostly with characteristic acoustic 
shadowing) [41] (Fig. 2). Histologically, there is calcification present in approximately 
95% of tumors [42]. Calcification is key to differentiating retinoblastoma from other 
mass lesions in a young child. US detects calcifications in 92–95% of cases where it is 
present histopathologically [42, 43]. Retinal detachment may also be observed, which 
is an important feature to define tumor growth pattern, either endophytic or exophytic, 
or a combination of both. Endophytic tumors arise from the inner layers of the retina 
and grow into the vitreous body. Frequently, small clusters of tumor cells detach 
from an endophytic mass, producing multiple floating tumor islands; this process is 
known as vitreous seeding. Exophytic tumors originate in the outer layers and grow 
in the subretinal space, which causes retinal detachment with subretinal exudate and 
possible subretinal tumor seeding. Tumors with exophytic growth more frequently 
have choroidal infiltration compared to endophytic tumors [44]. Diffusely infiltrating 
retinoblastoma is a rare histological form characterized by diffuse infiltration of the 
retina without a tumor mass [45]. Tumor height and diameter are usually measured 
at US, as these measurements are used for choice of treatment. Color Doppler can be 
useful for differentiating a vascularized tumor mass from echogenic effusions and for 
differentiation against developmental abnormalities such as persistent hyperplastic 
primary vitreous (PHPV; also known as persistent fetal vasculature, PFV), with the 
characteristic persisting hyaloid artery.
US is not the imaging modality of choice for direct evaluation of metastatic risk 
factors. Tumoral calcifications commonly obscure visualization of the optic nerve [41]. 
Indirect detection of optic nerve invasion by measurement of optic nerve diameter 
with a 3D-US technique has been reported in a single case report [46], hence its value 
remains unknown. 
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fig. 2 US reveals a hyperechoic tumor 
occupying the posterior segment of the globe. 
Calcium deposits, seen as highly reflective 
foci (arrows), are pathognomonic for 
retinoblastoma in a young child
CT
On CT, retinoblastoma is typically a mass of high density compared with the vitreous 
body, usually calcified and moderately enhancing after iodinated contrast medium 
administration. CT detection of calcifications in retinoblastoma has a sensitivity of 
81–96%, and an even higher specificity [47]. However, delineation of intraocular soft-
tissue detail is limited. The evidence from surveys suggests that CT is still regarded an 
obligatory imaging tool for evaluation of leukocoria, primarily because CT is supposed 
to be the best imaging modality for detection of intraocular calcifications [47–49]. 
However, justification of the irradiation of a large group of retinoblastoma patients 
requires a base of evidence of the procedure’s clinical effectiveness and possibly also 
radiation-effectiveness [50] for supplying (1) valuable additional information leading 
toward the diagnosis of retinoblastoma and (2) valuable additional information, 
compared to non-ionizing radiation modalities in detection of tumor extent. 
CT was the first imaging modality used to detect optic nerve invasion [51–53] and is 
historically assumed to be precise in detection of tumor extent [54–56]. However, this 
assumption is based on conflicting outdated literature, without thorough evidence 
by radiologic-pathologic correlation studies. The sensitivity of CT in detection of optic 
nerve invasion is actually very low, even in patients with extensive optic nerve invasion 
(length of invaded nerve segment > 2 mm) [21, 51, 53]. The specificity, accuracy and 
negative predictive value of CT remain artificially high because of the relatively low 
incidence of optic nerve invasion in normal-size nerves. An enlarged nerve due to 
massive tumor infiltration is rare in developed countries. Assuming retinoblastoma 
invasion into the optic nerve produces distortion of the anastomotic vascular network 
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in the anterior optic nerve region, Jacquemin and Karcioglu [52] considered that non-
visualization of the central retinal vessels is a reliable indicator of optic nerve invasion. 
However, these results were not confirmed by other studies [21]. 
MRi
Diagnostic MRI evaluation of a suspected retinoblastoma requires much more than 
performing a routine MR imaging examination of the orbit. High-resolution contrast-
enhanced MRI is the technique of choice and should be used whenever possible to 
answer the key clinical questions (to evaluate an intraocular mass and to determine 
disease extent; Fig. 3). MRI has proved to be the most sensitive technique for evaluating 
retinoblastoma, especially regarding tumor infiltration of the optic nerve, extraocular 
extension and intracranial disease [21,22,44,57,58]. A major factor influencing the 
success of MRI is the use of appropriate hardware and optimized pulse sequences 
with appropriate spatial resolution for ocular MRI [21, 22, 44, 57–61]. 
iMAGiNG STRATeGY
Diagnosis of retinoblastoma
Examination under general anesthesia with fundoscopy and US almost inevitably 
leads to the diagnosis. As US detects foci of calcification in almost all retinoblastomas, 
there is now little benefit of routine CT for detection of calcifications in suspected 
retinoblastoma. Due to technical development, US and MRI are currently almost as 
accurate as CT for detection of calcifications. Recently, Galluzzi et al. [42] showed 
that when data from ophthalmoscopy, US and MRI are put together, no calcifications 
detected on CT were missed. A high-resolution gradient-echo T2-weighted sequence 
showed promising results regarding detection of calcifications and has been shown to 
be more effective than spin-echo techniques [42, 44]. 
The differential diagnosis of retinoblastoma includes several non-neoplastic lesions 
that also cause leukocoria. After retinoblastoma, which accounts for 47–58% of cases 
of leukocoria in children, other causes in decreasing order of frequency include PHPV, 
Coats disease, larval granulomatosis (Toxocara canis), retinopathy of prematurity, and 
retinal astrocytic hamartoma [48]. Calcification is the most important differentiating 
feature of retinoblastoma. However, when clinical diagnosis remains uncertain, US 
and MRI help characterize and differentiate intraocular abnormalities, especially when 
ophthalmological evaluation is limited due to opaque ocular refractive media, as may 
occur in all of these conditions. The role of CT in the detection of (sometimes subtle) 
characteristic findings is limited due to its low soft-tissue contrast [48, 55].
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fig. 3 Transaxial T2-weighted (TR/TE, 3,460/116 ms) (a) and T1-weighted (TR/TE, 374/14 
ms) precontrast (b) and postcontrast (c) MRI of exophytically growing retinoblastoma 
with secondary retinal detachment. Retinoblastoma typically has low signal intensity 
compared to the vitreous body on T2-weighted images and intermediate signal intensity 
on precontrast T1-weighted images, and it demonstrates marked contrast enhancement
Detection of tumor extent
In the past, CT was used to determine tumor size, retro-orbital spread and intracranial 
growth; however, spread within the optic nerve past the cribriform lamina, and 
infiltration of choroid and sclera, which are important prognostic factors, are not 
reliably assessed with CT [51, 53]. Because of its superior soft-tissue contrast, MRI is 
more sensitive and specific than CT in detection of tumor extent and metastatic risk 
factors. MR imaging using high-resolution protocols is currently considered to be the 
most accurate and valuable tool in pretreatment staging of retinoblastoma, without 
known biological side effects. 
Standardized retinoblastoma MRi protocol
Although individual examinations should always be tailored to the specific queries 
in individual patients (laterality, disease extent, therapy options), there are general 
recommendations for MRI in retinoblastoma. In the following paragraphs we discuss 
the minimum requirements for diagnostic evaluation of retinoblastoma or mimicking 
lesions according to the consensus reached among members of the European 
Retinoblastoma Imaging Collaboration (ERIC). If these recommendations cannot 
be followed because of technical limitation, ERIC members recommend to refer the 
patient to the nearest (or national) reference center for retinoblastoma, where a 
multidisciplinary team of specialized physicians (ophthalmology, pediatric oncology, 
radiology, pathology, radiotherapy, clinical genetics, psychology) and specialized 
nurses will ensure that practice conforms to the best standards of care.
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Patient handling
Although the technical success of MRI usually depends on the cooperation of the 
patient, in retinoblastoma appropriate sedation techniques or general anesthesia 
are nowadays widely used, with a high yield of diagnostic scans. Nevertheless, in 
our experience the success rate of intravenous sedation is highly dependent on the 
presence of trained anesthetists and of the choice of radiofrequency coils. Especially, 
the use of small surface coils decreases the success rate, because these coils need to 
be accurately positioned close to the eye. The depth of sedation may be insufficient 
for accurate patient positioning. Therefore, general anesthesia is recommended for 
MRI in children with retinoblastoma. Another advantage of general anesthesia is 
the possibility to ensure that the eyelids are fully closed and to avoid uncontrolled 
eye movements by putting pads (fixed with tape) on the closed eyelids. Thereby 
susceptibility artifacts caused by air-tissue interface or by air bubbles under the eyelids 
is avoided, which is favorable for the image quality in the anterior eye segment. If 
possible, the MR examination can be combined with fundoscopy and US under the 
same general anesthetic. 
Hardware
Clinical MRI of orbit and eyes is mostly acquired using the current standard field 
strengths up to 1.5 T. Since adequate imaging of retinoblastoma requires high spatial 
resolution, the field strength of the MR system should be at least 1.5 T. The performance 
of scans at 1.5 T using a head coil is the most practical approach for evaluation of 
retinoblastoma. However, this combination usually gives insufficient signal-to-noise 
ratio (SNR) at required in-plane image resolution and section thickness. Therefore, 
scanning at 1.5 T should always be performed with one or two small surface coils 
(diameter ≤ 5 cm) to reliably detect small lesions and metastatic risk factors (Fig. 4). 
Indeed, the use of surface coils in ocular tumors has been reported to increase the 
diagnostic accuracy [44, 62]. The main advantage of higher field strengths (3 T) is the 
increased SNR. Publications on ocular 3-T MRI are still limited [63, 64]. At 3 T with 
multi-channel head coil or surface coils one can achieve high-resolution images similar 
to those obtained at 1.5 T with surface coils (Fig. 5). We think the diagnostic accuracy 
for detection of tumor extent might improve, but there is currently no published 
evidence for this.
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fig. 4 High-resolution MRI in retinoblastoma. The 
child is under general anesthesia. A small circular 
surface coil (arrow) is accurately positioned close 
to the affected eye
fig. 5 Transaxial contrast-enhanced 
T1-weighted (TR/TE, 722/14 ms) 
image obtained at 3.0 T using a 
32-channel head coil shows an 
exophytic retinoblastoma with 
secondary total retinal detachment 
and proteinacious subretinal 
effusion
imaging protocol
MRI protocols vary because of differences in available equipment and individual 
preferences. However, despite differences, certain basic elements are common to 
most imaging protocols for retinoblastoma. The minimal requirements for diagnostic 
evaluation of retinoblastoma or mimicking lesions according to the consensus reached 
among members of the European Retinoblastoma Imaging Collaboration (ERIC) 
are presented below and summarized in Table 1. A typical MR imaging protocol for 
retinoblastoma should always include high-resolution imaging of the affected eye(s) 
and imaging of the entire brain.
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Table 1. MRI protocol in Retinoblastoma*
Requirements
Scanner and coils
    Field strength above 1 T
    1.5 T system combined with one or two small surface coils (< 5 cm diameter)
    3.0 T system combined with multichannel head coil
Sequences (minimal requirements)
Orbits
    Transverse T2-W  (slice thickness ≤ 2 mm) 
    Optional: Transverse CISS (Siemens) / FIESTA (GE) / DRIVE (Philips)
Eye(s) and optic nerve(s)
    Inplane pixel size < 0.5 x 0.5 mm; slice thickness ≤ 2 mm
    Unilateral disease (or bilateral disease with only one eye strongly affected)
    Precontrast   T1-W; at least one plane (transverse or oblique-sagittal)
                              T2-W; at least one plane (transverse or oblique-sagittal)
    Postcontrast T1-W, no FS; two planes (transverse and oblique-sagittal)
Bilateral disease (both eyes strongly affected)
    Precontrast   T1-W (transverse)
                              T2-W (transverse)
    Postcontrast T1-W, no FS; two planes (oblique-sagittal on both eyes and transverse)
Brain
    Transverse     T2-W (slice thickness ≤ 4 mm)
    Postcontrast T1-W (2D SE with slice thickness ≤ 3 mm or 3D GRE ≤ 1 mm)
FS fat-saturation, SE spin-echo, GRE gradient-echo
* consensus among members of the European Retinoblastoma Imaging Collaboration 
(ERIC)
orbits
Regardless of laterality, at least one transaxial thin-slice (≤ 2 mm) T2-weighted 
sequence should cover both orbits. For T2-weighted imaging based on a (fast) spin-
echo technique, it is recommended to use a long TE (heavily T2-weighted; TE ≥ 120 ms) 
for generating the image contrast necessary to provide an optimal differentiation of 
retinoblastoma and surrounding vitreous or subretinal fluid (Fig. 6). Fat saturation 
combined with T2-weighted imaging is not recommended. When fat suppression is 
used, the resulting loss in SNR should be compensated (e.g., by increasing the number 
of acquisitions). 
T2-W spin-echo may be replaced by gradient-echo T2-weighted sequences such as 3D 
steady-state free precession sequences with slice thickness ≤ 1 mm (Fig. 6; vendor-
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specific acronyms: CISS [Constructive Interference in Steady State, Siemens], FIESTA 
[Fast Imaging Employing Steady State Acquisition, GE Healthcare]; DRIVE [Driven 
Equilibrium, Philips]) (slice thickness, ≤ 1 mm). These pulse sequences provide 
detailed images of both orbits and eyes, and allow accurate comparison of eye size, 
anterior chamber depth and laterality. Very small tumors can be depicted with these 
techniques.
fig. 6 a Thin-slice transaxial T2-weighted 
(TR/TE, 4,430/102 ms; section thickness, 2 
mm) image demonstrates retinoblastoma 
of the right eye with secondary retinal 
detachment. b Transaxial constructive 
interference steady-state (TR/TE, 14/7 ms) 
image of bilateral retinoblastoma with 
secondary retinal detachment. Notice the 
shallow anterior chamber of the right eye, 
a sign of increased intraocular pressure
eye and distal optic nerve
Increased spatial resolution will improve the accuracy of MRI in assessing the 
anatomical details of the papilla, lamina cribrosa and pre- and postlaminar segments 
of the optic nerve [65]. The continuous improvement of MR units and the use of small 
fields-of-view with either multi-channel head coils or surface coils now allows much 
higher image resolution. High spatial resolution means section thickness ≤ 2 mm and 
in-plane pixel size ≤ 0.5 × 0.5 mm. For optimal detection of optic nerve invasion, the 
image plane through the orbit (transaxial and sagittal oblique) should align with the 
orientation of the distal (1 cm) end of the nerve, just posterior to the lamina cribrosa 
(Fig. 7). One section in each of these sequences should be precisely aligned within the 
distal part of the optic nerve at the level of the middle of the optic disk. Although the 
use of the fat-saturation technique is highly recommended for contrast-enhanced MR 
imaging in orbital pathology, its use in high-resolution contrast-enhanced T1-weighted 
MRI in retinoblastoma is declining [44, 58]. In the minimal requirements for diagnostic 
evaluation of retinoblastoma or mimicking lesions according to the consensus 
reached among members of the ERIC, the use of fat saturation in contrast-enhanced 
T1-weighted sequences is no longer recommended.
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fig. 7 Recommended slice positions. One T2-weighted section in the sagittal oblique plane 
and one in the transaxial plane should be precisely aligned at the middle of the optic disk 
and the distal (at least 1 cm) end of the optic nerve. a Correct alignment of transaxial 
sections. b Correct alignment of sagittal oblique sections. c Detailed view of the distal optic 
nerve (line segment: imaging axis; distal 1 cm of the optic nerve between red dots)
•  Transaxial or sagittal oblique T1-weighted spin-echo helps detection of intraocular blood 
and subretinal fluid with high protein content. Retinoblastoma is slightly hyperintense 
with respect to the vitreous body. 
•  Transaxial or sagittal oblique heavily T2-weighted spin-echo provides detailed 
information about the classic low signal intensity of retinoblastoma and presence of 
retinal detachment. 
•  Transaxial and sagittal oblique contrast-enhanced T1-weighted spin-echo provides 
information about the enhancement of lesions, optic nerve- and ocular wall invasion, 
and anterior eye segment enhancement. 
The recommended protocol for high-resolution MR imaging of the eye(s) and distal 
optic nerve(s) differs slightly between unilateral or bilateral disease (Table 1, Figs. 8-9). 
Incidence of metastatic risk factors is highly dependent on tumor location and tumor 
size. Therefore, a distinction is made between bilateral disease with only one eye 
strongly affected (high-resolution MRI can be performed in the worst affected eye 
only) and extensive disease in both eyes (high-resolution MRI of both eyes). 
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fig. 8 In unilateral retinoblastoma (or bilateral disease with only one eye strongly affected), 
high-resolution MRI is done in the (most) affected eye only. Imaging example of a left 
unilateral lesion. a. Sagittal oblique T2-weighted (TR/TE 3,460/110 ms) image. b. Transaxial 
precontrast T1-weighted (TR/TE 360/13 ms) image. c. Transaxial postcontrast T1-weighted 
(TR/TE 360/13 ms) image. Notice the inhomogeneous enhancement pattern, which is 
common in retinoblastoma
fig. 9 MRI of bilateral retinoblastoma with 
extensive disease in both eyes should be 
performed with two surface coils. The field of 
view should be slightly increased to cover both 
eyes in the transaxial plane. Imaging example 
of bilateral lesions: a. Precontrast transaxial 
T1- weighted (TR/TE, 360/13 ms) image. b. 
Postcontrast transaxial T1- weighted (TR/TE, 
360/13 ms) image
brain
The brain should always be imaged in retinoblastoma patients for analysis of midline 
structures in order to depict trilateral retinoblastoma (i.e. PNET located mainly in the 
pineal gland, or more rarely in suprasellar area) or leptomeningeal spread. For a patient 
presenting with leukocoria suspicious of having retinoblastoma or already diagnosed 
as retinoblastoma based on clinical findings and US, the baseline evaluation should 
include an MR imaging of the brain that meets the standardized protocol. Imaging of 
the brain is performed with (multi-channel) headcoil only and should at least include 
the following or similar types of sequences:
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•  Transaxial fast spin-echo T2-weighted sequence (slice thickness, ≤ 4 mm). This sequence 
provides an overview of the brain anatomy and structural abnormalities (patients with 
13q deletion syndrome). 
•  Transaxial or sagittal contrast-enhanced T1-weighted sequence (2D spin-echo T1-
weighted with slice thickness ≤ 3 mm; or 3D gradient-echo with slice thickness ≤1 mm). 
This sequence provides information about enhancement of the pineal gland, presence of 
a midline PNET, leptomeningeal metastases and extensive optic nerve invasion. 
•  Coronal and sagittal high-resolution T2-weighted sequence (slice thickness, 1.5 mm). 
These sequences are optional but should be added to the protocol in case of an atypical 
pineal gland (partially cystic, irregular, enlarged). 
iMAGe ANALYSiS CHeCKLiST foR MR RePoRTiNG (TAbLe 2)
Tumor size and location
Compared to the vitreous body, retinoblastoma has moderately higher signal 
intensity on T1- and lower on T2-weighted images. Increased size of the globe, globe 
deformation and reduced anterior chamber depth are signs of increased intraocular 
pressure and are usually associated with buphtalmia (Fig. 10). These signs should be 
mentioned since they are associated with a higher risk of globe rupture and secondary 
orbital seeding during enucleation. Laterality and growth pattern should be mentioned 
as well as the location of the tumor, with respect to the equator of the eye (anterior, 
posterior or combined) and with respect to the papilla (the optic nerve disk) and the 
macula. One should in particular identify tumor close to the optic disk, because this 
may invade the nerve [22] (Fig. 11).
fig. 10 Retinoblastoma with signs of 
increased intraocular pressure following 
subretinal hemorrhage (fluid–fluid levels). 
a Bilateral retinoblastoma with increased 
size of the left eye (buphthalmus) and a 
shallow anterior chamber (arrow) seen on 
T2-weighted (TR/TE, 4,430/102 ms) image. b 
Bilateral retinoblastoma with focal bulging 
of the posterior eye segment (arrow) of the 
right eye and a shallow anterior chamber 
seen on T2-weighted (TR/TE, 4,430/102 ms) 
image
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fig. 11 Pre- (a) and postcontrast (b) transaxial T1-weighted (374/14) MR images show 
small nodular enhancement at the optic nerve disk (arrow), which represents superficial 
optic nerve invasion by intraocular tumor seeding (predilection site). c Abnormal 
contrastenhancement of the anterior eye segment combined with macroscopic tumor 
seedings (arrow)
Table 2. Retinoblastoma: Checklist for MRI radiology reports
Parameters
Tumor characteristics
    SI relative to the vitreous body; moderately high on T1-W and low on T2-W
    Laterality
    Growth Pattern
    Tumor size and location; in contact with optic nerve
    Buphthalmia
Tumor extension
    Optic nerve and meningeal sheath invasion
    Ocular wall invasion (choroid and sclera)
    Extraocular extension
Anterior eye segment
    Anterior chamber depth
    Enhancement
    Tumor invasion; ciliary body
Brain
    Trilateral retinoblastoma; pineal gland and supra- or parasellar region
    Leptomeningeal metastases
    Malformations
SI signal intensity
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optic nerve and meningeal sheath invasion
In normal-size optic nerves, the direct radiological criterion used to diagnose 
postlaminar nerve invasion is the presence of abnormal contrast enhancement 
(enhancement ≥ 2 mm in diameter) in the distal nerve [21] (Fig. 12). Interruption of 
the normal linear enhancement at the optic nerve disk (choroidoretinal complex) 
supports a suggestion of optic nerve invasion [22]. Postlaminar optic nerve or optic 
nerve menigeal sheath invasion should raise suspicion of leptomeningeal metastases. 
In such situations, additional contrast-enhanced sagittal T1-weighted imaging of the 
whole spine is recommended.
ocular wall invasion and extraocular extension
Discontinuity of the normal choroidal enhancement is the leading criterion for 
infiltration [22, 24] (Fig. 13). Massive choroidal invasion presents as focal choroidal 
thickening (Fig. 13). Increased enhancement and thickening of the entire uveal tract 
(choroid, ciliary body, iris) is a sign of uveitis, usually secondary to massive (sub) total 
tumor necrosis [22]. Protrusion of enhancing tissue through the thickened choroid into 
the (low signal-intensity) sclera or beyond is a sign of scleral invasion or extraocular 
extension, respectively.
fig. 12 Postcontrast transaxial T1-weighted (TR/
TE, 374/14 ms) MRI. Abnormal enhancement of 
the distal optic nerve in continuity with tumor is 
a sign of postlaminar optic nerve invasion
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fig. 13 Postcontrast transaxial T1-weighted 
(TR/TE, 305/15 ms) MRI. Intraocular enhancing 
retinoblastoma combined with focal 
choroidal thickening and a discontinuity 
of the linear enhancement pattern of the 
choroid (arrowheads) adjacent to the tumor 
mass is suspicious for tumor invasion. 
Histopathological examination of this eye 
showed massive choroidal invasion
Anterior eye segment
Anterior eye segment enhancement occurs frequently in retinoblastoma and is usually 
a sign of iris angiogenesis [27, 30]. Tumor invasion into the anterior eye segment (Fig. 11) 
is an infrequent finding, usually associated with anteriorly located retinoblastoma. 
Enhancement of the tumor extending into the ciliary body or beyond should raise 
suspicion of anterior eye segment invasion. Transaxial T2-weighted images of both 
orbits can be used to depict a decreased anterior chamber depth (Fig. 10). 
brain
Careful analysis of midline structures should be performed to depict trilateral 
retinoblastoma (i.e. PNET located mainly in the pineal gland, or rarely in the suprasellar 
area) (Fig. 14) or leptomeningeal spread (if patient shows extensive postlaminar optic 
nerve invasion enhancement). Congenital brain malformations occur mainly in patients 
with 13q- deletion syndrome [10]. Benign pineal cysts should not be misinterpreted as 
pineal PNET, even in children with retinoblastoma [10, 66]. Thin-section T2-weighted 
and contrast-enhanced T1-weighted slices are helpful for differential diagnoses. In 
doubtful cases, close follow-up with MRI is recommended.
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fig. 14 Pineoblastoma in a patient with 
hereditary unilateral retinoblastoma. 
Postcontrast axial T1-weighted (TR/TE, 
650/10 ms) MRI shows a cystic enhancing 
mass of the pineal gland (arrow) suspicious 
for pineoblastoma (trilateral retinoblastoma)
CONCLUSION
Together with US, high-resolution MR imaging has emerged as the most important 
imaging modality in the assessment of retinoblastoma—for diagnostic confirmation 
and for determination of local tumor extent and associated intracranial abnormalities. 
CT is no longer indicated in children with leukocoria because of (1) ionizing radiation 
and (2) no added diagnostic value. US combined with MRI using our suggested 
standardized retinoblastoma MRI protocol provides state-of-the-art pretreatment 
diagnostic evaluation in children with retinoblastoma. 
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AbSTRACT
Purpose. To evaluate eye size retrospectively by using magnetic resonance 
(MR) imaging to measure axial length (AL), equatorial diameter (ED), and eye 
volume (EV) in patients with retinoblastoma and to evaluate the possible effect 
of retinoblastoma on eye size.
Materials and Methods. Local ethics committee approval was obtained with 
waiver of informed consent. MR images of 100 patients with retinoblastoma 
(50 girls, 50 boys; mean age, 19 months; age range, 9 days to 68 months) were 
scored by one observer (AL, ED, EV, and tumor volume measurements), with 
a second observer reviewing all measurements. Normal eyes of patients with 
unilateral retinoblastoma served as controls. Interobserver measurement 
agreement was evaluated in a random subset of 50 eyes with use of intraclass 
correlation coefficients. Linear mixed model analysis was used with adjustments 
for age, laterality, and sex.
Results. Interobserver agreement was good (intraclass correlation coefficients 
≥ 0.89). Eyes with retinoblastoma had significantly shorter ALs (95% confidence 
interval [CI]: -0.57 mm, -0.16 mm; P = .001) and EDs (95% CI: -1.01 mm,-0.66 mm; 
P = .001) and significantly smaller EVs (95% CI: -336 mm3,-151 mm3; P < .001) than 
normal eyes. Within patients, a significant negative relationship was found 
between tumor volume and EV (P < .001)
Conclusion. MR imaging measurements of AL, ED, and EV were significantly 
smaller in eyes with retinoblastoma than in normal eyes. In addition, in patients 
with retinoblastoma, the larger the tumor volume, the smaller the eye.
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Retinoblastoma is a rare cancer of the eye, and it predominantly affects children 
younger than 5 years. Tumors can occur in both hereditary (usually bilateral) 
and nonhereditary (always unilateral) forms. Retinoblastoma is diagnosed on 
clinical grounds by means of extensive indirect ophthalmoscopy. Complementary 
investigations in characterizing and staging the extent of disease include patient 
history, physical examination, ultrasonography (US), and magnetic resonance (MR) 
imaging of the eyes and brain (1). A number of benign conditions can clinically 
resemble retinoblastoma, sometimes creating considerable diagnostic difficulty (2). 
The three conditions that most commonly resemble retinoblastoma are persistent 
hyperplastic primary vitreous, Coats disease, and ocular toxocariasis (3). Radiologic 
examinations can provide useful additional information to exclude similar lesions 
from the differential diagnosis. 
Disease in children’s eyes may be indicated by variations in ocular biometric 
parameters. Eyes with malformations, such as persistent hyperplastic primary vitreous 
or retinopathy of prematurity, are usually small, and small size is used as an important 
diagnostic criterion. In unilateral Coats disease (4), the affected globe is significantly 
smaller than the normal eye. Characteristically, eyes with retinoblastoma are assumed 
to be of normal size (4–10), and it is generally accepted that a small eye is sufficient 
evidence to rule out retinoblastoma (5,6). If this statement is valid, eye size could 
be used as an additional diagnostic tool to differentiate between retinoblastoma and 
other (benign) abnormalities included in the differential diagnosis. 
However, there is almost no objective information available in the literature about the 
size of eyes with retinoblastoma. Galluzzi et al (4) performed a preliminary study in 
which the axial length (AL) and equatorial diameter (ED) in 18 patients with unilateral 
retinoblastoma were measured with computed tomography (CT) (all patients) or 
MR imaging (four patients), and they found that the mean calculated eye volume 
(EV) (from the measured AL and ED) of affected eyes was not significantly different 
from that in normal eyes. In contrast to this finding, incidental case reports describe 
unilateral or bilateral retinoblastoma in microphthalmic eyes (11–16). In the presence 
of retinoblastoma, even an increase in eye size has been reported (5,6). 
Several imaging modalities are available for ocular biometric measurements; of 
these modalities, US is used most commonly. Existing age-related standard values 
and growth curves of ocular components are based on US results (17–19), but the 
frequent presence of extensive tumor calcifications hampers accurate US biometric 
measurements in eyes with retinoblastoma. Attempts were made to establish 
AL, ED, and EV standards with CT and MR imaging (4,20–22). However, these data 
must be interpreted prudently because of unclear methods and variations in the 
radiologic definitions used for AL and ED measurements and the generally accepted 
ophthalmologic US definitions. To our knowledge, quantitative MR imaging 
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assessment of AL, ED, and EV, according to ophthalmologic US definitions, has not 
been reported for patients with retinoblastoma. Thus, the purpose of our study was 
to evaluate eye size retrospectively by using MR imaging to measure AL, ED, and EV 
in patients with retinoblastoma, and to evaluate the possible effect of retinoblastoma 
on eye size.
MATeRiALS AND MeTHoDS
Patient selection
Local ethics committee approval was obtained; informed consent was waived. We 
retrospectively identified all patients with retinoblastoma who were evaluated at 
our institution between January 1992 and December 2004. Patients eligible for this 
study were those who underwent MR imaging with and without contrast material 
enhancement before chemotherapy or radiation therapy and for whom digital MR 
images were available that enabled adequate diagnostic interpretation. We identified 
150 patients with retinoblastoma seen during this period. In 39 patients, digital 
MR images were unavailable; five patients did not receive intravenous injection of 
contrast material; and in six patients, the quality of MR images was insufficient. The 
diagnosis of retinoblastoma was confirmed with extensive fundoscopy, US, and MR 
imaging. US findings were not collected, because in patients with retinoblastoma US 
was performed to measure tumor size and to detect tumor calcifications. Accurate 
measurement of affected eyes with US was hampered by tumor calcifications. One 
author (P.d.G.) reviewed the patients’ clinical records. The final study population 
consisted of 100 patients (50 boys, 50 girls) with a mean age of 19 months at MR 
imaging (age range, 9 days to 68 months) (Table 1). Retinoblastoma was familial in 
12 patients (12%) and sporadic in 88 (88%). The mean follow-up time after MR imaging 
was 74 months (range, 9–154 months).
Normal and affected eyes
Retinoblastoma was unilateral in 61 patients (61%) and bilateral in the remaining 39 
patients (39%) (Table 1). In the patients with unilateral retinoblastoma proved during 
follow-up, normal eyes were selected as controls. Within this group, we found two 
patients with a proved 13q deletion syndrome, in which microphthalmia is a common 
finding. Both normal eyes were excluded. Two other patients had already undergone 
enucleation of the affected eye before MR imaging. Within the patients with bilateral 
retinoblastoma, two children had undergone enucleation of one affected eye before 
MR imaging. Eyes of patients with unilateral and bilateral retinoblastoma were divided 
into three groups: 59 eyes of patients with unilateral retinoblastoma that were normal 
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at follow-up (control group), 59 eyes affected by unilateral retinoblastoma, and 76 
eyes affected by bilateral retinoblastoma.
Table 1. Demographic data of 100 patients with Retinoblastoma 
Unilateral Bilateral
No. of patients 61 39
Sex
    Male 32 (52) 18 (46)
    Female 29 (48) 21 (54)
Age at MR imaging (mo)
    Mean 24.5 10.5
    Range 2.4 - 68.1 0.3 - 38.2
Side of the affected eye
    Right 28 (46)
    Left 33 (54)
Note.—Except for age, data are numbers of patients. 
Data in parentheses are percentages.
MR imaging
MR imaging was performed at 1.0 T (Magnetom Impact Expert; Siemens, Erlangen, 
Germany) and 1.5 T (Magnetom Vision, Siemens; Magnetom Sonata, Siemens) with 
use of a head coil. Unenhanced transverse and sagittal T1-weighted spin-echo MR 
images were obtained with 350–500/14–15 (repetition time msec/echo time msec) 
and four signals acquired. Transverse spin-echo MR images were obtained with 
2000–2700/19–60 for intermediate-weighted MR images, 2000–2700/80–120 for T2-
weighted MR images, and one signal acquired. After intravenous injection of 0.1 mmol 
of gadopentetate dimeglumine per kilogram of body weight (Magnevist; Schering, 
Berlin, Germany), sagittal, transverse, and coronal fat-suppressed T1-weighted spin-
echo MR images (400–575/13–15, three signals acquired) were obtained. The section 
thickness for all images was 3 mm, with an intersection gap of 0.3 mm.
image interpretation and definitions
Two observers (P.d.G., J.A.C.; 4 and 12 years of experience with orbital MR imaging, 
respectively) reviewed the MR images. Both observers were blinded to the patients’ 
identity and clinical records. The first observer measured AL, ED, and EV in normal 
and affected eyes with a computerized image analysis tool that is available as part 
of our hospital’s picture archiving and communication system (Centricity Radiology 
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RA 600, version 6.1; GE Medical Systems, Milwaukee, Wis). To assess interobserver 
agreement for the measurements, the second observer independently obtained the 
same measurements in a random subset of 50 eyes (from the total of 194 eyes). 
After finalizing the measurements, the second observer reviewed all measurements 
obtained by the first observer. New measurements were obtained by means of 
consensus agreement only if there was discordance between the two observers 
regarding the initial measurements; otherwise, the original measurements of the first 
observer were maintained for statistical analysis. 
AL and ED measurements were obtained on transverse postcontrast T1-weighted 
MR images with use of a manually controlled distance-measuring function. T1-
weighted MR images are preferable to T2-weighted MR images because of the clear 
delineation of the choroid. Maximal dimensions of AL and ED were measured on 
transverse sections, which usually showed both insertions of the lateral and medial 
rectus muscle, the optic nerve, and the thickest lens section. AL was measured in the 
optic axis, which is a line that passes through the center of the lens, perpendicular 
to its anterior and posterior surfaces. AL was defined as the distance between the 
anterior corneal surface and the anterior surface of the enhancing choroid (Figure). 
This distance was chosen according to standardized measurements obtained with US 
in ophthalmology (ocular biometry), which are the basis of existing normal AL-to-age 
growth curves (17–19).
ED was defined as the maximum distance between inner surfaces of the enhancing 
choroid, perpendicular to the AL (Figure). EV was measured by manually drawing 
a region of interest on every section showing the eyeball. Regions of interest were 
placed on the anterior corneal edge, through the inner surface of the enhancing uvea 
(corpus ciliare and choroid), and back to the starting point. The area inside the outline 
was automatically calculated, and areas were multiplied by the MR section thickness 
plus the intersection gap to calculate a per-section EV. The total EV was obtained by 
summing the volume calculations for all sections. The total tumor volume of affected 
eyes was measured to evaluate the relationship between tumor size and AL, ED, and 
EV.
Statistical Analysis
All data were analyzed with the SPSS statistical software package (SPSS for 
Windows, version 12.0; SPSS, Chicago, Ill). Interobserver agreement was assessed 
by using intraclass correlation coefficients (ICCs) calculated with the two-way (eyes 
× observers) random-effects model. ICC was defined as the ratio of the between-eyes 
variance to the total variance. The 95% confidence intervals (CIs) were calculated with 
the delta method after Fisher z transformation.
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Transverse contrast-enhanced T1-weighted (450/14) fat-suppressed spin-echoMRimage 
shows unilateral retinoblastoma of the left eye. AL (vertical arrows) is defined as the 
distance between the anterior corneal surface and the anterior surface of the enhancing 
choroid. AL is drawn perpendicular to the anterior and posterior surface of the lens. ED 
(horizontal arrows) is defined as the maximum distance between inner surfaces of the 
enhancing choroid, perpendicular to the AL.
Patient characteristics were compared by means of an independent t test for 
continuous variables and a binomial test for dichotomous variables. Related continuous 
variables were compared with a paired t test. Quantitative MR imaging data (AL, ED, 
and EV) for individual eyes of patients with unilateral or bilateral retinoblastoma were 
analyzed with linear mixed models to adjust for data clustering within patients (23,24). 
Unstructured variance-covariance matrices were used. 
To enable the effect of retinoblastoma on each of the dependent variables to be 
studied, while at the same time controlling for confounding effects of age, sex, and 
laterality, the following parameters were entered into the statistical model (one 
model for each dependent variable): categorical factors of retinoblastoma (eyes with 
retinoblastoma vs normal eyes), sex (male vs female), laterality (unilateral vs bilateral), 
and the quantitative covariate (natural logarithm of age). Use of the natural logarithm 
of age to obtain a linear relationship with the dependent variables is reported to 
be advantageous (19). Parameter estimates of the intercept and slope coefficients 
(explanatory variables) of the fitted relationship are presented with their standard 
errors. The same model, without random intercept, was used to analyze eyes that 
showed (metachronous) tumor development in the second eye during follow-up 
(bilateralization). 
In addition, mixed-model analysis was used to look at the relationship between 
tumor volume and EV. This statistical method provides a powerful tool to disentangle 
between- and within-patient effects (23,24). Between-patient effect describes the 
effect of mean tumor volume on EV in each patient. Within-patient effect describes the 
effect of tumor volume on differences in EV between two eyes of the same patient. To 
facilitate analysis of this effect, within-patient centering (24) of tumor volume in one 
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eye around the mean tumor volume in each patient was performed. Both mean tumor 
volume (between) and centered tumor volume (within) are entered into the model, 
together with the factors of laterality and sex and the covariate (natural logarithm) of 
age. Testing for statistical interaction between explanatory variables was included in 
all regression models. Nonsignificant interaction terms were removed stepwise, and 
for significant interactions the effects were averaged with respect to the appropriate 
variables. All CIs are 95% CIs, and P values less than .05 were considered to indicate 
statistical significance for all statistical tests.
RESULTS
Except for age at MR imaging (t = 6.76, P < .001), there were no significant 
differences between patients with unilateral retinoblastoma and those with bilateral 
retinoblastoma, including difference in sex or the side of the affected eye.
interobserver agreement assessment
The ICC between the two observers was 0.97 (95% CI: 0.94, 0.98) for measurements 
of AL and 0.89 (95% CI: 0.82, 0.93) for measurements of ED, which indicated good 
agreement for both. Interobserver agreement for the volume measurement was 
especially good (ICC = 0.98; 95% CI: 0.95, 0.99). 
AL and eD measurements
The range in measurements of AL and ED showed a substantial overlap between 
normal eyes and eyes with retinoblastoma (Table 2). However, mean values for AL and 
ED were less for eyes with retinoblastoma than for normal eyes. The mean AL values 
were compared with the mean ED values for the three eye groups. The mean AL was 
significantly longer than the mean ED within all eye groups for normal eyes (t = 3.28, P 
= .002), eyes with unilateral retinoblastoma (t = 6.36, P < .001), and eyes with bilateral 
retinoblastoma (t = 3.07, P = .003). Eyes in female patients had a shorter mean AL 
and a shorter mean ED than eyes in male patients; this difference was not significant 
in most eye groups, except for the mean difference in AL for patients with unilateral 
retinoblastoma (t = 2.47; P = .016). 
Linear mixed model analyses (Table 3) showed a significant relationship between 
age and AL (P < .001) and between sex and AL (P = .02) after adjustment for other 
variables. When possible differences in age, sex, and laterality were taken into account, 
the relationship between AL and the presence of an intraocular retinoblastoma was 
significant (P = .001); the mean AL in eyes with retinoblastoma was 0.36 mm (95% CI: 
−0.57 mm, −0.16 mm) smaller than that in normal eyes.
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Age (P < .001) was independently associated with ED. In contrast to AL, ED showed no 
significant sex difference (95% CI: −0.007 mm, 0.73 mm; P = .05). For laterality, the EDs 
of affected eyes in patients with unilateral retinoblastoma were smaller than those in 
patients with bilateral retinoblastoma, but this difference was also not significant (95% 
CI: −0.90 mm, 0.003 mm; P = .05). After adjustment for these variables, the relationship 
between ED and retinoblastoma was highly significant (P < .001); the mean ED in eyes 
with retinoblastoma was 0.87 mm (95% CI: −1.01 mm, −0.66 mm) smaller than that in 
normal eyes.
ev measurements
There was a substantial overlap in EV between normal and affected eyes (Table 2). 
The volume of eyes was smaller in female patients than in male patients in all groups, 
but this difference was not significant. With linear mixed model analysis (Table 3), the 
difference in mean EV between female and male patients remained nonsignificant 
(P = .11). The relationship between EV and age showed a highly significant relationship 
(P < .001). Laterality-, sex-, and age-adjusted mean EV appeared to be 244 mm3 smaller 
for eyes with retinoblastoma than for normal eyes (95% CI: −336 mm3, −151 mm3; P < 
.001). 
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Table 2. Measurements of AL, ED and EV in 100 patients with Retinoblastoma 
Unilateral Retinoblastoma in 61 patients Bilateral 
Retinoblastoma in 39 
Measurements 59 Normal Eyes 59 Retinoblastoma 
Eyes
patients and 76 
affected eyes
AL (mm)
Total
    Mean (SE) 20.6 (0.14) 20.1 (0.16) 18.9 (0.16)
    SD 1.1 1.3 1.4
    Range 18.0 - 22.4 15.3 - 22.8 15.6 - 21.8
Male eyes
    Mean (SE) 20.7 (0.20) 20.5 (0.21) 19.0 (0.20)
    SD 1.1 1.2 1.2
    Range 18.0 - 22.4 18.7 - 22.8 16.9 - 21.8
Female eyes
    Mean (SE) 20.4 (0.18) 19.7 (0.23) 18.9 (0.23)
    SD 1.0 1.2 1.5
    Range 18.2 - 21.9 15.3 - 21.2 15.6 - 21.6
ED (mm)
 Total
    Mean 20.2 (0.15) 19.3 (0.18) 18.6 (0.17)
    SD 1.2 1.4 1.5
    Range 17.8 - 23.2 16.0 - 22.8 15.0 - 22.7
Male eyes
    Mean 20.4 (0.22) 19.6 (0.25) 18.7 (0.26)
    SD 1.3 1.4 1.5
    Range 17.8 - 23.2 16.3 - 22.8 15.0 - 22.7
Female eyes
    Mean 20.0 (0.20) 18.9 (0.24) 18.5 (0.23)
    SD 1.1 1.3 1.5
    Range 18.2 - 23.1 16.0 - 21.2 15.9 - 21.4
EV (mm3)
Total
    Mean 5018 (110) 4728 (118) 3935 (93)
    SD 841 906 814
    Range 3279 - 7511 2612 - 7505 2449 - 6403
Male eyes
    Mean 5058 (144) 4900 (152) 3989 (128)
    SD 812 847 746
    Range 3303 - 6685 3291 - 6846 2887 - 6403
Female eyes
    Mean 4972 (171) 4537 (179) 3891 (134)
    SD 888 946 871
    Range 3279 - 7511 2612 - 7505 2449 - 5738
Note.—Data in parentheses are standard errors of the mean. SD = standard deviation.
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Table 3. Linear Mixed Model Effect of Retinoblastoma on AL, ED and EV
Variable Parameter Estimate 95% CI for parameter P Value
AL (mm)
    Intercept 17.5
    Retinoblastoma vs 
    normal
-0.36 -0.57, -0.16 .001
    Unilateral vs 
    bilateral
-0.004 -0.36, 0.35 .98
    Male vs female 0.34 0.06, 0.62 .02
    Age (natural 
    logarithm)
0.95 0.81, 1.09 < .001
ED (mm)
    Intercept 17.8
    Retinoblastoma vs 
    normal
-0.87 -1.01, -0.66 < .001
    Unilateral vs 
    bilateral
-0.45 -0.90, 0.003 .05
    Male vs female 0.36 -0.007, 0.73 .05
    Age (natural 
    logarithm)
0.90 0.71, 1.08 < .001
EV (mm3)
    Intercept 2951
    Retinoblastoma vs 
    normal
-244 -336, -151 < .001
    Unilateral vs 
    bilateral
-46 -293, 202 .72
    Male vs female 165 -39, 369 .11
    Age (natural 
    logarithm)
676 573, 779 < .001
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Table 4. Linear Mixed Model Effect of Retinoblastoma Tumor Volume on EV
Variable Parameter Estimate 95% CI for Parameter P Value
Intercept 2869
Unilateral vs bilateral -694 -1248, -140 .02
Male vs female 151 -45, 347 .13
Mean tumor volume 
(mm3)*
0.13 -0.12, 0.39 .30
Unilateral Retinoblastoma†
    Age (natural 
    logarithm) 
857 697, 1016 < .001
    Centered tumor 
    volume (mm3)‡ 
-0.12 -0.18, -0.06 < .001
Bilateral Retinoblastoma†
    Age (natural 
    logarithm) 
545 416, 675 < .001
    Centered tumor 
    volume (mm3)‡ 
-0.27 -0.39, -0.16 < .001
* Between-patient effect.
† Laterality showed a significant interaction with age (P = .003) and centered tumor volume 
(P = .03).
‡ Within-patient effect.
Tumor volume
Tumor volume could be measured in all eyes (n = 59) in patients with unilateral 
retinoblastoma. Twenty-four of the patients with bilateral retinoblastoma had tumors 
large enough to obtain measurements in both eyes (n = 48), and nine patients had 
detectable tumors in one eye (n = 9). In the remaining 19 eyes, the tumor was not 
detected at MR imaging (n = 12) or MR imaging was performed before the second 
eye was affected (before bilateralization) (n = 7). Analysis of the latter small subgroup 
revealed a smaller mean EV of 406 mm3 before clinical presentation of retinoblastoma 
during follow-up. However, this relationship was not significant (95% CI: −1021 mm3, 
209 mm3; P = .19). The mean tumor volume was 1030 mm3 ± 720 (± standard deviation; 
range, 14–2882 mm3) for the whole group, 1320 mm3 ± 626 (range, 26–2882 mm3) for 
patients with unilateral retinoblastoma, and 731 mm3 ± 691 (range, 14–2372 mm3) for 
patients with bilateral retinoblastoma. The linear mixed model for the effect of tumor 
volume on EV (Table 4) showed significant interactions between age and laterality (P 
= .003) and between centered tumor volume and laterality (P = .03).
To determine the effects of these interactions between laterality and age and between 
laterality and centered tumor, we analyzed the effects within each laterality group. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
85
Ey
e 
Si
ze
 in
 R
et
in
ob
la
st
om
a
Again, age showed a significant relationship with EV, but this effect was stronger for 
eyes of patients with unilateral retinoblastoma (95% CI: 697 mm3, 1016 mm3; P < .001) 
than for eyes of patients with bilateral retinoblastoma (95% CI: 416 mm3, 675 mm3; P 
< .001). Within patients, a significant negative relationship was found between tumor 
volume and EV for eyes of patients with bilateral retinoblastoma (95% CI: −0.39 mm3, 
−0.16 mm3; P < .001) and patients with unilateral retinoblastoma (95% CI: −0.18, −0.06; 
P < .001). Between patients, no relationship was present (P = .30).
DISCUSSION
In our study, eyes with retinoblastoma and those without retinoblastoma 
showed significant differences in important biometric variables and EV. Eyes with 
retinoblastoma had significantly shorter ALs and EDs and significantly smaller EVs than 
normal eyes, and in the patients with retinoblastoma, a negative relationship between 
tumor volume and EV was found. We eliminated possible confounding factors, such 
as sex, age, and laterality, by using a multilevel regression model. Age contributed 
significantly to the increase in AL, ED, and EV. 
There were differences in mean age between the control group and the retinoblastoma 
group in our study, caused mainly by the inclusion of patients with bilateral 
retinoblastoma in the retinoblastoma group. Patients with bilateral retinoblastoma 
generally present at an earlier age than those with unilateral retinoblastoma. Given 
that patients with bilateral retinoblastoma tend to be younger, the mean AL, ED, and 
EV in patients with bilateral retinoblastoma are smaller than those in patients with 
unilateral retinoblastoma. When an adjustment for age was included in the statistical 
models for AL, ED, and EV, no significant differences were found between affected 
eyes for bilateral and unilateral retinoblastoma. 
The range in AL, ED, and EV measurements showed substantial overlap between 
normal and affected eyes, and the differences in size between normal and affected 
eyes were small. We found mean differences of 0.36 mm for AL, 0.87 mm for ED, and 
244 mm3 for EV. Although our study revealed that eyes affected by retinoblastoma 
were smaller than normal eyes in most patients, it must be pointed out that in some 
patients with unilateral retinoblastoma the affected eye may be as large as the normal 
eye or even slightly larger. However, a smaller affected eye should no longer be used 
to rule out retinoblastoma or to favor a diagnosis of persistent hyperplastic primary 
vitreous, Coats disease, or retinopathy of prematurity. Significantly higher values for 
mean AL in comparison with mean ED could be explained by the fact that the eye is 
not a perfect sphere and that protrusion of the cornea and anterior chamber increase 
the AL. 
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The negative relationship between retinoblastoma and AL, ED, and EV suggests that 
growth is inhibited in affected eyes. Given the location of disease within the posterior 
part of the eye, it may be postulated that the area of the globe usually undergoing 
maximal growth is mechanically restricted by the biologic stress of the tumor. 
Supportive evidence comes from the finding of a negative relationship between 
tumor size and EV in patients with retinoblastoma: The tumor volume is greatest in 
the eyes with the smallest volume. Although in our patients there was no significant 
relationship between an increase in tumor volume and an increase in EV, in a group 
of patients with more advanced (extraocular) disease, this relationship might be 
significant. 
Besides mechanical restriction by the tumor, other factors may influence growth of 
the affected eye. Although the difference was not significant, the smaller mean EV 
in the subgroup of eyes in which a metachronous tumor developed during clinical 
follow-up suggests that (locally acting) growth factors may also influence this process. 
Since the sample size of this subgroup is small, future research must be performed to 
evaluate whether a smaller EV can be used as a risk factor for metachronous tumor 
development in the other eye. 
Comparison of our biometric results with those of previous studies is limited in scope 
because our study was not designed to correlate MR imaging measurements with US 
biometric results. US biometry is not possible in eyes with retinoblastoma because 
of artifacts secondary to intratumoral calcifications. To our knowledge, previous 
validation studies for MR imaging measurement of AL and ED have not been reported 
in the literature, but measurements of small volumes in the eye with the same 
volumetric method proved to be accurate (25). Although existing studies on ocular 
biometry in children have mainly involved AL measurements obtained with US, current 
MR imaging data in the control group resemble US measurements in the literature 
(17–19,21,26–28). However, AL measurements may be slightly underestimated with 
the MR imaging technique because the measured axis can be tilted from the true axis, 
MR imaging can skip over the plane that includes the true axis, or both (29). 
Our study had some limitations. Because patients with retinoblastoma are rare, we 
used a retrospective design to create a large study group. Patients were recruited 
during a 12-year period, and three different MR imagers combined with a head coil 
were used. The MR images were not as good as those that can currently be acquired 
with high-spatial-resolution surface coils and high field strength. The use of normal 
eyes in patients with unilateral retinoblastoma as controls may represent a selection 
bias compared with a random selection from the general population. However, to 
deal with this data structure, we used a statistical method designed for clustered data. 
Since it was not a goal of our study to compare results of normal eyes with reported 
normal values, the lack of MR imaging–based reference data is of minor importance. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
87
Ey
e 
Si
ze
 in
 R
et
in
ob
la
st
om
a
Furthermore, the variables of age, laterality, and sex were included in all models as 
explanatory variables to allow us to study the (independent) effect of retinoblastoma 
on eye size. Considering these points together, we believe that valid comparisons 
may be performed between eyes with retinoblastoma and our control group. Further 
investigations in patients with retinoblastoma and age-matched normal control 
groups are necessary to confirm these differences in ocular biometry and evaluate the 
diagnostic yield. 
In conclusion, MR imaging measurements of AL, ED, and EV were significantly 
smaller in eyes with retinoblastoma than in normal eyes. In addition, in patients 
with retinoblastoma, a larger tumor volume corresponded to a smaller eye. These 
outcomes suggest that the use of eye size as an additional parameter to differentiate 
between retinoblastoma and (benign) simulating lesions should be considered 
carefully, and a decreased eye size should not be used to exclude retinoblastoma or 
to favor a diagnosis of simulating lesions.
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INTRODUCTION
Retinal dysplasia is a rare cause of childhood leukocoria, which can cause considerable 
diagnostic difficulty in the differentiation of benign and malignant intraocular 
pathology. When clinical diagnosis is uncertain, ocular MR imaging helps to 
characterize and differentiate between intraocular pathologies. However, in contrast 
to many lesions in the differential diagnosis of leukocoria, to our knowledge, detailed 
MR imaging findings in retinal dysplasia have not been previously reported. We report 
MR imaging findings of unilateral retinal dysplasia with concurrent optic nerve aplasia.
CASe RePoRT
A 6-month-old boy was admitted with a history of a smaller left eye since birth and 
leukocoria for 1 month. He was born to nonconsanguineous parents at 41 weeks’ 
gestation. Ophthalmic examination revealed no abnormalities in the right eye. The left 
eye was microphthalmic, with a corneal diameter of 9 mm (right, 10 mm). A yellowish-
white retrolental mass, projecting from the inferomedial quadrant into the vitreous, 
was present (Fig 1). The mass in combination with retinal detachment obscured clear 
visualization of optic nerve disc and macula. Prominent irregular feeder vessels and 
small focal hemorrhages covered the surface of the mass. Differential diagnosis 
based on these findings included ciliary body medulloepithelioma, anteriorly located 
retinoblastoma, and persistent hyperplastic primary vitreous (PHPV).
Ultrasonography showed a noncalcified mass with high reflectivity. MR imaging 
showed a mass arising from the nasal ciliary body region with high signal intensity 
(SI) on T1-weighted (T1WI) and low SI on T2-weighted (T2WI) images, combined with 
a normal-appearing vitreous and tent-shaped retinal detachment with subretinal 
exudate (Fig 2). The anterior chamber and lens showed no abnormalities. The right 
orbit, optic nerve, and portions of the optic chiasm related to the nerve were normal. 
The optic nerve and sheath complex were not visible within the left orbit or anywhere 
along the usual course of the nerve (Fig 2). Total aplasia of the left optic nerve was 
not combined with other congenital central nervous system (CNS) abnormalities. 
The mass showed intense homogeneous enhancement. Ultrasonography and MR 
imaging findings were more consistent with medulloepithelioma or PHPV, and a 
retinoblastoma could be ruled out. Five weeks later, enucleation was required due to 
enlargement of the mass with an increase of intraocular pressure, shallowness of the 
anterior chamber, and progression toward a phthisis bulbi. 
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fig 1. Fundus photograph of the 
left eye shows a retrolental mass 
(D, arrows) in the inferomedial 
quadrant of the vitreous (V) with 
large irregular feeder vessels, 
focal hemorrhages, and retinal 
detachment (R, arrowheads).
Histopathologic examination revealed a total absence of the optic nerve, scleral 
lamina cribrosa, and central retinal vessels. A vascularized mass was present anteriorly 
in the vitreous cavity on either side of the lens, adjacent to the ciliary body (Fig 3). The 
anterior eye segment showed no abnormalities. The mass consisted of an abnormal 
retinal differentiation, with disorganization, proliferation, and rosette formation in 
the photoreceptor cell layer. In the thin retina that was not incorporated in the mass, 
no ganglion cell layer was present. The posterior eye segment showed no persisting 
hyaloid artery or a thin stalk connecting the posterior lens and the optic disc region, 
presumed to represent a remnant of the Cloquet canal. The pathologic diagnosis was 
retinal dysplasia with concurrent optic nerve aplasia. 
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Fig 2. Axial T1WI (A) image shows a 
hyperintense mass in the anterior 
part of the vitreous (V), adjacent 
to the ciliary body (CB) on either 
side of the lens, combined with a 
tent-shaped retinal detachment 
with hyperintense subretinal 
fluid (SF). T2WI (B) image 
shows retinal detachment as a 
hypointense fine linear structure 
(R) and clearly demarcates the 
dysplastic retinal tissue (D). 
After we applied the contrast 
material (C, contrast-enhanced 
fat-suppressed T1WI image), the 
latter shows enhancement (D), in 
contrast to the detached retina 
(R) and subretinal fluid. Coronal 
contrastenhanced fat-suppressed 
T1WI (D) MR images reveal 
absence of the optic nerve (asterisk) in an otherwise normal orbit. sop indicates superior 
ophthalmic vein; oa, ophthalmic artery.
fig 3. A, Gross examination shows the detached retina (R) and the yellowish dysplastic 
retinal tissue (D), which is adjacent to the ciliary body (CB). The subretinal fluid is located 
inside the tent-shaped retinal detachment (R) and cannot be seen on this gross specimen. 
B, Microscopic examination shows the dysplastic retinal tissue behind the lens arising 
from the retina (R). The mass does not invade the ciliary body or the anterior chamber 
(hematoxylin-eosin [H&E], original magnification 3.5 objective). C, Detail of the mass shows 
still vaguely recognizable retinal tissue near the lens (L) and ciliary body (CB), with rosette 
formation composed of photoreceptor cells (H&E, original magnification 20 objective). D, 
Detail of the region in which the optic nerve was expected shows absence of the optic disc, 
lamina cribrosa, and optic nerve. Orbital connective tissue with a collection of small (ciliary) 
vessels is present behind the eye (H&E, original magnification 20 objective). C indicates 
choroid; S, sclera.
a group of congenital disorders, such as Norrie disease, tri-
somy 13, or Walker-Warburg syndrome. Ocular findings in
these disorders are mostly bil teral and accompanied by sys-
temic and CNS abnormalities. Unilateral retinal dysplasia is
usually not associated with a specific syndrome. Histopatho-
logic examination demonstrates a reduction or complete ab-
sence of retinal ganglion cells, their nerve fibers, and retinal
blood vessels, which can result in a congenital (usually tent-
shaped) retinal detachment, a retinalmalformation combined
with rosette formation and optic nerve aplasia.
Clinically, retinal dysplasia may present itself in a wide
range of severity, from simple to massive folding of the retina,
central stalks with retinal tissue extend-
ing from the optic disc to the back of the
lens, and complete retinal detachment
leading to highly disorganized microph-
thalmic eyes.1 If the intraocular prolifer-
ation is large enough, it may produce
leukocoria. Leukocoria and retinal de-
tachment in children require prompt
further investigation because retino-
blastoma should be included in the dif-
ferential diagnosis. Usually, the under-
lying disease causing leukocoria can be
deducted by ophthalmoscopy alone or
in combination with ultrasonography.
When clinical diagnosis is uncertain,
caused by an obscured view or an atyp-
ical-appearing tumor, M imaging
helps to characterize and differentiate between intraocular
pathologies.
On MR imaging, a retinal detachment presents as a fine
linear structure, which is limited anteriorly at the ora serrata
and posteriorly at the optic disc. Compared with the vitreous,
the SI of the detached retina is high on T1WI images, low on
T2WI images, and might show some contrast enhancement.
In our patient, retinal dysplasia showed the same SI character-
istics as those of normal detached retinal tissue; however, the
enhancement after gadolinium administration was much
stronger. It is likely that enhancement of dysplastic retinal tis-
sue varies with the quality and number of blood vessels. De-
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Fig 3. A, Gross examination shows the detached retina (R) and the yellowish dysplastic retinal tissue (D), which is adjacent to the ciliary body (CB). The subretinal fluid is located inside
the tent-shaped retinal detachment (R) and cannot be seen on this gross specimen. B, Microscopic examination shows the dysplastic retinal tissue behind the lens arising from the retina
(R). The mass does not invade the ciliary body or the anterior chamber (hematoxylin-eosin [H&E], original magnification3.5 objective). C, Detail of the mass shows still vaguely recognizable
retinal tissue near the lens (L) and ciliary body (CB), with rosette formation composed of photoreceptor cells (H&E, original magnification 20 objective). D, Detail of the region in which
the optic nerve was expected shows absence of the optic disc, lamina cribrosa, and optic nerve. Orbital connective tissue with a collection of small (ciliary) vessels is present behind the
eye (H&E, original magnification 20 objective). C indicates choroid; S, sclera.
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Fig 2. Axial T1WI (A) image shows a hyperintense mass in
the anterior part of the vitreous (V), adjacent to the ciliary
body (CB) on either side of the lens, combined with a
tent-shaped retinal detachment with hyperintense subretinal
fluid (SF). T2WI (B ) image shows retinal detachment as a
hypointense fine linear structur (R) and clearly demarcates
the dysplastic retinal tissue (D). After we applied the con-
trast material (C, contrast-enhanced fat-suppressed T1WI
image), the latter shows enhancement (D), in contrast to the
detached retina (R) and subretinal fluid. Coronal contrast-
enhanced fat-suppressed T1WI (D ) MR images reveal ab-
sence of the optic nerve (asterisk) in an otherwise normal
orbit. sop indicates superior ophthalmic vein; oa, ophthalmic
artery.
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DISCUSSION
Retinal dysplasia is more of a descriptive term, rather than a delineation of a clinical 
condition and may be a component of a group of congenital disorders, such as Norrie 
disease, trisomy 13, or Walker-Warburg syndrome. Ocular findings in these disorders 
are mostly bilateral and accompanied by systemic and CNS abnormalities. Unilateral 
retinal dysplasia is usually not associated with a specific syndrome. Histopathologic 
examination demonstrates a reduction or complete absence of retinal ganglion cells, 
their nerve fibers, and retinal blood vessels, which can result in a congenital (usually 
tent-shaped) retinal detachment, a retinal malformation combined with rosette 
formation and optic nerve aplasia. 
Clinically, retinal dysplasia may present itself in a wide range of severity, from simple 
to massive folding of the retina, central stalks with retinal tissue extending from 
the optic disc to the back of the lens, and complete retinal detachment leading to 
highly disorganized microphthalmic eyes (1). If the intraocular proliferation is large 
enough, it may produce leukocoria. Leukocoria and retinal detachment in children 
require prompt further investigation because retinoblastoma should be included in 
the differential diagnosis. Usually, the underlying disease causing leukocoria can be 
deducted by ophthalmoscopy alone or in combination with ultrasonography. When 
clinical diagnosis is uncertain, caused by an obscured view or an atypical-appearing 
tumor, MR imaging helps to characterize and differentiate between intraocular 
pathologies. 
On MR imaging, a retinal detachment presents as a fine linear structure, which is 
limited anteriorly at the ora serrata and posteriorly at the optic disc. Compared with 
the vitreous, the SI of the detached retina is high on T1WI images, low on T2WI images, 
and might show some contrast enhancement. In our patient, retinal dysplasia showed 
the same SI characteristics as those of normal detached retinal tissue; however, the 
enhancement after gadolinium administration was much stronger. It is likely that 
enhancement of dysplastic retinal tissue varies with the quality and number of blood 
vessels. Despite thickening of the dysplastic retinal tissue, the characteristic linear 
structure of a retinal detachment was preserved. This MR imaging feature might 
allow differentiation of retinal dysplasia from lesions, such as retinoblastoma or 
medulloepithelioma, which appear as solid masses. 
The differential diagnosis of a retrolental intraocular mass in children, with a 
hyperintense SI on T1WI and a hypointense SI on T2WI images, combined with retinal 
detachment, which can have MR imaging features identical to those in our patient, 
can be anteriorly located retinoblastoma, PHPV, or medulloepithelioma. Anteriorly 
located retinoblastoma can present without characteristic calcifications and is more 
common in older children compared with typical cases; it arises from the posterior 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
97
M
R
 im
ag
in
g 
fin
di
ng
s 
in
 r
et
in
al
 d
ys
p
la
si
a 
retina in younger children (2,3). Theoretically, positron-emission tomography might 
differentiate dysplasia and neoplasms, but this differentiation has not been confirmed 
for retinoblastoma (4). However, findings of vitreous seeding or extension into the iris 
and anterior chamber may help to diagnose retinoblastoma. 
PHPV results from failure of embryonic fibrovascular primitive stroma (the hyaloid 
system) to regress; it may continue to proliferate and create a tubular structure 
extending from the posterior surface of the lens to the optic disc (5). This solid 
component usually shows enhancement on postcontrast images. The common 
presence of a retinal detachment, abnormalities of the lens and anterior chamber, 
and absence of calcifications can be helpful in the diagnosis. 
Masses that are localized mainly in the ciliary body are more suggestive of 
medulloepithelioma, a congenital tumor of the ciliary body epithelium. From the 
ciliary body, the tumor may spread posteriorly along the retina and anteriorly along 
the posterior surface of the lens. Calcifications and retinal detachment are associated 
findings seen in (advanced) medulloepithelioma, and the tumors are well enhanced 
after contrast administration (3). 
Although the diagnosis of intraocular pathology is usually clinically obvious and the 
presented MR imaging findings are not specific for retinal dysplasia, awareness of this 
disease and the presentation on MR imaging might be helpful to differentiate between 
other benign or malignant intraocular pathology and to reach an early diagnosis.
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AbSTRACT
Purpose. To assess diagnostic accuracy of preoperatively performed magnetic 
resonance (MR) imaging for detection of tumor extent in a large patient 
population with histopathologically proved retinoblastoma. 
Materials and Methods. Local ethics committee approval and informed 
consent were not required for retrospective review of patients’ images and 
records. Fifty-eight eyes in 28 girls (mean age, 21 months; range, 2–59 months) 
and 28 boys (mean age, 24 months; range, 2–76 months) with retinoblastoma 
were retrospectively reviewed by one radiologist on unenhanced T1-weighted, 
dual-echo T2-weighted, and gadolinium-enhanced T1-weighted MR images. MR 
imaging parameters such as growth pattern, anterior chamber hyperintensity, 
and involvement of choroid, ciliary body, optic nerve, sclera, orbital fat, and 
pineal gland were determined. Tumor volume was measured and correlated 
to metastatic risk factors. Imaging and pathologic findings were compared. 
Statistical analysis was performed by using logistic regression with log 
likelihood ratio χ2 test or Fisher exact test. 
Results. Choroidal invasion was suspected with MR imaging in 21 eyes; findings 
were false-positive in 13 eyes and false-negative in three (73% sensitivity, 72% 
specificity, 72% accuracy). Anterior chamber hyperintensity on T1-weighted 
MR images obtained after contrast agent administration correlated well with 
clinical presence of reactive neovascular processes. MR imaging findings were 
true-positive in 21 of 32 eyes with proved prelaminar optic nerve invasion (66% 
sensitivity) and false-positive in one (96% specificity, 79% accuracy). Postlaminar 
optic nerve invasion was correctly detected in two eyes; in two other eyes, 
this metastatic risk factor was missed (50% sensitivity, 100% specificity, 97% 
accuracy). Scleral and extrascleral tumor invasion were correctly excluded in 
all eyes. Tumor volume was statistically associated with prelaminar optic nerve 
invasion (P = .001) and choroidal invasion (P = .031). 
Conclusion. MR imaging is accurate for tumor staging and detection of 
metastatic risk factors; detection of intraocular tumor infiltration remains 
difficult. Tumor volume, measured with MR imaging, was associated with 
prelaminar optic nerve and choroidal involvement. 
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INTRODUCTION
Retinoblastoma, the most common pediatric intraocular neoplasm, is a highly 
malignant tumor of the primitive neural retina, and it occurs in one in 17 000 live 
births (1). Because of early diagnosis and improved treatment methods, cure rates 
greater than 90% have been achieved in western countries. Extraocular extension 
of retinoblastoma develops in less than 10% of patients (2) and is associated with a 
considerably higher mortality rate (3–5). Retinoblastoma spreads by direct extension 
into the orbit along scleral emissary vessels through hematogenous dissemination, 
invasion of the optic nerve, and dispersion through the cerebrospinal fluid after tumor 
cells in the optic nerve invade the leptomeninges (6). 
The characteristic appearance of retinoblastoma is a unifocal or multifocal elevated 
white pedunculated mass that is finely vascularized, sometimes with a large feeder 
vessel and calcified foci caused by tumor necrosis. 
The growth pattern of retinoblastoma can be subdivided into three types: endophytic, 
exophytic, and combined endophytic and exophytic (7). Endophytic tumors arise 
from inner layers of the retina and grow into the vitreous. Frequently, small clusters 
of tumor cells detach from the endophytic mass, producing multiple floating tumor 
islands; this process is known as vitreous seeding. Exophytic tumors start in the outer 
layers and growth is in the subretinal space, which causes nonrhegmatogenous retinal 
detachment with subretinal exudate and possible subretinal tumor seeding. 
Beside enucleation, conservative treatment methods, such as thermochemotherapy, 
radioactive plaque therapy, cryotherapy, laser photocoagulation, external-beam 
radiation therapy, and tumor reduction chemotherapy, can be applied. The treatment 
of retinoblastoma depends on several parameters: tumor volume and localization, 
intraocular tumor extension, extraocular stage of disease, and laterality (side) of 
tumor. In the staging of the extent of disease, magnetic resonance (MR) imaging 
should include evaluation of intraocular tumor extension (choroid, sclera, prelaminar 
optic nerve) and extraocular (postlaminar or orbital invasion) or intracranial 
(pineoblastoma or metastases) tumor spread. 
The reported predictors for metastatic retinoblastoma are invasion of the optic nerve 
(3,8–11), invasion of the choroid (8,9,12), and orbital involvement (3,9). Khelfaoui et al 
(9) also found that anterior chamber involvement is associated with an increased risk 
for metastases. Optic nerve invasion is reported to be present more often in patients 
with exophytic retinoblastoma, tumor thickness of 15 mm or larger, secondary 
glaucoma, and vitreous hemorrhage (11). A finding of rubeosis iridis should also alert 
the clinician to suspect optic nerve invasion (13). Factors predictive for choroidal 
invasion are rubeosis iridis (12,13) and optic nerve invasion (12). There is some 
controversy about whether exophytic retinoblastoma is a risk factor for choroidal 
invasion and optic nerve invasion (12,14). 
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Diagnosis of retinoblastoma is made on the basis of clinical findings at extensive 
indirect ophthalmoscopy, with the patient receiving a general anesthetic, and at 
ultrasonography (US). Routinely performed complementary investigations for 
differential diagnosis and tumor staging are physical examination, examination of 
blood and cerebrospinal fluid, and MR imaging. Computed tomography is not routinely 
performed, because cumulative effects of repeated exposure to ionizing radiation 
could have substantial consequences for patients with hereditary retinoblastoma, 
such as an increased risk for the development of second primary tumors. 
MR imaging is considered to be the best imaging technique for the differential 
diagnosis between retinoblastoma and pseudoneoplastic lesions, particularly 
in patients with opaque ocular refractive media that reduce the yield of indirect 
ophthalmoscopy (15–19). Heavily T2-weighted images, unenhanced T1-weighted MR 
images, and gadolinium-enhanced fat-suppressed T1-weighted MR images proved to 
be complementary in the characterization and staging of retinoblastoma (15,17,19–23). 
Many authors reported the role of MR imaging in retinoblastoma, but still very little 
is known about the diagnostic accuracy of MR imaging in the staging of the extent of 
disease in retinoblastoma. Until now, to our knowledge, researchers in two studies 
evaluated the clinical value of MR imaging findings in comparison with histopathologic 
results after enucleation (20,23). The numbers of patients included in those studies, 
however, were relatively small. 
The purpose of our study was to assess the diagnostic accuracy of preoperatively 
performed MR imaging for the detection of tumor extent in a large patient population 
with histopathologically proved retinoblastoma.
MATeRiALS AND MeTHoDS
Patient Population
Patients were selected from a series of 120 patients with retinoblastoma who were 
followed up at our institution between December 1992 and October 2002. Patients 
eligible for this retrospective study were those with histopathologically proved 
retinoblastoma, who were primarily treated with enucleation (81 patients) and who 
underwent pretreatment 1.0- or 1.5-T MR imaging, which enabled adequate image 
interpretation. Inclusion criteria were met by 64 patients. Clinical data were collected 
from inpatient and outpatient medical records at our institution and included sex, age, 
affected eye, follow-up period, adjuvant treatment, and results of ophthalmoscopy 
and US. 
Two patients did not receive intravenous injection of contrast material, and in six 
patients, quality of histopathologic material hampered proper pathologic analysis. 
These patients were excluded from the study. Thus, the final study population 
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consisted of 56 patients, with a mean age at enucleation of 22 months (median, 17 
months; range, 2–76 months). There were 28 girls (age range, 2–59 months; mean 
age, 21 months; median age, 16 months) and 28 boys (age range, 2–76 months; 
mean age, 24 months; median age, 19 months). In two boys, bilateral enucleation 
had been performed. Thus, data obtained about 58 eyes could be evaluated. Mean 
time between MR imaging and enucleation was 6 days (median, 5 days; range, 1–17 
days). All patients underwent ophthalmoscopy and US after they received a general 
anesthetic. In all patients, tumor calcification was documented by using US. Our local 
ethics committee did not require its approval or informed consent for retrospective 
review of a patient’s records and images. 
MR imaging
MR imaging studies were performed at 1.0 T (Magnetom Impact Expert; Siemens, 
Erlangen, Germany) and 1.5 T (Magnetom Vision, Magnetom Sonata; Siemens), with use 
of a standard head coil. Before gadolinium-based contrast agent injection, transverse 
and sagittal T1-weighted MR images were obtained with repetition time msec/echo 
time msec of 350–500/14–15 and four acquisitions. Transverse T2-weighted MR images 
were obtained with the following parameters: 2000–2700/19–60 (intermediate-
weighted MR images) and 2000–2700/80–120 (T2-weighted MR images) and one 
acquisition. After intravenous injection of 0.1 mmol/kg gadopentetate dimeglumine 
(Magnevist; Schering, Berlin, Germany), sagittal, transverse, and coronal T1-weighted 
MR images (400–575/13–15, three acquisitions) were obtained with (43 patients) 
or without (13 patients) fat suppression. Fat suppression was accomplished with a 
frequency-selective presaturation pulse. Section thickness in all images was 3 mm, 
with an intersection gap of 0.3 mm. A spin-echo technique was used for all imaging 
sequences, with a matrix of 256 × 256 and a resolution of 0.8 × 0.8 mm. After injection 
of a gadolinium-based contrast agent, brain imaging was performed with 5-mm-thick 
T1-weighted MR images obtained with 500–650/14–15 and two acquisitions. During 
MR imaging, children were sedated with a mixture of 1 mg/kg of promethazine 
hydrochloride (Centrafarm Services, Etten-Leur, the Netherlands) injection, 1 mg/kg of 
pethidine (Pharmachemie, Haarlem, the Netherlands), and 0.25 mg/kg of droperidol 
(Janssen-Cilag, Tilburg, the Netherlands), after premedication with 0.4 mg/kg of 
diazepam (Stesolid; Alpharma, Baarn, the Netherlands). 
image interpretation
The MR images were evaluated by an observer (J.A.C.) who had 11 years of experience 
with orbital and brain MR imaging and who was blinded to histopathologic findings. 
After injection of a gadolinium-based contrast agent at T1- and T2-weighted MR 
imaging, evaluation was conducted of the following features: growth pattern 
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(endophytic, exophytic, or a combination of the two); anterior chamber hyperintensity; 
and involvement of the choroid (tumor extension or inflammation), ciliary body, optic 
nerve (prelaminar, postlaminar, or no invasion), sclera, orbital fat (tumor extension or 
inflammation), and pineal gland (trilateral retinoblastoma). T2-weighted MR images 
were also used to assess vitreous hemorrhage and retinal detachment. These images, 
in combination with T1-weighted images obtained before gadolinium-based contrast 
agent injection, were used to evaluate subretinal fluid. Subretinal fluid was classified 
as follows: category 1, fluid with a sedimentation effect (gravitational fluid-fluid level) 
classified as subretinal hemorrhage; category 2, hyperintense fluid on precontrast 
T1- and T2-weighted MR images classified as subretinal hemorrhage or proteinaceous 
subretinal effusion; and category 3, isointense fluid on precontrast T1-weighted 
images and hyperintense fluid on T2-weighted images classified as subretinal effusion 
with low protein content. 
Signal intensity (SI) of the ipsilateral and contralateral vitreous was measured in 26 
patients on pre- and postcontrast T1-, intermediate-, and T2-weighted MR images. 
Excluded from SI measurement were patients with bilateral disease, vitreous 
hemorrhage (clinical, MR imaging, or histopathologic findings), subtotal or total 
retinal detachment, or a tumor of large size. For each patient, one representative 
level was selected to measure SI of the ipsilateral and contralateral vitreous with all 
sequences by using the region-of-interest function of the MR imaging system and 
custom-designed dedicated software. Regions of interest (approximately 15 mm2) 
were placed in the section in which ipsilateral and contralateral vitreous had the 
largest anteroposterior diameter. The proportional difference in SI between ipsilateral 
and contralateral vitreous was calculated. The transverse relaxation times were 
estimated from the ratio of the SI on two echoes (echo time 1 [TE1] and echo time 2 
[TE2], 20–80 msec and 60–120 msec, respectively) from the equation: T2 ≈ (TE2 − TE1)/
ln[SI(TE1)] − ln[SI(TE2)] (20). Tumor location was coded as anterior or posterior to 
the equator. The latter was subcategorized into macular, juxtapapillar, and posterior 
to the equator but not macular or juxtapapillar. Volume of tumor was measured 
on transverse postcontrast T1-weighted MR images in 56 enucleated eyes. In two 
patients with bilateral enucleation, only data from the largest tumor volume were 
included for consideration. In eyes with multifocality, only the tumor with the largest 
volume was included. In every section in which tumor was present, this structure 
was manually surrounded by a region of interest, and the surface of this region was 
calculated. All these surfaces of tumor in different sections were added and multiplied 
by section thickness (3 mm) and intersection gap (0.3 mm). On the basis of median 
tumor volume, tumor volumes were categorized into four subgroups: very small, less 
than 0.65 cm3; small, 0.65–1.30 cm3; medium, greater than 1.30–1.95 cm3; and large, 
greater than 1.95 cm3. 
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Anterior chamber hyperintensity on postcontrast T1-weighted MR images, vitreous 
hemorrhage, and vitreous tumor seeding were compared with ophthalmoscopic 
findings obtained with the patient receiving a sedative. An MR imaging finding 
of retinal detachment was compared with clinical findings (ophthalmoscopic and 
US findings), because of the large number of artifacts caused by histopathologic 
preparation of enucleated eyes. Follow-up findings were chosen to be the standard 
for pineal gland lesions. 
Pathologic Analysis
Pathologic analysis was performed by an observer (P.v.d.V., a pathologist with 9 years 
of experience in ophthalmopathology, who diagnoses virtually all retinoblastoma cases 
in the Netherlands, as the VU University Medical Center is the center of treatment for 
this tumor) who was blinded to MR imaging findings. After surgery, enucleated eyes 
were fixed in 4% formaldehyde for 24 hours, washed with both 70% and 99% alcohol for 
24 hours, and embedded in paraffin. Whole-eye sections were cut parallel to the optic 
nerve with a thickness of 4–6 μm (depending on the amount of tumor calcification) 
and stained with hematoxylin-eosin. Growth pattern and tumor extension into the 
choroid, ciliary body, optic nerve, sclera, and orbital fat were assessed. 
Tumor extension into the optic nerve was categorized with reference to the cribriform 
lamina of the sclera as pre- or postlaminar invasion. Also, presence or absence of 
tumor cells in the vitreous, choroidal inflammation, and orbital inflammation were 
assessed. Histopathologic data were used as the standard for corresponding MR 
imaging features. After first evaluation of MR imaging and histopathologic findings, 
a second review (J.A.C.) of false-positive and false-negative MR imaging findings was 
performed to evaluate structural causes of disagreement. 
Statistical Analysis
Statistical comparisons of SIs were performed by using a nonparametric Mann-Whitney 
U test for comparing differences in two distributions. The Mann-Whitney U test was 
selected because of the nonnormality of the distributions, together with a small data 
set and large differences in standard deviations of the groups. For comparisons, one-
tailed tests were used with statistical software (SPSS, version 9.0; SPSS, Chicago, Ill). 
Accuracy of MR imaging findings was calculated as the percentage of true-positive 
plus true-negative findings compared with the total number of examined patients. 
Sensitivity was calculated as a percentage by dividing true-positive findings by the sum 
of true-positive and false-negative findings. Specificity was calculated as a percentage 
by dividing true-negative findings by the sum of true-negative and false-positive 
findings. Logistic regression analysis was performed by using a log likelihood ratio 
χ2 test to investigate the association between tumor volume and the dichotomous 
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dependent variables of choroidal and prelaminar optic nerve invasion. The odds ratio 
was estimated for each independent variable. The Fisher exact test was computed for 
the association between tumor volume and postlaminar tumor invasion because of 
the low prevalence of abnormal findings. For significance of differences in distribution 
of variables, a difference with a P value of .05 was considered statistically significant.
RESULTS
Patient Characteristics
Eighteen (32%) patients, nine boys and nine girls, had bilateral disease; both eyes were 
enucleated in two of them (n = 20 eyes). Mean age at enucleation was 15 months 
(median age, 10 months; range, 2–38 months). In patients with unilateral disease, the 
right eye was involved in 20 patients, 11 boys and nine girls (mean age, 23 months; 
median age, 18 months; range, 3–76 months); the left eye was involved in 18 patients, 
eight boys and 10 girls (mean age, 30 months; median age, 28 months; range, 7–65 
months) (n = 38 eyes). Histopathologic confirmation was obtained in all 58 eyes. 
Postoperative adjuvant chemotherapy was applied in six (11%) patients, because of 
the higher risk of metastases. Mean follow-up time after MR imaging was 51 months 
(median, 49 months; range, 3–121 months). One patient died because of metastatic 
disease, without a pineal gland tumor. 
MR imaging Characteristics of Retinoblastoma and vitreous Tumor Seeding
In all retinoblastomas, MR imaging depicted lesions with characteristic SI: hyperintense 
with respect to the vitreous on T1-weighted MR images and hypointense on T2-weighted 
MR images. After intravenous administration of gadopentetate dimeglumine, all 
tumors showed enhancement. Mean proportion of ipsilateral to contralateral T2 
relaxation times was estimated to be 0.93 ± 0.09 (standard deviation) for vitreous 
without ipsilateral tumor seeding and 0.90 ± 0.15 for vitreous with ipsilateral tumor 
seeding (P = .32, Mann-Whitney U test). In eyes with vitreous tumor seeding compared 
with eyes without tumor seeding, no statistically significant differences were present 
in proportions of SI between ipsilateral and contralateral vitreous on pre- and post-
contrast T1-, T2-, and intermediate-weighted MR images (Table 1).
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Table 1. Mean increase of ipsilateral SI with respect to the contralateral vitreous for vitreous 
with and without tumor seeding
Vitreous with seeding Vitreous without 
seeding
Sequence n = 18 n = 8 P Value*
T1-weighted
    Precontrast 13.1 ± 6.3 7.7 ± 11.1 .17
    Postcontrast 11.8 ± 8.7 8.0 ± 11.6 .27
Intermediate-
weighted
9.2 ± 7.2 4.0 ± 11.8 .18
T2-weighted  7.3 ± 6.4 3.5 ± 10.4 .15
Note. Data are the percentages of mean increase in ipsilateral SI ± standard deviation. 
*Mann-Whitney U test
Growth Pattern
In one child, the tumor growth pattern could not be assessed because of insufficient 
histopathologic material. Histopathologic tumor growth pattern was endophytic in 
24 (42%) of 57 eyes and exophytic in 26 (46%); in seven (12%) eyes, both exophytic 
and endophytic tumor growth patterns coexisted simultaneously. The endophytic 
growth pattern was suspected on MR images in 22 eyes but was false-positive in 
eight of them. Eleven false-negative observations occurred. Tumor was classified on 
MR images as exophytic in 32 eyes, but the classification in 12 eyes was not correct, 
and in six eyes, exophytic tumor growth pattern was missed. MR imaging findings 
suggested a combination of two growth patterns (endophytic and exophytic) in 
three eyes, but these observations were incorrect because only one pattern of tumor 
growth was present in histopathologic sections. In the statistical analysis, eyes with a 
combination of endophytic and exophytic growth pattern at histopathologic analysis 
or MR imaging were considered to be part of both growth pattern groups (Table 2). 
Sensitivity of MR imaging for depiction of the endophytic growth pattern was 61%, 
with a specificity of 77%, and sensitivity and specificity of MR imaging for depiction of 
the exophytic growth pattern were, respectively, 76% and 58% (Table 2).
Retinal Detachment and vitreous Hemorrhage
During clinical examination, retinal detachment was rated positive in 38 (69%) of 55 
eyes; in three eyes, the retina could not be observed because of blood in the anterior 
chamber or a hazy cornea. At MR imaging, detachment of the retina was suspected 
in 36 eyes, and in these, findings in only two did not correlate with clinical findings 
(sensitivity, 89%; specificity, 88%) (Table 2). Subretinal fluid accumulation was detected 
at MR imaging in 35 eyes and was classified as category 1 in five eyes and category 2 in 
six eyes. Subretinal fluid accumulation was detected at MR imaging and was classified 
as category 3 (subretinal effusion) in 24 eyes. 
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Vitreous hemorrhage was clinically present in two (4%) of 55 eyes and could not be 
judged in three. At MR imaging, vitreous hemorrhage was present in three (6%) of 50, 
and no residual vitreous was left in eight eyes because of the large size of the tumor 
(four eyes) or total retinal detachment (four eyes). Both clinical and MR imaging 
evaluations were not possible in one eye. In the remaining 48 eyes, findings in 47 were 
true-negative and those in one were false-positive (Table 2). 
Choroid and Ciliary body
Choroidal invasion was detected histopathologically in 11 (19%) eyes; eight of those 
were also rated as abnormal at MR imaging (Table 2). Inhomogeneous contrast 
enhancement and local thickening of the choroid adjacent to the tumor on T1-
weighted gadolinium-enhanced MR images was judged as a possible infiltration (Fig 
1). A large number of false-positive findings (13 eyes) were reported, leading to a 
sensitivity of 73% and a specificity of 72% (Table 2). In all false-positive findings, little 
normal retinal tissue was left between tumor and choroid, which decreased contrast 
between two enhancing structures at MR imaging (Fig 2). Only in three eyes was 
choroidal invasion missed: two eyes showed microscopic invasion and one showed 
invasion to a larger extent (Fig 3). In three eyes, the choroid was seen as a diffuse 
thickened hyperintense ring-shaped structure at MR imaging with all sequences. 
Histopathologic sections showed marked invasion of the choroid by inflammatory 
cells (Fig 4). In one eye, choroidal inflammation (with a ring-shaped enhancement 
pattern) penetrated the optic nerve more than 1 mm on postcontrast T1-weighted 
MR images, which could easily be interpreted as tumor invasion (Fig 5a). At histologic 
investigation, a granuloma in the optic nerve head was found (Fig 5b).
Histopathologic examination showed no invasion of the ciliary body in our study 
group. At MR imaging, the ciliary body and tumor could not be discriminated in 10 
eyes (Fig 6). MR imaging observations were probably false-positive, because in eight 
eyes, tumor was adjacent to this structure, and in two eyes a lens luxation from the 
ciliary body hampered proper anatomic interpretation.
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Table 2. MR Imaging Features Compared with Histopathologic and Clinical Findings
Variable No. of 
Eyes
TP FP TN FN Accuracy 
(%)*
Sensitivity 
(%)†
Specificity 
(%)‡
HISTOPATHOLOGICAL FINDINGS
    Extraocular spread
Orbital fat 
invasion
58 0 0 58 0 100 (58/58) 0 (0/ 0) 100 (58/58)
Postlaminar 
invasion
58 2 0 54 2 97 (56/58) 50 (2/4) 100 (58/58)
    Intraocular spread
Prelaminar 
invasion
58 21 1 25 11 79 (46/58) 66 (21/32) 96 (25/26)
Choroidal 
invasion
58 8 13 34 3 72 (42/58) 73 (8/11) 72 (34/47)
Scleral 
invasion
58 0 0 58 0 100 (58/58) 0 (0/ 0) 100 (58/58)
Ciliary body 
invasion
58 0 10 48 0 83 (48/58) 0 (0/ 0) 83 (48/58)
    Growth pattern
Endophytic 57§ 19 6 20 12 68 (39/57) 61 (39/57) 77 (20/26)
Exophytic 57§ 25 10 14 8 68 (39/57) 76 (25/33) 58 (14/24)
CLINICAL FINDINGS
Anterior 
chamber 
abnormality
57ǁ 15 5 37 0 91(52/57) 100 (15/15) 88 (37/42)
Retinal 
detachment
55# 34 2 15 4 89 (49/55) 89 (49/55) 88 (15/17)
Vitreous 
hemorrhage
48** 0 1 47 0 98 (47/48) 0 (0/ 0) 98 (47/48)
Note.—FN false-negative finding, FP false-positive finding, TN true-negative finding, and 
TP true-positive finding.
* The calculation of (TP + TN)/N was used to derive the numerator in parentheses. Numbers 
in parentheses were used to calculate the percentages.
† The calculation of TP/(TP + FN) was used to derive the numerator in parentheses. Numbers 
in parentheses were used to calculate the percentages.
‡ The calculation of TN/(TN + FP) was used to derive the numerator in parentheses. Numbers 
in parentheses were used to calculate the percentages.
§ In one eye, growth pattern could not be assessed because of insufficient histopathologic 
material.
ǁ Ophthalmoscopy was not possible because of a hazy cornea (n = 1).
# Ophthalmoscopy was not possible because of a hazy cornea (n = 1) and blood in the 
anterior chamber (n = 2).
** Ophthalmoscopy was not possible because of a hazy cornea (n = 1) and blood in the 
anterior chamber (n = 2). At MR imaging, no residual vitreous was left because of total 
retinal detachment (n = 4) or because of the large size of the tumor (n = 4). Both clinical 
and MR imaging evaluations were not possible in one eye.
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figure 1. Bilateral retinoblastoma in 21⁄2-year-old boy. 
Transverse T1-weighted gadolinium-enhanced MR 
image (370/14) of left eye shows inhomogeneous 
enhancement pattern and local thickening of the 
choroid, adjacent to the tumor, and these findings 
were suspicious for extensive tumor invasion 
(arrows). Histopathologic examination results 
confirmed these findings.
figure 2. Retinoblastoma in 18-month-old boy. (a) Transverse gadolinium-enhanced T1-
weighted MR image (500/15) of right eye shows retinoblastoma and choroid with similar 
SI. Choroidal invasion could not be excluded with MR imaging, because tumor and choroid 
showed similar SI. Notice asymmetric enhancement of the iris (arrow), which was clinically 
confirmed by the presence of rubeosis iridis. (b) Histopathologic examination did not 
show invasion of the choroid (C) by retinoblastoma (R). Choroid is not affected, because 
retinal pigment epithelium layer (arrowheads) is intact. (Hematoxylin-eosin stain; original 
magnification, 20 objective.)
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figure 3. Retinoblastoma in 31⁄2-year-old boy. (a) Transverse gadolinium-enhanced T1-
weighted fat-suppressed MR image (575/15) of right eye shows tumor mass (arrowheads) 
surrounded by hyperintense subacute subretinal bleeding. Notice local thickening of 
choroid (black arrow) lateral to the optic nerve caused by massive tumor invasion. 
Increased SI (white arrow) posterior to the eyeball is present and was suspicious for 
postlaminar tumor invasion. (b) Transverse T2-weighted MR image (2200/120) shows 
characteristic hypointense retinoblastoma surrounded by hyperintense subretinal fluid. (c) 
Histopathologic specimen shows massive invasion of retinoblastoma (R) into the choroid 
(C). Sclera (S) is not affected. (Hematoxylin-eosin; original magnification, 10 objective.) (d) 
Histopathologic specimen shows same findings as in c and postlaminar optic nerve (O) 
invasion (arrow). (Hematoxylin-eosin; original magnification, 20 objective.)
figure 4. Bilateral retinoblastoma in 10-month-old boy. (a) Transverse T1-weighted MR image 
(480/15) of left eye obtained after gadolinium-based contrast agent administration shows 
hyperintense enhancing ring, which appears to be a diffuse thickened choroid, probably 
related to inflammation secondary to an intraocular tumor (arrows). (b) Microscopic 
specimen shows a detail of optic nerve (O), choroid (C), and sclera (S). Inflammatory cells, 
present in choroid, caused MR image enhancement. (Hematoxylin-eosin stain; original 
magnification, 20 objective.)
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figure 5. Bilateral retinoblastoma in 2-month-old girl. (a) Transverse T1-weighted fat-
suppressed MR image (541/15) of right eye obtained after administration of gadolinium-
based contrast agent shows strong enhancement and diffuse thickening of the choroid, 
probably related to choroidal inflammation. This enhancement extends into the optic 
nerve (arrow) and was suspicious for postlaminar tumor invasion. (b) Microscopic 
specimen shows retinoblastoma (R), with massive necrosis, sclera (S), and inflammation 
of choroid (C). A granuloma (arrow) was detected in the optic nerve head and was 
responsible for contrast enhancement pattern on MR image. No tumor invasion into optic 
nerve (O), choroid, or sclera was present. (Hematoxylineosin stain; original magnification, 
5 objective.)
figure 6. Unilateral retinoblastoma in 20-month-old girl. (a) Transverse T1-weighted MR 
image (575/15) of right eye obtained after gadolinium-based contrast agent administration 
shows large tumor mass with inhomogeneous enhancement. Tumor invasion of the 
ciliary body (arrows) was suspected but was a false-positive finding, probably because 
of insufficient spatial resolution. The iris manifests as a hyperintense band anterior 
to the lens as a result of rubeosis iridis detected with ophthalmoscopic examination. 
(b) Histopathologic specimen shows a detail of the ciliary body (CB) (arrows) without 
tumor infiltration. Tumor (R) is adjacent to the ciliary body, anterior chamber, and iris (I). 
(Hematoxylin-eosin stain; original magnification, 10 objective.)
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Anterior Chamber Abnormalities
The anterior chamber of one eye could not be examined by using ophthalmoscopy 
because of the presence of a hazy cornea. In 15 (26%) of 57 eyes, anterior chamber 
hyperintensity on postcontrast T1-weighted MR images could be explained by the 
clinical presence of hyperemia (six eyes), uveitis (one eye), and iris neovascularization 
(rubeosis iridis) (eight eyes) (Figs 2a, 7). In five eyes, no clinical explanation could be 
found for marked enhancement of the iris.
figure 7. Unilateral retinoblastoma in 12-month-
old boy. (a) Transverse gadolinium-enhanced 
T1-weighted fat-suppressed MR image (475/14) 
shows an enhancing tumor mass (arrowheads) 
of right eye. Notice extreme enhancement of 
the iris (arrow) compared with appearance of 
left eye. Clinical examination revealed rubeosis 
iridis of the right eye. (b) Histopathologic 
specimen shows a detail of the anterior chamber 
(AC), cornea (CO), and lateral part of the iris (I). 
Marked increase of blood vessels is present in 
the iris (arrowheads). (Hematoxylin-eosin stain; 
original magnification, 20 objective.)
optic Nerve
Histopathologic presence of optic nerve invasion was prelaminar in 32 (55%) eyes and 
postlaminar in four (7%) eyes. Prelaminar tumor invasion was suspected at MR imaging 
in 22 eyes (Fig 8), and observations in one of 22 eyes were incorrect. This parameter 
was characterized by a high rate of false-negative findings (11 eyes). In these 11 eyes, 
seven eyes showed microscopic or superficial optic nerve head invasion, one eye 
showed substantial invasion of the optic nerve anterior to the lamina cribrosa (Fig 
9), one eye showed tumor at the level of the lamina cribrosa, and two eyes showed 
tumor posterior to the lamina cribrosa (Fig 10), without extension to the section 
edge of the optic nerve. In 25 eyes, MR images showed a linear enhancement pattern 
of the optic disc, indicating absence of prelaminar optic nerve invasion (Figs 11, 12). 
The sensitivity of MR imaging in detection of prelaminar optic nerve infiltration was 
66%, with a specificity of 96% and an accuracy of 79%. Postlaminar involvement was 
correctly suspected in two of four eyes (sensitivity, 50%; specificity, 100%; accuracy, 
97%) (Figs 3, 13).
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figure 8. Unilateral retinoblastoma in 12-month-old boy. (a) Transverse gadolinium-
enhanced T1-weighted MR image (475/14) of right eye shows prelaminar optic nerve 
invasion (arrow) as an interruption of linear enhancement pattern of the choroidoretinal 
complex at the optic disc. (This finding was rated as true-positive.) (b) Histopathologic 
specimen shows retinoblastoma (R) that infiltrated optic nerve (O) up to lamina cribrosa 
(LC), which indicated prelaminar invasion. (Hematoxylin-eosin stain; original magnification, 
5 objective.)
figure 9. Unilateral retinoblastoma in 20-month-old girl. (a) Transverse gadolinium-
enhanced T1-weighted MR image (575/15) of right eye shows large tumor mass associated 
with prelaminar optic nerve invasion (arrow), which was not suspected. Notice absence 
of bulk of tumor mass near the optic disc. (b) Histopathologic specimen depicts optic disc 
(O) invaded by retinoblastoma (R). (Hematoxylin-eosin stain; original magnification, 10 
objective.)
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figure 10. Bilateral retinoblastoma in 15-month-old girl. (a) Transverse T1-weighted MR 
image (375/14) of left eye obtained after gadolinium-based contrast agent administration 
shows retinoblastoma at posterior part of the eyeball with normal thickness of underlying 
optic nerve disc and linear enhancement pattern of choroidoretinal complex (arrow) and 
choroid. Both prelaminar and postlaminar tumor invasion of the optic nerve were not 
suspected. (b) Histopathologic specimen of optic nerve (O) revealed postlaminar tumor 
(R) invasion (arrow). (Hematoxylin-eosin stain; original magnification, 10 objective.)
figure 11. Unilateral retinoblastoma in 26-month-old girl. (a) Transverse gadolinium-
enhanced T1-weighted MR image (575/15) of left eye. Normal thickness of the optic disc 
is seen with linear enhancement pattern (arrow), a finding that was not suspicious for 
invasion of this structure. Enhancement of choroid (arrowheads) adjacent to the tumor 
does not indicate tumor infiltration. (b) Macroscopic histopathologic specimen shows 
retinoblastoma (R) and confirms absence of optic nerve (O) and choroidal (c) invasion. 
Retinal detachment ( ) is an artifact caused by histopathologic preparation. (Hematoxylin-
eosin stain; original magnification, 3.5 objective.)
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figure 12. Unilateral retinoblastoma in 17-month-old girl. 
Transverse gadolinium-enhanced T1-weighted MR image 
(575/15) of left eye. Temporal part of the eye shows enhancing 
retinoblastoma (hyperintense signal), combined with 
subretinal hemorrhage (temporal and nasal). Choroidoretinal 
complex shows linear enhancement pattern (arrowhead), 
which indicates absence of prelaminar invasion. Normal 
thickness of optic disc is seen. Histopathologic examination 
results confirmed these findings.
figure 13. Unilateral retinoblastoma in 14-month-old boy. (a) Transverse gadolinium-
enhanced T1-weighted fat-suppressed MR image (575/15) of eyes. Contrast between tumor 
and vitreous is diminished because of subretinal blood. Increased SI of the postlaminar optic 
nerve in continuity with tumor was suspicious for postlaminar tumor invasion (long arrow). 
Notice shallowness of anterior chamber combined with SI increase of the iris (short arrow). 
Rubeosis iridis was detected with ophthalmoscopic examination. Shallowness is probably 
related to presence of neovascular glaucoma combined with elevated intraocular pressure, 
which is an indication for enucleation without delay. (b) Transverse T2-weighted MR image 
(2200/120) shows total retinal detachment (black arrow) with subretinal hypointense 
tumor mass (white arrow). Characteristic blood-fluid level (arrowheads) indicates acute 
subretinal hemorrhage. (c) Histopathologic specimen shows retinoblastoma (R) with 
postlaminar optic nerve invasion, detachment of retina (arrowheads), and shallow anterior 
chamber (AC). Choroid (C) and sclera (S) were not invaded by tumor. (Hematoxylin-eosin 
stain; original magnification, 3.5 objective.) Optic nerve (O) is also involved. Inset: Detail 
of optic nerve shows postlaminar tumor invasion (arrows). (Original magnification, 10 
objective.)
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Sclera and orbit
Histopathologically, scleral and extrascleral tumor extension and orbital inflammation 
were not present in our study group. In all eyes, the sclera was seen on postcontrast 
T1-weighted MR images as a continuous hypointense zone around the enhancing 
choroid, without interruption by hyperintense enhancing retinoblastoma. Scleral and 
extrascleral tumor invasion were correctly excluded in all eyes (Table 2). 
Tumor volume and its Correlations
Mean primary tumor volume in 56 eyes was 1.33 cm3 (median, 1.30 cm3; range, 0.04–
2.88 cm3). In eight (14%) eyes, mean primary tumor volume was very small; in 20 (36%), 
it was small; in 19 (34%), it was medium; and in nine (16%), it was large. 
The number of eyes with prelaminar invasion increased with increasing tumor volume. 
Very small tumors showed 25% prelaminar invasion. Small, medium, and large tumors 
showed an invasion risk of 40%, 68%, and 78%, respectively. A significant association 
between tumor volume and prelaminar invasion was found (χ2 = 11.1, odds ratio = 5.5, 
P = .001) (Table 3). Location of tumor in the eye had no significant relationship with 
prelaminar tumor invasion risk. Risk of tumor extension into the choroid also increased 
with increasing tumor volume from 0% for very small tumors (<0.65 cm3), to 10% for 
small tumors, to 26% for medium tumors, and to 33% for tumors with a volume greater 
than 1.95 cm3. The association between tumor volume and choroidal invasion was 
significant (χ2 = 4.7, odds ratio = 3.7, P = .031) (Table 3). Furthermore, very small tumors 
did not invade the choroid, and in the group of small tumors, two eyes demonstrated 
some degree of invasion. These findings resulted in a 7% risk for choroidal invasion in 
tumors smaller than 1.30 cm3. Postlaminar invasion occurred in four eyes, and tumor 
volume was more than 0.65 cm3 in all of these eyes. Two (10%) eyes with postlaminar 
invasion were in the group of small tumors. In both the medium tumor group and the 
large tumor group, invasion was present in one eye. No significant association was 
found (P = .926, Fisher exact test), probably because of the small number of eyes with 
postlaminar invasion (Table 3).
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Table 3. Association between Tumor Volume in 56 Eyes and Histopathologic Variables
Very Small
( 0.65 cm3)
Small
(0.65–1.30 cm3)
Medium
(1.30–1.95 cm3)
Large 
(1.95 cm3)
Variable No. of Eyes (n = 8) (n = 20) (n = 19) (n = 9)
Choroidal invasion
    No 46 8 (100%) 18 (90%) 14 (74%) 6 (67%)
    Yes* 10 0 (0%) 2 (10%) 5 (26%) 3 (33%)
Prelaminar invasion 
    No 26 6 (75%) 12 (60%) 6 (32%) 2 (22%)
    Yes† 30 2 (25%) 8 (40%) 13 (68%) 7 (78%)
Postlaminar invasion
    No 52 8 (100%) 18 (90%) 18 (95%) 8 (89%)
    Yes ‡ 4 0 (0%) 2 (10%) 1 (5%) 1 (11%)
Note.—Data are numbers of eyes. Numbers in parentheses are percentages.
* For the data in this row, χ2 was 4.7; odds ratio, 3.7; and P value, .031 (logistic regression 
with log likelihood ratio χ2 test).
† For the data in this row, χ2 was 11.1; odds ratio, 5.5; and P value, .001 (logistic regression 
with log likelihood ratio χ2 test).
‡ P = .926 (Fisher exact test).
DISCUSSION
High-spatial-resolution MR imaging has become a very useful diagnostic tool 
for clinicians to rely on in evaluation of patients with retinoblastoma. Although 
ophthalmoscopy and US are of great value in the diagnosis of and the determination of 
the status of intraocular disease, MR imaging with high soft-tissue contrast resolution 
and multiplanar capabilities enables pretreatment intraocular and extraocular tumor 
staging with rather high diagnostic accuracy. 
In regard to retinoblastoma, the data about diagnostic accuracy of MR imaging in the 
staging of the extent of disease are scarce. To our knowledge, researchers in only 
two previous studies reported their results about the clinical value of MR imaging 
findings in comparison with histopathologic findings after enucleation (20,23) (Table 
4). In both studies, the number of patients included was relatively small. Barkhof 
et al (20) analyzed 18 patients with a 0.6-T MR imaging unit with thicker sections 
and no fat suppression. Schueler et al (23) compared preoperative MR images 
with histologic findings after enucleation in 21 cases. Because of the increase in 
spatial and contrast resolution, possibilities for the detection of smaller lesions of 
intraocular retinoblastoma appeared promising. Sensitivity and specificity in regard 
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to optic nerve invasion and sensitivity in the detection of choroidal invasion, however, 
were disappointing. Furthermore, no correlation between the degree of choroidal 
infiltration at histologic analysis and the appearance of this finding on MR images was 
present.
Table 4. Diagnostic Accuracy of MR Imaging for Retinoblastoma
Accuracy (%) Sensitivity (%) Specificity (%)
Variable Study 
1
Study 
2
Study
3
Study 
1
Study 
2
Study
3
Study 
1
Study
2
Study
3
Extraocular spread
Orbital fat 
invasion
94 
(17/18)
100 
(21/21)
100 
(58/58)
100 
(1/1)
0 
(0/0)
0
(0/0)
94 
(16/17)
100 
(21/21)
100 
(58/58)
Postlaminar 
invasion
89 
(16/18)
95 
(20/21)
97 
(56/58)
67 
(2/3)
0 
(0/1)
50 
(2/4)
93 
(14/15)
100
(20/20)
100 
(58/58)
Intraocular spread
Prelaminar 
invasion
56 
(10/18)
52 
(11/21)
79 
(46/58)
27 
(3/11)
75 
(6/8)
66 
(21/32)
100 
(7/7)
38 
(5/13)
96 
(25/26)
Choroidal 
invasion
67 
(12/18)
57 
(12/21)
72 
(42/58)
100 
(8/8)
35 
(5/14)
73 
(8/11)
40 
(4/10)
100
(7/7)
72 
(34/47)
Scleral 
invasion
83 
(15/18)
95 
(20/21)
100 
(58/58)
100 
(1/1)
0 
(0/0)
0
(0/0)
82 
(14/17)
95 
(20/21)
100 
(58/58)
Ciliary body 
invasion
67 
(12/18)
ND 83 
(48/58)
100 
(1/1)
ND 0
(0/0)
65 
(11/17)
ND 83 
(48/58)
Growth pattern
Endophytic ND ND 68 
(39/57)
ND ND 61 
(19/31)
ND ND 77 
(20/26)
Exophytic ND ND 68 
(39/57)
ND ND 76 
(25/33)
ND ND 58 
(14/24)
Clinical finding
Anterior 
chamber 
abnormality
ND ND 91
(52/57)
ND ND 100 
(15/15)
ND ND 88 
(37/42)
Retinal 
detach-
ment*
61 
(11/18)
ND 89 
(49/55)
50 
(7/14)
ND 89 
(34/38)
100 
(4/4)
ND 88 
(15/17)
Note.—Study 1 is that of Barkhof et al (20); study 2, that of Schueler et al (23); and study 3, 
that of de Graaf et al (present study).
See Table 2 for an explanation of the calculations that were used to derive the numerators 
in parentheses for study 3 data. For study 3 data, numbers in parentheses are those used 
to calculate the percentages. ND = no data.
* Barkhof et al compared MR imaging findings with histopathologic findings
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Vitreous seeding is an important factor in the staging of intraocular dissemination, 
and its presence decreases the possibility of conservative treatment methods. In our 
study, we observed an unusually high SI in the vitreous of the involved eye in some 
cases, but no statistically significant association with the presence of tumor seeding 
was found. Alterations of vitreous SI at MR imaging that are associated with neoplastic 
lesions are reported in the literature for choroidal melanoma (24) and retinoblastoma 
(20,25). Since seeding could not explain changes in vitreous signal, other processes 
must be responsible. 
High level of vascular endothelial growth factor, which is produced in hypoxic retinal 
and retinoblastoma cells (13), may mediate hypoxia-initiated tumor angiogenesis (26), 
and it increases fluid permeability from blood vessels (27). The elevated SI within the 
vitreous fluid was thought to be related to protein leakage into the vitreous, which 
shortens T1 and T2 relaxation times (28). 
Accuracy of MR imaging in the recognition of endophytic and exophytic growth 
patterns was not high in our study. Exophytic tumors are commonly detached, with 
a characteristic V-shaped configuration, subretinal fluid collections, and a typical 
hemispherical appearance. Accuracy of MR imaging in the detection of retinal 
detachment with accumulation of subretinal fluid is high, but the value of these 
attendant characteristics at MR imaging in the evaluation of tumor growth pattern 
is restricted, because retinal detachment and subretinal fluid occurred in tumors with 
both endophytic and exophytic growth patterns. 
The choroid, which is the enhancing inner layer of the bulbar wall between 
hypointense vitreous and sclera, can be infiltrated by tumor, and tumor infiltration 
causes replacement of normal structure. On postcontrast T1-weighted MR images, 
tumor infiltration may be seen as a local thickening of the choroid or a discontinuity in 
normal linear enhancement beneath the retinoblastoma. Involvement of the choroid 
increases the risk of metastatic disease because of its rich vascular network (8,9,12). 
Detection of choroidal invasion is sometimes hampered by the amount of retinal 
destruction. The entire replacement of retinal pigment epithelium by tumor hampers 
discrimination between enhancing choroid and enhancing tumor tissue. In all false-
positive MR imaging observations, no delineation of tumor tissue was possible, 
probably because of partial-volume effects. Histopathologic findings corresponded 
well with MR imaging findings. 
Inflammatory reaction of the choroid, secondary to retinoblastoma, appears to be 
responsible for effusion at the choroidal interstitium. Serous choroidal effusion is 
demonstrated as a ring-shaped area of high SI at MR imaging with all sequences (29). 
Accumulation of fluid with high protein content in the choroidal interstitium, as a 
result of inflammatory transudation from the choroidal vasculature in combination 
with inflammation hyperemia, may be responsible for SI increase on both T1- and 
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T2-weighted MR images. After gadolinium-based contrast agent administration, the 
ring-shaped configuration becomes clearer. Choroidal inflammation combined with a 
granuloma in the optic nerve head may lead to an erroneous diagnosis, because the 
contrast enhancement pattern may mimic optic nerve invasion. 
Detection of ciliary body invasion by retinoblastoma caused similar problems, with 
false-positive findings as a consequence. Discrimination between tumor and ciliary 
body was not reliable because of partial-volume effects and lack of spatial resolution. 
Involvement of the ciliary body, as part of the anterior uveal tract, could also be 
associated with an increased risk for hematogenous dissemination and should be 
considered as an indication for enucleation without delay. 
Neovascularization in combination with protein leakage from vessels possibly 
causes increased SI of the anterior chamber. The presence of rubeosis iridis (iris 
neovascularization) is strongly correlated to the presence of choroidal and prelaminar 
invasion, and the presence of rubeosis iridis makes enucleation the only therapeutic 
option (12,13). Marked enhancement on postcontrast T1-weighted MR images of the 
anterior chamber may represent a vascular reaction to intraocular ischemia, although 
in five patients no clinical explanation was found for local SI increase. A differentiation 
between reactive hyperemia and rubeosis iridis was not possible at MR imaging. SI 
elevation in the anterior chamber could provide clinicians complementary information 
in estimation of the risk of metastatic disease. 
Optic nerve invasion, especially to the postlaminar degree, represents a sign of tumor 
aggressiveness and is associated with a significant increase of metastatic disease and 
mortality rate (3,8–11). With use of gadolinium-based contrast agents for contrast 
enhancement, tumor invasion of the optic nerve can reliably be determined by 
observation of interruption of linear enhancement at the choroidoretinal complex. 
Accuracy in detection of SI changes at the prelaminar optic disc is rather high, and this 
criterion seems very specific for tumor invasion. Sensitivity remains low, because MR 
imaging is not able to depict microscopic invasion. In some cases, even substantial 
prelaminar invasion was missed because of unimpaired linear enhancement. The 
volume of the tumor appears to be the best predictor for optic nerve invasion. 
Thickening of the intact enhancing choroidoretinal complex also proved to be 
predictive. Enhancement confined to a tumor that involves the optic disc and interrupts 
linear enhancement of the choroidoretinal complex is very specific for tumor invasion 
of the prelaminar optic nerve, but in the absence of this sign, microscopic invasion 
cannot be excluded, whereas other signs may also predict prelaminar optic nerve 
invasion. 
Sensitivity of MR imaging in the detection of postlaminar optic nerve invasion was also 
low and, again, specificity was high. Enhancement extending from the tumor into the 
optic nerve is a confident sign of postlaminar invasion, but absence of enhancement 
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does not always exclude the presence of postlaminar optic nerve involvement. The 
diagnostic accuracy for postlaminar tumor invasion seems high, but data may be 
inaccurate because of the small number of patients. 
Scleral invasion and extraocular dissemination were not present in our patients. 
Although exclusion of this form of tumor invasion was histopathologically proved in 
all eyes, the clinical value of these results remains unknown, because the sensitivity 
of MR imaging is probably not high enough to detect microscopic and small areas of 
scleral and extrascleral tumor extension. 
In recent years, the role for nonoperative treatment modalities has increased and 
chemoreduction therapy, combined with focal treatment modalities, has been 
introduced (30). In consequence of this trend, more children are treated without 
proper histopathologic assessment of risk factors for metastasis. Several studies 
focused on clinical features that may be used to predict the presence of metastatic 
disease and extraocular recurrence (3,8,11,12,31). 
We found a strong association between increase in tumor volume and risk of 
prelaminar optic nerve invasion (P = .001). Location of the tumor in the eye, however, 
was not significantly related to the risk of optic nerve invasion. Some peripheral 
tumors were accompanied by prelaminar optic nerve invasion, possibly because of 
the simultaneous presence of vitreous seeding. Frequent appearance of vitreous or 
subretinal tumor seeding and a continuous fluid flow from the vitreous into the optic 
nerve is suggested by Wolter (32), thus explaining the selective motion of free-floating 
retinoblastoma cells toward the optic nerve head. Postlaminar optic nerve invasion 
did not show a significant relationship with tumor volume, but the value of this finding 
is limited because of the small number of eyes with postlaminar optic nerve invasion. 
Although in a previous report clinical tumor diameter and tumor thickness were 
not predictive of choroidal invasion (12), our study showed a significant association 
between tumor volume and choroidal invasion (P = .031). Absence of choroidal invasion 
under very small tumors could be related to the unique resistance to tumor invasion 
demonstrated by the retinal pigment epithelial layer and the Bruch membrane (33). 
This study had limitations. It was a retrospective study, and one experienced radiologist 
performed image analysis. Our MR imaging technique, with use of a standard head 
coil for evaluation, was limited. Use of orbital surface coils, which provide an increase 
in spatial resolution and in image contrast and a reduction in artifacts, may improve 
sensitivity and specificity. Some of the MR imaging studies were performed without 
fat suppression after gadolinium-based contrast agent administration, which limits 
evaluation of tumor invasion into orbital fat. Furthermore, improvement of study 
results could also be realized by future use of gadolinium-enhanced three-dimensional 
gradient-echo sequences instead of spin-echo techniques. 
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In conclusion, the results of this study suggest that modern MR imaging is more 
sensitive and more specific in tumor staging and determination of metastatic risk 
factors compared with the results documented in previous reports. Detection of 
intraocular tumor infiltration remains difficult, however, because spatial resolution 
and signal-to-noise ratio are still not high enough to reduce false-positive and false-
negative observations. Tumor volume, as measured with MR imaging, was predictive 
of prelaminar optic nerve infiltration and choroidal involvement.
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INTRODUCTION
Neoadjuvant chemotherapy is useful in the management of extensive forms of 
retinoblastoma with radiologically detectable optic nerve invasion at diagnosis (1). 
Magnetic resonance imaging (MRI) can detect various degrees of optic nerve invasion 
as enhancement extending from an intraocular tumour into the optic nerve. However, 
pretreatment false positive MRI findings based on inflammation occur occasionally 
(2). We describe a case of unilateral retinoblastoma and false positive MRI findings of 
extensive optic nerve involvement.
CASe RePoRT
A 3 year old girl presented with retinoblastoma of the right eye. Ophthalmic 
examination revealed a large exophytic growing tumour, a shallow anterior chamber, 
rubeosis iridis, and an elevated intraocular pressure. T2WI showed a hypointense 
subretinal tumour mass with similar signal intensity (SI) compared to both optic nerves 
(Fig 1a ). No delineation of the ipsilateral optic nerve with surrounding cerebrospinal 
fluid was possible. On additional short tau inversion recovery (STIR) MRI, the optic 
nerve showed an increased SI from the postlaminar part to the orbital apex. Contrast 
enhanced T1WI showed enhancement of the tumour mass (tumour volume 2.1 cm3). 
Thickening and marked enhancement of the entire intraorbital part of the optic nerve 
was seen, being suspicious for extensive tumour invasion (Fig 1b ). Based on these 
findings, retinoblastoma with extensive optic nerve invasion was diagnosed, and one 
course of etoposide-carboplatin chemotherapy was administered. Follow up MRI 
(Fig 2 ), 4 weeks after admission, disclosed a tumour mass reduction (tumour volume 
0.5 cm3, 77% volume reduction), a decrease in range of contrast enhancement of the 
optic nerve, without evident normalisation of signal pattern on T2WI and STIRWI. 
Enucleation was performed using an altered surgical approach by the neurosurgeon 
and ophthalmologist, which allowed 15 mm of optic nerve to be removed under 
direct vision. Histopathology revealed a largely necrotic intraocular retinoblastoma, 
without any degree of optic nerve invasion. Normal architecture of the optic nerve 
was only disturbed at the lamina cribrosa, with local presence of reactive gliosis, but 
without any presence of residual necrotic tumour cells. Immunohistochemistry stains 
for MIB-1 and CD-45 revealed no tumour cells, but did show a lymphocytic infiltrate 
throughout the optic nerve (Fig 2c). The dura showed no thickening or inflammation. 
A second uncommon histopathological finding in the optic nerve was endothelial cell 
proliferation and swelling, with total obliteration of some vessels as a consequence 
(Fig 2d).
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figure 1. A 3 year old girl with unilateral retinoblastoma of the right eye. MRI findings on 
asmission. (A) Axial T2WI (TR/TE, 3000/120) shows an exophytic growing tumour mass 
conbines with a V-shaped retinal detachment and hyperintense (proteinaceous) subretinal 
Auid. Compared to the normal optic nerve, the affected site shows absence of cerebrospinal 
fluid in the optic nerve sheath. (B) Contrast enhances axial fat suppressed T1WI (TR/TE, 
575/13) (level corresponding (A)) shows an enhancing tumour mass of the right eye with 
marked enhancement and tthickening of the intraorbital part of the optic nerve (arrows), 
in continuity with the intraocular mass, being suspicious for extensive tumour invasion.
figure 2. Follow up MRI study and histopathological findings after one course of 
chemoreduction therapy performed 4 weeks after initial presentation. Axial T2WI (TR/
TE, 2200/120) (A) and contrast enhanced axial fat suppressed T1WI (TR/TE, 475/14) 
(B) show a mrked reduction in intraocular tumour volume. The optic nerve shows 
persisting abnormalities on T2WI (A), with a decrease of enlargement and contrast 
enhancement (arrow), which was interpreted as residual optic nerce invasion (B). (C) 
Immunohistochemical staining with CD-45 antibodies for lymphocytes objective) (D) 
Detail of the optic nerve shows endothelial proliferation in a vessel wall (arrows) with 
total abliteration of the lumen. (Haematoxylin and eosin stain; original magnification 40x 
objective).
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DISCUSSION
The combination of inflammation and endothelial proliferation in our patient, which 
are thought to be responsible for at least the residual optic nerve enhancement 
after neoadjuvant chemotherapy, have never been described before as a possible 
cause of (post-treatment) false positive MRI. However, a striking discrepancy 
between pretreatment radiologically detectable extensive optic nerve invasion and 
post-treatment histopathology, without any remaining signs of a former minimal 
or extensive post-laminar invasion is left unsolved. Histopathological findings in 
eyes after multiple courses of chemoreduction therapy for retinoblastoma are well 
documented and consist mainly of viable and necrotic tumour cells and gliosis, 
without presence of inflammation or endothelial proliferation (3,4). The latter occurs 
characteristically in brain tissue and is associated with contrast enhancement in 
brain tumours (5). Only Bellaton et al (1) published three cases with a comparable 
discrepancy of extensive optic nerve invasion on pretreatment MRI without any 
remaining histopathological signs of former extensive tumour invasion after two or 
three courses of chemotherapy, although a slight residual enhancement is reported in 
at least one patient. Unfortunately, they did not mention a possible histopathological 
substrate for (residual) enhancement. In conclusion, optic nerve enhancement on 
MRI is an indicator for tumour invasion, but it must be taken into consideration that 
other histopathological changes (inflammation, endothelial proliferation) can occur 
in combination with retinoblastoma and may mimic (residual) tumour invasion, also 
after neoadjuvant chemotherapy.
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AbSTRACT
background and purpose. Although pineoblastoma is the main brain 
abnormality associated with hereditary retinoblastoma, recent studies suggest 
an association with pineal cysts. This association is important because some 
pineoblastomas mimic pineal cysts. If there is a relationship, then radiologists 
should be aware of it because diagnostic confusion is possible. Mental 
retardation and congenital brain anomalies are also reported in patients with 
retinoblastoma, mostly in combination with 13q deletion syndrome. In this 
retrospective study, the presence of brain abnormalities on MR images in a 
large group of consecutive patients with retinoblastoma is evaluated. 
Materials and Methods. Brain MR images of 168 patients with retinoblastoma 
from 1989 to 2009 were evaluated by 2 radiologists for tumors, structural 
anomalies, myelinization, and coincidental findings. Clinical records were 
reviewed for laterality, heredity, and the presence of the 13q deletion syndrome. 
Results. The hereditary group (patients with bilateral and unilateral proved 
RB1-germline mutation) included 90 (54%) of 168 patients. Seven patients 
had 13q deletion syndrome. Normal findings on brain MR images were seen 
in 150 (89%) patients. Five pineoblastomas were detected, all in patients with 
hereditary retinoblastoma (5.5% in the hereditary subgroup). Nine pineal cysts 
were detected (2.2% in the hereditary subgroup). Corpus callosum agenesis was 
found in 1 patient and a Dandy-Walker variant in 1 patient, both in combination 
with 13q deletion syndrome. 
Conclusions. Pineoblastoma is associated with hereditary retinoblastoma, and 
structural brain abnormalities are restricted to patients with the 13q deletion 
syndrome. The incidence of pineal cysts in patients with retinoblastomas 
is similar to that in healthy children and is not associated with hereditary 
retinoblastoma.
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INTRODUCTION
Retinoblastoma is the most common intraocular tumor in early childhood, occurring 
in 1/17,000 live births (1). Retinoblastoma cells contain a mutation or deletion of the 
retinoblastoma gene (RB1 gene), a tumor-suppressor gene, located on chromosome 
13q14 (2,3). Approximately 40% of patients with retinoblastoma have hereditary disease 
(mostly bilateral tumors), while the remainder (60%) have unilateral nonhereditary 
disease. A minority is due to a cytogenetically detectable interstitial deletion of 
variable size with a minimal overlapping region in band 13q14 (4). It is reported that 
midline intracranial neuroblastic tumors of either the suprasellar or the pineal region 
(pineoblastoma) are present in approximately 5%–15% of patients with hereditary 
retinoblastoma (5).
Besides midline malignant tumors, benign intracranial abnormalities are also reported 
in the retinoblastoma population, in particular the presence of pineal cysts. In 
the literature, an association between hereditary retinoblastoma and pineal cysts 
is suggested. Popovic et al (6) reported an incidence of pineal lesions (cysts and 
pineoblastoma) of 6.4% in their retinoblastoma population. All pineal lesions were 
present in the bilaterally affected hereditary patients. In this subgroup, they found 
an equal incidence of 5.3% for both pineal cysts and pineoblastoma. The combination 
of retinoblastoma, suprasellar tumor, and pineal cystis is also reported, which, 
according to Popovic et al,(7) further adds to a possible relationship between 
hereditary retinoblastoma and pineal lesions. Karatza et al.(8) reported 11 patients 
with retinoblastoma with pineal cysts simulating pineoblastoma. They recommended 
that clinicians should be aware of the presence of this benign lesion when performing 
routine neuroimaging, especially in patients with bilateral disease. 
However, pineal cysts are quite common in the general population. In postmortem 
cases, pineal cysts are encountered in 25%–40% of people of all ages (9,10). In 
recent literature, an incidence of 0.4%–2.2% on MR images in the general pediatric 
population between 0 and 5 years of age has been reported (11). It is already known 
that pineoblastoma is associated with retinoblastoma. If the same is true for pineal 
cysts, then radiologists should be aware of the association. Distinct imaging criteria 
in distinguishing pineoblastomas from pineal cysts should be evaluated to avoid 
diagnostic and therapeutic confusion. 
Retinoblastoma may occur in the presence of 13q deletion syndrome. The risk of 
retinoblastoma development in patients with this syndrome is approximately 80% (3,4) 
Besides retinoblastoma, this syndrome has a spectrum of clinical features, including 
moderate-to-severe developmental delay. Baud et al (4) reported a variable degree 
of mental retardation in patients with retinoblastoma with associated 13q cytogenic 
abnormalities. Only in case reports, describing patients with 13q deletion syndrome 
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or in combination with retinoblastoma, are congenital brain abnormalities or brain 
disorders indicative of cognitive symptoms reported (4,7,12–24). Ballarati et al.(25) 
reported central nervous system anomalies such as Dandy-Walker malformation, 
cerebellar hypoplasia, cortical dysplasia, and agenesis of the corpus callosum in 
patients with 13q deletion. Although one can assume that these symptoms are due 
to 13q deletion syndrome, it is interesting to evaluate whether (structural) brain 
abnormalities are involved in patients with retinoblastoma. To our knowledge, no 
large correlative study has been performed on the presence of retinoblastoma and 
brain abnormalities on MR imaging. The purpose of this retrospective study was 
to evaluate the presence of brain abnormalities on MR images in a large group of 
consecutive patients with retinoblastoma. 
MATeRiALS AND MeTHoDS
Patients
Patients eligible for this retrospective study were those at our institution with 
retinoblastoma who had undergone MR imaging of the brain that enabled adequate 
image interpretation between 1989 and 2009. To avoid alteration in the brain due 
to aging, we only evaluated patients younger than 5 years of age. The diagnosis of 
retinoblastoma was confirmed in all patients with extensive funduscopy, sonography, 
and MR imaging. In case of enucleation, the diagnosis was confirmed by histopathology. 
In this period, we identified 245 patients with retinoblastoma, and all patients had 
undergone MR imaging. However, in 77 patients, brain imaging studies were absent 
or incomplete and, therefore, excluded. The total number of included patients was 
168. The need for informed consent was waived because of the retrospective nature 
of the study. Clinical records were reviewed by 1 reviewer for the patient’s sex, age at 
first MR imaging, laterality, heredity, and the presence of 13q deletion syndrome. In 
patients with brain abnormalities, the evaluation of pre- or posttreatment MR imaging 
had to exclude treatment-induced brain abnormalities. 
Patients with bilateral disease or a positive family history of retinoblastoma or a 
defect in the RB1 gene found in chromosomal/deoxyribonucleic acid analysis were 
classified as having hereditary disease. All other patients were classified as having 
nonhereditary disease (1). 
MR imaging
MR imaging was performed at 1T (Magnetom Impact Expert; Siemens, Erlangen, 
Germany) and 1.5T (Magnetom Vision and Sonata, Siemens). Within the past 20 years, 
MR imaging protocols for retinoblastoma have changed. In the beginning, whole-
brain MR imaging sequences were more common in retinoblastoma MR imaging 
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protocols in combination with a standard-quadrature head coil. Due to technologic 
developments and improved coil design, attention shifted to small-FOV imaging of the 
orbits by using surface coils. MR imaging protocols did not differ between unilaterally 
and bilaterally affected patients. Postcontrast axial T1-weighted MR images covering 
the whole brain were available in all included patients. In only 48 of 168 patients were 
axial T2-weighted MR images of the brain available. 
image Analysis
MR imaging examinations were individually reviewed by 2 radiologists with, 
respectively, 4 and 9 years of experience in pediatric neuroradiology. Disagreement 
was resolved by consensus. The parameters evaluated on MR imaging were selected 
on the basis of literature study (4,7,12–24) and were divided into the following 
categories: benign or malignant tumor (tumor of the pineal gland, pineal cyst, 
or other); structural anomalies (corpus callosum agenesis, holoprosencephaly, 
encephalocele, Dandy-Walker malformation or a variant, hypoplasia of the basic 
pontis, microcephaly and polymicrogyria, or other); and degree of myelinization, 
ventriculomegaly, or coincidental findings. Special attention was paid to myelinization 
to clarify possible cognitive symptoms. The diagnosis of a pineal tumor was made if 
the pineal gland was enlarged, solid, and isointense to gray matter on T1-weighted 
images with homogeneous and intense contrast enhancement.6 A pineal cyst was 
diagnosed if the pineal gland was enlarged and had a central region hypointense 
with respect to white matter on T1-weighted images and isointense with respect to 
CSF on T2-weighted images and a thin wall of 2 mm with discrete rim enhancement 
after gadolinium injection.6 The diameters of pineal cysts and pineoblastomas were 
measured. 
RESULTS
Clinical findings
The mean age at first MR imaging of the 168 patients was 17 months (range, 0–59 
months). Bilateral retinoblastoma was present in 78 patients (46%) and unilateral 
disease in 90 patients (54%). Seventy-nine patients with retinoblastoma were female 
(47%) (41 bilateral, 38 unilateral) and 89 (53%) were male (36 bilateral, 53 unilateral). 
The hereditary group consisted of 90 patients and the nonhereditary group of 78 
patients. Seven hereditary patients (8%) were diagnosed with 13q deletion syndrome. 
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MR imaging findings
Brain MR imaging showed no abnormalities in 150 (89%) patients. Brain abnormalities 
were found in 18 patients (11%), with the pineal gland as the most commonly affected 
site (14 patients, 78%) (Table). Pineoblastoma was found in 5 patients at a mean age 
of 20 months (range, 1–39 months), all with hereditary retinoblastoma (3.0% overall 
incidence, and 5.5% in the hereditary group). The mean interval between diagnosis 
of ocular and intracranial tumor was 16.4 months. In 1 patient (10 months of age), 
the pineoblastoma was detected with the diagnosis of retinoblastoma (synchronous 
tumors). In the other 4 patients, the pineoblastoma was discovered at a later stage; 6, 
15, 25, and 37 months after the diagnosis of retinoblastoma (metachronous tumors). 
In patients 6, 8, and 9, the tumor presented as a solid mass isointense with respect to 
gray matter on precontrast T1-weighted images and showed a homogeneous intense 
contrast enhancement in the pineal region (diameters respectively, 55, 16, and 49 mm) 
(Table). In patients 5 and 7, the tumor consisted of a heterogeneous mass with intense 
contrast enhancement and areas with low signal intensity on T1-weighted images 
and high signal intensity on T2-weighted images, suspicious for central necrosis. In 
patient 5, the configuration of the lesion mimicked a pineal cyst (Fig 1). On axial images 
however, the diagnosis of pineoblastoma was more evident because there was an 
asymmetric nodular thickening of the enhancing wall. The thickness of the enhancing 
wall varied from 3 to 7 mm. Histopathology revealed a pineoblastoma with central 
necrosis.
The total incidence of pineal cysts in our study was 5.4% (9 patients), with an incidence 
of 9.0% in the nonhereditary group (7 patients; mean age, 20 months; range, 10–34 
months) and 2.2% in the hereditary group (2 patients; mean age, 9 months; range, 
9–10 months) (Fig 2). The mean size of the cysts in the nonhereditary group was 4.8 
mm (range, 3–7 mm) and 4 mm in the hereditary group (range, 3–5 mm). In 2 patients, 
follow-up MR imaging was available and showed no change in the pineal cysts.
Besides pineoblastoma and pineal cysts, a diversity of brain abnormalities was found. 
Corpus callosum agenesis occurred in 1 patient with hereditary retinoblastoma 
(Fig 3), and in another patient, a hereditary Dandy-Walker variant occurred. Both 
were known to have a 13q deletion syndrome. In the other 5 patients (71%) with 13q 
deletion syndrome, no brain abnormalities were present. One patient with hereditary 
retinoblastoma showed DV. 
Evaluation of white matter abnormalities was only possible in 48 patients because of 
incomplete series of T2-weighted images of the brain in 120 patients. In this subgroup, 
no white matter abnormalities were observed and all patients with retinoblastoma 
showed normal myelinization. 
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Table 1. MR imaging findings in retinoblastoma patients
Patient No./
Age (Mo)/Sex Heredity Pre-t. MRI MRI findings (side) Size (mm)
1/1/ M Yes Yes DV (temporal and atrium)
2/13/M Yes Yes Dandy-Walker variant with DV
3/4/F Yes Yes CCA (corpus/splenium),
vermis hypoplasia, DV
4/10/M Yes Yes Trignocephalia, DV
5/10/M Yes Yes Pineoblastoma 15
6/39/F Yes Yes Pineoblastoma 55
7/5/F Yes Yes Pineoblastoma 59
8/1/M Yes Yes Pineoblastoma 16
9/37/F Yes Yes Pineoblastoma 49
10/34/M No Yes Pineal cyst 7
11/16/F No Yes Pineal cyst 6
12/31/M No Yes Pineal cyst 6
13/15/F Yes Yes Pineal cyst 5
14/0/F No Yes Pineal cyst 4
15/23/F No Yes Pineal cyst 3
16/9/F Yes Yes Pineal cyst 3
17/10/M No Yes Pineal cyst 4
18/18/M No Yes Pineal cyst 3
Pre-t MRI pre-treatment MRI, DV dilated ventricles, CCA corpus callosum agenesis
fig 1. Patient 5, a 10-month-old with hereditary retinoblastoma and pineoblastoma. A, 
Sagittal T1-weighted postgadolinium MR image shows a cystic mass in the pineal gland. B, 
Axial T1-weighted image shows an asymmetric nodular thickening of the tumor wall. The 
thickness of the enhancing wall varies from 3 to 7 mm, suspicious for pineoblastoma.
evident because there was an asymmetric nodular thickening
of the enhancing wall. The thickness of the enhancing wall
varied from 3 to 7 mm. Histopathology revealed a pineoblas-
toma with central necrosis.
The total incidence of pineal cysts in our study was 5.4%
(9 patients), with an incidence of 9.0% in the nonhereditary
group (7 patients; mean age, 20 months; range, 10–34
months) and 2.2% in the hereditary group (2 patients; mean
age, 9 months; range, 9–10 months) (Fig 2). The mean size of
the cysts in the nonhereditary group was 4.8 mm (range, 3–7
mm) and 4mm in the hereditary group (range, 3–5mm). In 2
patients, follow-up MR imaging was available and showed no
change in the pineal cysts.
Besides pineoblastoma and pineal cysts, a diversity of brain
abnormalities was found. Corpus callosum agenesis occurred
in 1 patient with hereditary retinoblastoma (Fig 3), and in
another patient, a hereditary Dandy-Walker variant occurred.
Both were known to have a 13q deletion syndrome. In the
other 5 patients (71%) with 13q deletion syndrome, no brain
abnormalities were present. One patient with hereditary reti-
noblastoma showed DV.
Evaluation of whitematter abnormalities was only possible
in 48 patients because of incomplete series of T2-weighted
images of the brain in 120 patients. In this subgroup, no white
matter abnormalities were observed and all patients with ret-
inoblastoma showed normal myelinization.
Discussion
In this study, we present an overview of brain abnormalities in
a large group of patients with retinoblastoma.
Pineoblastoma is themost well-known brain pathology as-
sociated with retinoblastoma, a combination known as trilat-
eral retinoblastoma, occurring in 1.5%–5% of all patients and
in 5%–15% in the hereditary subgroup.5,22 Besides the pineal
region, tumors may also occur in the suprasellar or parasellar
region. Our study showed similar results, with an incidence of
3.0% in the whole study group and 5.5% concerning only the
hereditary group.
Three of 5 pineoblastomas showed a typical imaging pat-
tern: a solid homogeneous lobulated enlarged pineal gland,
isointense with gray matter on T1-weighted images with in-
tense homogeneous contrast-enhancement. In the other 2
MR imaging findings in patients with retinoblastoma
Patient No./
Age (Mo)/Sex Heredity Pre-t. MRI MRI Findings (Side) Size (mm)
1/1/M Yes Yes DV (temporal and atrium)
2/13/M Yes Yes Dandy-Walker variant with DV
3/4/F Yes Yes CCA (corpus/splenium), vermis hypoplasia, DV
4/10/M Yes Yes Trigonocephalia, DV
5/10/M Yes Yes Pineoblastoma 15
6/39/F Yes Yes Pineoblastoma 55
7/5/F Yes Yes Pineoblastoma 59
8/1/M Yes Yes Pineoblastoma 16
9/37/F Yes Yes Pineoblastoma 49
10/34/M No Yes Pineal cyst 7
11/16/F No Yes Pineal cyst 6
12/31/M No Yes Pineal cyst 6
13/15/F Yes Yes Pineal cyst 5
14/10/F No Yes Pineal cyst 4
15/23/F No Yes Pineal cyst 3
16/9/F Yes Yes Pineal cyst 3
17/10/M No Yes Pineal cyst 4
18/18/M No Yes Pineal cyst 3
Fig 1. Patient 5, a 10-month-old with hereditary retinoblastoma and pineoblastoma. A, Sagittal T1-weighted postgadolinium MR image shows a cystic mass in the pineal gland. B, Axial
T1-weighted image shows an asymmetric nodular thickening of the tumor wall. The thickness of the enhancing wall varies from 3 to 7 mm, suspicious for pineoblastoma.
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matter abnormalities were observed and all patients with ret-
inoblastoma showed normal myelinization.
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eral retinoblastoma, occurring in 1.5%–5% of all patients and
in 5%–15% in the hereditary subgroup.5,22 Besides the pineal
region, tumors may also occur in the suprasellar or parasellar
region. Our study showed similar results, with an incidence of
3.0% in the whole study group and 5.5% concerni only the
heredit ry group.
Three of 5 pineoblastomas showed a typical imaging pat-
tern: a solid homogeneous lobulated enlarged pineal gland,
isointense with gray matter on T1-weighted images with in-
tense homogeneous contrast-enhancement. In the other 2
MR imaging findings in patients with retinoblastoma
Patient No./
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Fig 1. Patient 5, a 10-month-old with hereditary retinoblastoma and pineoblastoma. A, Sagittal T1-weighted postgadoliniu R image shows a cystic mass in the pineal gland. B, Axial
T1-weighted image shows an asymmetric nodular thickening of the tumor wall. The thickness of the enhancing wall varies from 3 to 7 mm, suspicious for pineoblastoma.
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DISCUSSION
In this study, we present an overview of brain abnormalities in a large group of 
patients with retinoblastoma. Pineoblastoma is the most well-known brain pathology 
associated with retinoblastoma, a combination known as trilateral retinoblastoma, 
occurring in 1.5%–5% of all patients and in 5%–15% in the hereditary subgroup (5,22). 
Besides the pineal region, tumors may also occur in the suprasellar or parasellar 
region. Our study showed similar results, with an incidence of 3.0% in the whole study 
group and 5.5% concerning only the hereditary group.
Three of 5 pineoblastomas showed a typical imaging pattern: a solid homogeneous 
lobulated enlarged pineal gland, isointense with gray matter on T1-weighted images 
with intense homogeneous contrast-enhancement. In the other 2 pineoblastomas, 
low signal intensity on T1-weighted images and high signal intensity on T2-weighted 
images with heterogeneous enhancement areas were present. One pineoblastoma 
even mimicked a pineal cyst due to a large central area of histopathologically proved 
necrosis. The thickness of this cyst wall (7 mm), however, did not correspond with 
the criteria of pineal cyst (thickness, 2 mm). This finding can cause confusion in the 
diagnosis of pineoblastoma, and it could have been erroneously diagnosed as a pineal 
cyst, with severe clinical consequences (8). This has been reported only once before. 
Sugiyama et al.(26) reported a case of a pineoblastoma with a large central cyst, 
histopathologically due to central necrosis. In our patient, the pineoblastoma was 
discovered in an early stage synchronously with the intraocular tumor on baseline MR 
imaging without clinical symptoms due to pineoblastoma. 
pineoblastomas, low signal intensity on T1-weighted images
and high signal intensity on T2-weighted images with hetero-
geneous enhancement areas were present. One pineoblastoma
even mimick d a pineal cyst due to a large central re of
histopathologically proved necrosis. The thickness of this cyst
wall (7 mm), however, did not correspond with the criteria of
pineal cyst (thickness,2mm). This finding can cause confu-
sion in the dia osis of pineoblastoma, and it could have been
erroneously diagnosed as a pineal cyst, with severe clinical
consequences.8 This has been reported only once before. Sug-
iyama et al26 reported a case of a pineoblastoma with a large
central cyst, histopat logically due to central necrosis. In our
patient, the pineoblastoma was discovered in an early stage
synchronouslywith the intraocular tumor on baselineMR im-
aging without clinical symptoms due to pineoblastoma.
Central necrosis can be present in large and small pine-
oblastomas, and especially small pineoblastomas with central
necrosis can mimic a pineal cyst. In our experience, the thick-
ness and appearance of the cyst wall before and after contrast
administration on MR imaging are indeed important to dif-
ferentiate a pineal cyst and pineoblastoma. Pineal cysts show a
thin wall (2 mm) with discrete enhancement, whereas pine-
oblastomas with central necrosis show a nodular thickened
wall with homogeneous wall enhancement.
In our screening for brain abnormalities in 168 patients
with retinoblastoma, pineal cysts were detected in 5.4% of the
patients. Sener10 performed a review of MR imaging in 500
children and 500 adults and found no pineal cysts in children
younger than 12 years of age. The sensitivity of this study,
however, could have been limited by using 0.5T MR imaging
in evaluation. Sawamura et al27 found 79 cysts in 6023 patients
but none in children younger than 10 years of age. However,
only MR images in 73 children of 10 years of age and younger
were evaluated.
The study of Al-Holou et al11 was the only one in which the
incidence of pineal cysts on MR imaging was examined in
healthy children younger than 5 years of age. They reported an
incidence of 2.0%, almost similar to that in our hereditary
group. In this study, the pineal cyst population was compared
with an age- and sex-matched control population. Popovic
et al6,7 also reported almost the same incidence as in our over-
all study group (5.3%). They found cysts in patients with bi-
lateral hereditary retinoblastoma, but no pineal cysts in the
patients with nonhereditary retinoblastoma. These previously
mentioned studies included only pineal cysts of 5 mm. In
our study of patientswith retinoblastoma younger than 5 years
of age, 5 of the 9 cysts were5 mm (4 of the 5 pineal cysts in
the onhereditary group).
A follow-up study in a matched control group would be
necessary to examine the high incidence of pineal cysts in the
patients with nonhereditary compared with hereditary retino-
blastoma with t same criteria used in our study. In previous
studies, only Karatza et al8 reported the occurrence of pineal
cysts in patients with nonhereditary retinoblastoma. They re-
viewed 1400 medical records of patients with retinoblastoma
and f nd 3 pineal cysts (0.2%) in patients with unilateral and
8 pineal cysts (0.6%) in patients with bilateral retinoblastoma.
These low incidences are probably due to screening for pineal
cysts in medical records instead of re-evaluation of MR im-
ages. In our experience, these cysts are not always described in
medical records as a finding. However, for assessing the asso-
ciation between retinoblastoma and pineal cysts, the incidence
of pineal cysts in the hereditary group is interesting. Given the
incidence of 2.2% in the hereditary group, which is similar to
the incidence in the healthy population,11 there is no associa-
tion between hereditary retinoblastoma and pineal cysts. Al-
though it is important to be aware of pineoblastomasmimick-
ing a pineal cyst, there is no evidence that pineal cysts occur
more often in patients with retinoblastoma comparedwith the
healthy pediatric population.
In our study group, larger structural brain abnormalities
occurred only in combination with a 13q deletion syndrome.
One patient with 13q deleti n syndrome had a corpus callo-
sum agenesis and another patient showed a Dandy-Walker
variant with DV. This brain abnormality is also described in
previous case reports. Alanay et al28 reported a patient with a
thin corpus callosum and a Dandy-Walker malformation.
Conclusions
In conclusion, pineoblastoma is associated with hereditary
retinoblastoma, and structural brain abnormalities are re-
stricted to the patients with 13q deletion syndrome. The inci-
Fig 2. Patient 10. Contrast-enhanced T1-weighted MR image of a 34-month-old patient
with nonhereditary retinoblastoma with a pineal cyst, with a diameter of 7 mm.
Fig 3. Patient 3. Sagittal T1-weighted image of a 4-month-old with 13q deletion syndrome
and bilateral retinoblastoma shows agenesis of the splenium of the corpus callosum.
1388 Rodjan  AJNR 31  Sep 2010  www.ajnr.org
pineoblastomas, low signal intensity on T1-weighted images
and high signal intensity on T2-weighted images with hetero-
geneous enhancement areas were present. One pineoblastoma
even mimicked a pineal cyst due to a large central area of
histopathologically proved necrosis. The thickness of this cyst
wall (7 mm), however, did not correspond with the criteria of
pineal cyst (thickness,2mm). This finding can cause confu-
sion in the diagnosis of pineoblastoma, and it could have been
erroneously diagnosed as a pineal cyst, with severe clinical
consequences.8 This has been reported o ly once before. Sug-
iyama et al26 reported a case of a pineoblastoma with a large
central cyst, histopathologically due to central necrosis. In our
patient, the pineoblastoma was discov red in an early stage
synchronouslywith the intraocular tumor on baselineMR im-
aging without clinical symptoms due to pineoblastoma.
Central necrosis can be present in large and small pine-
oblastomas, and especially small pine blastomas with central
necrosis can mimic a pineal cyst. In our experience, the thick-
ness and appearance of the cyst wall before and after contrast
administration on MR imaging are indeed important to dif-
ferentiate a pineal cyst and pineoblastoma. Pineal cysts show a
thin wall (2 mm) with discrete enhancement, whereas pine-
oblastomas with central necrosis show a nodular thickened
wall with homogeneous wall enhancement.
In our screening for brain abnormalities in 168 patients
with retinoblastoma, pineal cysts were detected in 5.4% of the
patients. Sener10 performed a review of MR imaging in 500
children and 500 adults and found no pineal cysts in children
younger than 12 years of age. The sensitivity of this study,
however, could have been limited by using 0.5T MR imaging
in evaluation. Sawamura et al27 found 79 cysts in 6023 patients
but none in children younger than 10 years of age. However,
only MR images in 73 children of 10 years of age and younger
were evaluated.
The study of Al-Holou et al11 was the only one in which the
incidence of pineal cysts on MR imaging was examined in
healthy children younger than 5 years of age. They reported an
incidence of 2.0%, almost similar to that in our hereditary
group. In this study, the pineal cyst population was compared
with an age- and sex-matched control population. Popovic
et al6,7 also reported almost the same incidence as in our over-
all study group (5.3%). They found cysts in patients with bi-
lateral hereditary retinoblastoma, but no pineal cysts in the
patients with nonhereditary retinoblastoma. These previously
ent oned studies included only pineal cysts of 5 mm. In
our study of patientswith retinoblastoma younger than 5 years
of age, 5 of the 9 cysts were5 mm (4 of the 5 pineal cysts in
the nonhereditary group).
A follow-up study in a matched control group would be
necessary to examine the high incidence of pineal cysts in the
patients with nonhereditary compared with hereditary retino-
blastoma with the same criteria used in our study. In previous
studies, only Karatza et al8 reported the occurrence of pineal
cysts in patients with nonhereditary retinoblastoma. They re-
viewed 1400 medical records of patients with retinoblastoma
and found 3 pineal cysts (0.2%) in patients with unilateral and
8 pineal cysts (0.6%) in patients with bilateral retinoblastoma.
These low incidences are probably due to screening for pineal
cysts in edical records instead of re-evaluation of MR im-
ages. In our experience, these cysts are not always described in
medical records as a finding. However, for assessing the asso-
ciation between retinoblastoma and pineal cysts, the incidence
of pineal cysts in the hereditary group is interesting. Given the
incidence of 2.2% in the hereditary group, which is similar to
the incidence in the healthy population,11 there is no associa-
tion between hereditary retinoblastoma and pineal cysts. Al-
though it is important to be aware of pineoblastomasmimick-
ing a pineal cyst, there is no evidence that pineal cysts occur
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Central necrosis can be present in large and small pineoblastomas, and especially 
small pineoblastomas with central necrosis can mimic a pineal cyst. In our 
experience, the thickness and appearance of the cyst wall before and after contrast 
administration on MR imaging are indeed important to differentiate a pineal cyst and 
pineoblastoma. Pineal cysts show a thin wall (<2 mm) with discrete enhancement, 
whereas pineoblastomas with central necrosis show a nodular thickened wall with 
homogeneous wall enhancement. 
In our screening for brain abnormalities in 168 patients with retinoblastoma, pineal 
cysts were detected in 5.4% of the patients. Sener (10) performed a review of MR 
imaging in 500 children and 500 adults and found no pineal cysts in children younger 
than 12 years of age. The sensitivity of this study, however, could have been limited 
by using 0.5T MR imaging in evaluation. Sawamura et al.(27) found 79 cysts in 6023 
patients but none in children younger than 10 years of age. However, only MR images 
in 73 children of 10 years of age and younger were evaluated. 
The study of Al-Holou et al.(11) was the only one in which the incidence of pineal 
cysts on MR imaging was examined in healthy children younger than 5 years of age. 
They reported an incidence of 2.0%, almost similar to that in our hereditary group. In 
this study, the pineal cyst population was compared with an age- and sex-matched 
control population. Popovic et al.(6,7) also reported almost the same incidence as in 
our overall study group (5.3%). They found cysts in patients with bilateral hereditary 
retinoblastoma, but no pineal cysts in the patients with nonhereditary retinoblastoma. 
These previously mentioned studies included only pineal cysts of >5 mm. In our study 
of patients with retinoblastoma younger than 5 years of age, 5 of the 9 cysts were <5 
mm (4 of the 5 pineal cysts in the nonhereditary group). 
A follow-up study in a matched control group would be necessary to examine the high 
incidence of pineal cysts in the patients with nonhereditary compared with hereditary 
retinoblastoma with the same criteria used in our study. In previous studies, only 
Karatza et al.(8) reported the occurrence of pineal cysts in patients with nonhereditary 
retinoblastoma. They reviewed 1400 medical records of patients with retinoblastoma 
and found 3 pineal cysts (0.2%) in patients with unilateral and 8 pineal cysts (0.6%) 
in patients with bilateral retinoblastoma. These low incidences are probably due to 
screening for pineal cysts in medical records instead of re-evaluation of MR images. In 
our experience, these cysts are not always described in medical records as a finding. 
However, for assessing the association between retinoblastoma and pineal cysts, the 
incidence of pineal cysts in the hereditary group is interesting. Given the incidence of 
2.2% in the hereditary group, which is similar to the incidence in the healthy population 
(11) there is no association between hereditary retinoblastoma and pineal cysts. 
Although it is important to be aware of pineoblastomas mimicking a pineal cyst, there 
is no evidence that pineal cysts occur more often in patients with retinoblastoma 
compared with the healthy pediatric population. 
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In our study group, larger structural brain abnormalities occurred only in combination 
with a 13q deletion syndrome. One patient with 13q deletion syndrome had a corpus 
callosum agenesis and another patient showed a Dandy-Walker variant with DV. This 
brain abnormality is also described in previous case reports. Alanay et al.(28) reported 
a patient with a thin corpus callosum and a Dandy-Walker malformation.
CONCLUSION
In conclusion, pineoblastoma is associated with hereditary retinoblastoma, and 
structural brain abnormalities are restricted to the patients with 13q deletion 
syndrome. The incidence of pineal cysts in retinoblastoma is similar to that in healthy 
children and is not associated with hereditary retinoblastoma. 
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MR imaging studies of retinoblastoma 
related angiogenesis and tumor vitality.

CHAPTeR 5.1
Contrast-enhancement of the 
anterior eye segment in patients 
with retinoblastoma: correlation 
between clinical, MR imaging and 
histopathologic findings
Pim de Graaf 
Paul van der Valk
Annette C. Moll 
Saskia M. Imhof
Antoinette Y.N. Schouten-van Meeteren
Dirk L. Knol
Jonas A. Castelijns
AJNR Am J Neuroradiol 2010; 31:237-245
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
156
Ch
ap
te
r 5
.1
AbSTRACT
Purpose. AES contrast-enhancement is recognized in a substantial number 
of retinoblastoma-affected eyes. We retrospectively investigated the 
histopathologic basis of AES contrast-enhancement on MR images in 
retinoblastoma. 
Materials and Methods. Pretreatment contrast-enhanced MR images were 
obtained from 42 children with retinoblastoma. Forty-two enucleated eyes were 
included in this study, AES enhancement was evaluated by using a 3-point score, 
and these data were correlated with clinical, MR imaging, and histopathologic 
findings. Additionally, 14 specimens were immunohistochemically analyzed for 
CD31, VEGF, and Flt-1 expression. Statistical correlations with AES enhancement 
were assessed by using a linear-by-linear association test and univariate and 
multivariate ordinal regressions.
Results. The degree of abnormal AES enhancement was moderate in 15 (36%) 
eyes and strong in 14 (33%) eyes, whereas 13 (31%) eyes showed normal AES 
enhancement. In multivariate analysis, the degree of AES enhancement 
showed statistically significant correlations with iris surface-vessel count (P = 
.05) and optic nerve invasion (P = .04) in the enucleated eye and with tumor 
volume (P = .02) as detected on MR imaging. No significant associations 
between AES enhancement and VEGF expression in the iris were observed. 
Flt-1 (P = .04) staining in iris stroma and IA as detected with CD31 staining (P = 
.009) both yielded a statistically significant positive correlation with abnormal 
AES enhancement. 
Conclusion. The degree of abnormal AES enhancement on MR imaging in 
retinoblastoma reflects angiogenesis in the iris. AES enhancement is also a 
hallmark of advanced retinoblastoma because its degree correlates with tumor 
volume and optic nerve invasion.
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INTRODUCTION
Conservative treatment strategies can be successful in the avoidance of enucleation 
and external beam radiation therapy in the early stages of retinoblastoma and in 
some patients with advanced intraocular disease (1). As a consequence, more children 
are treated without histopathologic confirmation of diagnosis and, more important, 
without knowledge of risk factors for predicting disease dissemination and prognosis. 
Current histopathologic risk factors for metastasis include invasion to the postlaminar 
optic nerve, AES, or massive invasion of ocular coats (choroid and sclera) (2–4). MR 
imaging provides the opportunity for a noninvasive evaluation of these risk factors 
with reasonable diagnostic accuracy (5–8). 
Tumor angiogenesis is also a histopathologic risk factor for local tumor invasion 
and systemic dissemination in retinoblastoma (9,10); initial reports on vascular 
targeting therapy in mouse models of retinoblastoma show promising results (11). 
However, evaluation of angiogenic activity has been performed only in vitro on the 
histopathology of enucleated eyes. The degree of angiogenesis can be assessed by 
evaluation of angiogenic markers, such as MVD or expression of VEGF and its receptors 
(9,10,12–14). High tumor MVD is correlated to invasive growth and metastasis and is 
associated with poor prognosis (9,10). VEGF is highly expressed in retinoblastoma, 
and in addition to promoting angiogenesis, VEGF causes an increased vascular 
permeability in neovascular capillary beds with subsequent BOB breakdown (12–14). 
Furthermore, released VEGF in the posterior eye segment is able to diffuse into the 
aqueous of the AC, where it induces IA, spatially separated from the tumor location 
(12,14–17). When IA occurs, a membrane of new vessels forms across the iris and AC 
angle, eventually causing a secondary glaucoma. Retinoblastoma-associated IA, for 
which enucleation is usually performed, is considered a bad prognostic factor for 
globe salvage and vision. 
Abnormal AES enhancement is present in approximately 22%–41% of MR imaging 
examinations for retinoblastoma and seems to be an indicator of more aggressive 
behavior (6,8,18). Surprisingly, this phenomenon is barely reported in the literature, 
and underlying pathophysiology and its histopathologic correlates are still unclarified. 
We postulated that AES enhancement may reflect the status of retinoblastoma-
induced IA in vivo. The purpose of our study was to retrospectively investigate the 
histopathologic basis of abnormal AES enhancement on MR imaging in retinoblastoma. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
158
Ch
ap
te
r 5
.1
MATeRiALS AND MeTHoDS
Patient population
Patients with retinoblastoma who underwent MR imaging between January 1998 and 
January 2004 were considered for this retrospective study. Patients were included 
in the study if they met the following criteria: 1) having undergone enucleation of 
the eye with retinoblastoma, without therapeutic interventions in the affected eye 
before enucleation; and 2) having undergone pretreatment 1.5T contrast-enhanced 
MR imaging under general anesthesia, which enabled adequate image interpretation. 
Forty-eight patients met these inclusion criteria. However, 2 pathologic specimens 
could not be retrieved from the archives and the quality of 4 pathologic specimens 
hampered proper analysis, so they were excluded from the study. The final study 
population consisted of 42 patients with a mean age at MR imaging of 22 months 
(age range, 2–68 months). There were 18 girls (mean age, 22 months; age range, 2–68 
months) and 24 boys (mean age, 21 months; age range, 2–64 months). None of the 
7 (17%) bilaterally affected patients underwent enucleation of both eyes. Thus, data 
obtained about 42 eyes could be evaluated. The right eye was enucleated in 19 (45%) 
and the left eye, in 23 (55%) patients. The mean interval between MR imaging and 
enucleation was 5 days (range, 1–12 days). Only 1 (2%) patient showed a positive family 
history for retinoblastoma. 
All patients underwent ophthalmoscopy and sonography after we administered 
a general anesthetic. In all patients, tumor calcification was documented by using 
sonography. Medical records were examined by 1 reviewer to assess tumor recurrence 
or metastases, IOP, presence of vitreous or subretinal tumor seeding, and AES 
abnormalities, including tumor seeding, AC depth, hypopyon or pseudohypopyon, 
hyperemia, or IA. Our local ethics committee did not require its approval or informed 
consent for retrospective review of a patient’s records and images.
MR imaging Technique
MR imaging was performed with 1.5T systems (Vision or Sonata; Siemens, Erlangen, 
Germany) with use of a head coil. MR imaging included transverse and sagittal spin-
echo T1-weighted images (TR/TE, 500/15 ms; 4 acquisitions), transverse spin-echo 
T2-weighted images (TR/TE, 2000–2700/60 ms [intermediate-weighted images] and 
2000–2700/120 ms [T2-weighted images], 1 acquisition), followed by fat-suppressed 
spin-echo T1-weighted images (TR/TE, 575/15 ms; 3 acquisitions) in 3 directions obtained 
shortly after intravenous administration of 0.2 mmol/L gadolinium chelate (Magnevist; 
Schering, Berlin, Germany) per kilogram of body weight. For all sequences, section 
thickness was 3 mm, with a 0.3-mm intersection gap. 
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image Analysis
MR images were reviewed by 2 observers with 16 and 7 years of experience with 
orbital MR imaging. Both observers were blinded to the original MR imaging reports 
and clinical and histopathologic information. T2-weighted images were used to 
assess retinal detachment (no detachment, some amount of detachment, or total 
detachment) and decreased AC depth (yes/no). The latter was assessed by a visual 
comparison with the contralateral AC. On T1-weighted images obtained before and 
after contrast material injection, an independent evaluation was conducted of the 
degree of AES enhancement with a 3-point scale: strong (equal to or greater than the 
intensity of choroidal enhancement), moderate (less than choroidal enhancement), 
and normal AES enhancement (no perceptible enhancement within the AES) (Fig 1). 
After completing image interpretations, the 2 reviewers compared their independent 
results and discrepancies were resolved in consensus. 
Tumor-volume measurements were performed by 1 observer on contrast-enhanced 
axial T1-weighted images with use of a computerized image-analysis tool that 
is available as part of the PACS of our hospital (Centricity Radiology RA 600; GE 
Healthcare, Milwaukee, Wisconsin). In every section in which tumor was present, 
this structure was manually surrounded by a region of interest. Surfaces of regions 
of interest were automatically calculated, and all surfaces in different sections were 
summed afterward and multiplied by section thickness and intersection gap. Tumor 
volumes were categorized into 4 subgroups (6): very small, <0.65 cm3; small, 0.65–1.30 
cm3; medium, >1.30–1.95 cm3; and large, >1.95 cm3. 
Histopathologic Analysis
One pathologist with 11 years’ experience in ophthalmopathology, who was blinded 
to patients’ clinical records and MR imaging findings, specifically re-evaluated all 
included eyes. Histopathologic evaluation, by using H&E staining, included the 
following: localization of tumor bulk with respect to the equator (anterior, posterior, 
or a combination); amount of tumor necrosis (semiquantitatively estimated according 
to the percentage of necrotic tumor area); involvement of choroid (inflammation, 
minimal or massive tumor invasion), sclera, ciliary body, AES, and optic nerve invasion 
(pre- or postlaminar). One or 2 sections of each specimen showing representative 
parts of the iris were judged microscopically at x40 magnification for the presence of 
IA. IA classification was based on groups defined by Pe’er et al (12): 0, no angiogenesis; 
1, fine isolated capillaries with the normal iris structure remaining intact; 2, a layer of 
thin capillaries covering the iris surface; and 3, a prominent vascular membrane with 
flattening of the iris surface with or without ectropion uvea. In 5 high-power fields 
(original magnification, x40), the total number of iris vessels and the number of 
vessels directly beneath the anterior iris surface were counted. Neovessels (Pe’er 1–3) 
outside the anatomic anterior iris surface were not included in both vessel counts. 
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fig 1. Transverse contrast-enhanced T1-
weighted fat-suppressed spin-echo MR 
images of 3 different patients with unilateral 
retinoblastoma of the right eye show the 
grading of AES enhancement on a 3-point 
scale: normal AES enhancement (no 
perceptible enhancement within the AES) 
(A, arrow ); moderate AES enhancement 
(less than choroidal enhancement) (B, arrow 
); and strong AES enhancement (equal to 
or greater than the intensity of choroidal 
enhancement) (C, arrow ). All the unaffected 
(left) eyes show normal AES enhancement.
immunohistochemical Staining
Only 16 formalin-fixed and paraffin-embedded archival tissue blocks still contained 
some iris tissue and could, therefore, be retrieved from the pathology archives 
for additional immunohistochemical staining. Deparaffinized 4-µm sections were 
immunohistochemically stained by using the avidin-biotin-peroxidase complex 
and direct antibodies against CD31 (DAKO, Glostrup, Denmark), VEGF (Santa 
Cruz Biotechnology, Santa Cruz, California) and Flt-1 (Santa Cruz Biotechnology). 
Appropriate negative and positive controls were used throughout. Additionally, 2 
specimens contained a large amount of iris pigment, which hampered proper analysis, 
so they were excluded from immunohistochemical analysis. In this small subgroup of 
14 eyes, classification of IA was repeated on CD31-stained specimens. Evaluation of 
VEGF and Flt-1 staining intensity in the iris was graded as follows: negative, weak, or 
strong. 
22%–41% of MR imaging examinations for retinoblastoma
and seems to be an indicator of more aggressive behavior.6,8,18
Surprisingly, this phenomenon is barely reported in the liter-
ature, and underlying pathophysiology and its histopathologic
correlates are still unclarified. We postulated that AES en-
hancement may reflect the status of retinoblastoma-induced
IA in vivo. The purpose of our study was to retrospectively
investigate the histopathologic basis of abnormal AES en-
hancement on MR imaging in retinoblastoma.
Materials and Methods
Patient Population
Patients with retinoblastoma who underwent MR imaging between
January 1998 and January 2004 were considered for this retrospective
study. Patients were included in the study if they met the following
criteria: 1) having undergone enucleation of the eye with retinoblas-
toma, without therapeutic interventions in the affected eye before
enucleation; and 2) having undergone pretreatment 1.5T contrast-
enhanced MR imaging under general anesthesia, which enabled ade-
quate image interpretation. Forty-eight patients met these inclusion
criteria.However, 2 pathologic specimens could not be retrieved from
the archives and the quality of 4 pathologic specimens hampered
proper analysis, so they were excluded from the study. The final
study population consisted of 42 patients with a mean age at MR
imaging of 22 months (age range, 2–68 months). There were 18 girls
(mean age, 22 months; age range, 2–68 months) and 24 boys (mean
age, 21 months; age range, 2–64 months). None of the 7 (17%) bilat-
erally affected patients underwent enucleation of both eyes. Thus,
data obtained about 42 eyes could be evaluated. The right eye was
enucleated in 19 (45%) and the left eye, in 23 (55%) patients. The
mean interval between MR imaging and enucleation was 5 days
(range, 1–12 days). Only 1 (2%) patient showed a positive family
history for retinoblastoma.
All patients underwent ophthalmoscopy and sonography after we
administered a general anesthetic. In all patients, tumor calcification
was documented by using sonography. Medical records were exam-
ined by 1 reviewer to assess tumor recurrence or metastases, IOP,
presence of vitreous or subretinal tumor seeding, and AES abnormal-
ities, including tumor seeding, AC depth, hypopyon or pseudo-
hypopyon, hyperemia, or IA. Our local ethics committee did not re-
quire its approval or informed consent for retrospective review of a
patient’s records and images.
MR Imaging Technique
MR imaging was performed with 1.5T systems (Vision or Sonata;
Siemens, Erlangen, Germany) with use of a head coil. MR imaging
included transverse and sagittal spin-echo T1-weighted images (TR/TE,
500/15 ms; 4 acquisitions), transverse spin-echo T2-weighted images
(TR/TE, 2000–2700/60 ms [intermediate-weighted images] and
2000–2700/120ms [T2-weighted images], 1 acquisition), followed by
fat-suppressed spin-echo T1-weighted images (TR/TE, 575/15 ms;
3 acquisitions) in 3 directions obtained shortly after intravenous ad-
ministration of 0.2mmol/L gadolinium chelate (Magnevist; Schering,
Berlin, Germany) per kilogram of body weight. For all sequences,
section thickness was 3 mm, with a 0.3-mm intersection gap.
Image Analysis
MR images were reviewed by 2 observers with 16 and 7 years of expe-
rience with orbital MR imaging. Both observers were blinded to the
original MR imaging reports and clinical and histopathologic infor-
mation. T2-weighted images were used to assess retinal detachment
(no detachment, some amount of detachment, or total detachment)
and decreased AC depth (yes/no). The latter was assessed by a visual
comparison with the contralateral AC. On T1-weighted images ob-
tained before and after contrast material injection, an independent
evaluation was conducted of the degree of AES enhancement with a
3-point scale: strong (equal to or gr ater than the intensity of choroi-
dal enhancement), moderate (less than choroidal enhancement), and
normal AES enhancement (no perceptible enhancement within the
AES) (Fig 1). After completing image interpretations, the 2 reviewers
compared their independent results and discrepancies were resolved
in consensus.
Tumor-volume measurements were performed by 1 observer on
contrast-enhanced axial T1-weighted images with use of a computer-
ized image-analysis tool that is available as part of the PACS of our
hospital (Centricity Radiology RA 600; GE Healthcare, Milwaukee,
Wisconsin). In every section in which tumor was present, this struc-
Fig 1. Transverse contrast-enhanced T1-weighted fat-suppressed spin-echo MR images of
3 different patients with unilateral retinoblastoma of the right eye show the grading of AES
enhancement on a 3-point scale: normal AES enhancement (no perceptible enhancement
within the AES) (A, arrow ); moderate AES enhancement (less than choroidal enhancement)
(B, arrow ); and strong AES enh ncement (equal to or greater than the intensity of choroidal
enhancement) (C, arrow ). All the unaffected (left) eyes show normal AES enhancement.
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Statistical Analysis
All statistical calculations were performed by using SPSS, Version 12.0 (SPSS, 
Chicago, Illinois). Interobserver agreement of the MR imaging analysis regarding 
AES enhancement and AC depth was calculated by using the weighted Cohen κ 
with squared loss. κ Values <0.40 were considered to indicate poor agreement; 
0.41–0.60, moderate; 0.61–0.80, substantial; and >0.81, excellent agreement (19). 
For statistical associations with AES enhancement, the linear-by-linear association 
test was performed for categoric variables; and ordinal regression, for continuous 
variables. Finally, a stepwise multivariate ordinal regression of AES enhancement on 
variables found to have a statistically significant association with it in the univariate 
analyses was calculated. Statistical comparisons for immunohistochemical data 
were performed by using the Spearman rank correlation. Log- and square-root 
transformations of variables were performed when appropriate. A P value < .05 was 
considered statistically significant.
RESULTS
Clinical findings
Mean follow-up time after enucleation was 83 months (range, 47–130 months). During 
follow-up, 1 patient (2%) developed histologically confirmed local recurrence. In 20 
(48%) eyes, IOP was not measured. Mean IOP was 19 mmHg; and in 8 (36%) eyes, IOP 
was elevated (>22 mmHg). Tumor seeding to the vitreous and subretinal space was 
present in 18 (43%) and 14 (33%) eyes, respectively. Clinically, we noted the following 
findings in the anterior segment: hypopyon, 1 (2%) eye; hyperemia, 7 (17%) eyes; IA, 2 
(5%) eyes; and tumor seeding, 1 (2%) eye. AC depth was decreased in 7 (17%) eyes. 
MR imaging findings
Retinal detachment was observed in 31 (74%) eyes, of which 14 (45%) eyes showed 
a total detachment. A shallow AC was detected on MR imaging in 12 (29%) eyes (Fig 
2). Abnormal contrast enhancement in the AES was observed in 29 (69%) eyes. The 
enhancement was classified as moderate in 15 (36%) and strong in 14 (33%) eyes (Fig 
3A). Agreement between the 2 observers in the assessment of AES parameters, AC 
depth (κ = 0.84) and contrast-enhancement of the AES (κ = 0.89), was very good. 
Mean tumor volume was 1326.6 mm3. In 6 (14%) eyes, mean tumor volume was very 
small; in 16 (38%), it was small; in 13 (31%), it was medium; and in 7 (17%), it was large. 
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fig 2. Transverse T2-weighted spin-echo MR images of 2 different patients 
with unilateral retinoblastoma of the left eye. A, A large intraocular 
retinoblastoma and a normal AC depth in comparison with the unaffected 
right eye. B, A large intraocular retinoblastoma and a decrease in AC 
depth (arrow) in comparison with the unaffected right eye.
Histopathologic findings
Retinoblastoma was located anterior to the equator in 4 (10%) eyes, and tumor growth 
from posterior to anterior beyond the equator was observed in 14 (33%) eyes. The mean 
amount of tumor necrosis was 26.7%. Minimal choroidal inflammation was observed in 
9 (21%) eyes; and tumor invasion, in 9 (21%) eyes. Massive choroidal invasion or scleral 
invasion, both important metastatic risk factors, did not occur in our study population. 
The extent of optic nerve invasion was prelaminar in 17 (41%) eyes and postlaminar in 
3 (7%) eyes. AES invasion was found histopathologically in 1 (2%) eye. IA was classified 
as stage 0 in 28 (67%) eyes, stage 1 in 9 (21%) eyes, stage 2 in 4 (10%) eyes, and stage 3 
in 1 (2%) eye. The mean iris vessel count and mean iris surface vessel count of 42 eyes 
were determined as 81.1 and 8.7, respectively. 
Correlation of AeS enhancement with Clinical, MR imaging, and Histopathologic 
findings
Clinical, MR imaging, and histopathologic findings and results of univariate statistical 
comparisons between the degree of AES enhancement and clinical, MR imaging, and 
histopathologic variables are described in Tables 1–3, respectively. The number of eyes 
with abnormal AES enhancement increased with increasing tumor volume. Very small 
tumors showed an abnormal (moderate) AES enhancement in only 1 (17%) eye. Small, 
medium, and large tumors showed moderate AES enhancement in 38%, 23%, and 
71%, respectively. Strong AES enhancement occurred in 14 eyes, and tumor volume 
was >0.65 cm3 in all of these eyes. Furthermore, all large tumors (volume >1.95 cm3) 
showed some degree of abnormal AES enhancement. In the absence of abnormal AES 
enhancement, there was no tumor invasion of the AES or postlaminar optic nerve, 
whereas 2 (15%) eyes showed prelaminar optic nerve invasion and 4 (31%) eyes showed 
minimal choroidal invasion.
ture was manually surrounded by a region of interest. Surfaces of
regions of interest were automatically calculated, and all surfaces in
different sections were summed afterward and multiplied by section
thickness and intersection gap. Tumor volumes were categorized into
4 subgroups6: very small,0.65 cm3; small, 0.65–1.30 cm3; medium,
1.30–1.95 cm3; and large,1.95 cm3.
Histopathologic Analysis
One pathologist with 11 years’ experience in ophthalmopathology,
who was blinded to patients’ clinical records and MR imaging find-
ings, specifically re-evaluated all included eyes. Histopathologic eval-
uation, by using H&E staining, included the following: localization of
tumor bulk with respect to the equator (anterior, posterior, or a com-
bination); amount of tumor necrosis (semiquantitatively estimated
according to the percentage of necrotic tumor area); involvement of
choroid (inflammation, minimal or massive tumor invas on), sclera,
ciliary body, AES, and optic nerve invasion (pre- or postlaminar).
One or 2 sections of each specimen showing representative parts of
the iris were judged microscopically at 40 magnification for the
presence of IA. IA classification was based on groups defined by Pe’er
et al12: 0, no angiogenesis; 1, fine isolated capillaries with the normal
iris structure remaining intact; 2, a layer of thin capillaries covering
the iris surface; and 3, a prominent vascular membrane with flatten-
ing of the iris surface with or without ectropion uvea. I 5 igh-power
fields (original magnification, 40), the total number of iris vessels
and the number of vessels directly beneath the anterior iris surface
were counted. Neovessels (Pe’er 1–3) outside the anatomic anterior
iris surface were not incl ded in bot vess l cou ts.
Immunohistochemical Staining
Only 16 formalin-fixed and paraffin-embedded archival tissue blocks
still contained some iris tissue and could, therefore, be re rieved from
the pathology archives for additional immunohistochemical staining.
Deparaffinized 4-m sections were immunohistochemically stained
by using the avidin-biotin-peroxidase complex and direct antibodies
against CD31 (DAKO, Glostrup, Denmark), VEGF (Santa Cruz Bio-
technology, Santa Cruz, California) and Flt-1 (Santa Cruz Biotech-
nology). Appropriate negative and positive controls were used
throughout. Additionally, 2 specimens contained a large amount of
iris pigment, which hampered proper analysis, so they were excluded
from immunohistochemical analysis. In this small subgroup of 14
eyes, classification of IA was repeated on CD31-stained specimens.
Evaluation of VEGF and Flt-1 staining intensity in the iris was graded
as follows: negative, weak, or strong.
Statistical Analysis
All statistical calculationswere performedbyusing SPSS,Version 12.0
(SPSS, Chicago, Illinois). Interobserver agreement of theMR imaging
analysis regarding AES enhancement and AC depth was calculated by
using the weighted Cohen  with squared loss.  values 0.40 were
considered to indicate poor agreement; 0.41–0.60, moderate; 0.61–
0.80, substantial; and0.81, excellent agreement.19 For statistical as-
sociations with AES enh ncement, the linear-by-linear association
test was performed for categoric variables; and ordinal regression, for
continuous variables. Finally, a stepwise multivariate ordinal regres-
sion of AES enhancement on variables found to have a statistically
significant ssociation with it in the univariate analyses was calcu-
lated. Statistical comparisons for immunohistochemical data were
performed by using the Spearman rank correlation. Log- and square-
root transformations of variables were performed when appropriate.
A P value .05 was con idered statistically significa t.
Results
Clinical Findings
Mean follow-up time after enucleation was 83months (range,
47–130months). During follow-up, 1 patient (2%) developed
histologically confirmed local recurrence. In 20 (48%) eyes,
IOP was ot measured. Mean IOP w s 19 mm Hg; a d in 8
(36%) eyes, IOP was elevated (22 mm Hg). Tumor seeding
to the vitreous and subretinal space was present in 18 (43%)
and 14 (33%) eyes, respectively. Clinically, we noted the fol-
lowing findings in the ant rior segment: hypopyon, 1 (2%)
eye; hyperemia, 7 (17%) eyes; IA, 2 (5%) eyes; and tumor
seeding, 1 (2%) eye. AC depth was decreased in 7 (17%) eyes.
MR Imaging Findings
Retinal detachment was observed in 31 (74%) eyes, of which
14 (45%) eyes showed a total detachment. A shallow AC was
detected on MR imaging in 12 (29%) eyes (Fig 2). Abnormal
co trast enha cem nt in the AES was observed in 29 (69%)
eyes. The enhancement was classified asmoderate in 15 (36%)
and strong in 14 (33%) eyes (Fig 3A). Agreement between the
2 observers in the assessment of AES parameters, AC depth
( 0.84) and contrast-enhancement of the AES ( 0.89),
was very good. Mean tumor volume was 1326.6 mm3. In 6
(14%) eyes, mean tumor volume was very small; in 16 (38%),
it was small; in 13 (31%), it wasmedium; and in 7 (17%), it was
large.
Fig 2. Transverse T2-weighted spin-echo MR images of 2 different patients with unilateral retinoblastoma of the left eye. A, A large intraocular retinoblastoma and a normal AC depth
in comparison with the unaffected right eye. B, A large intraocular retinoblastoma and a decrease in AC depth (arrow) in comparison with the unaffected right eye.
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fig 3. Unilateral retinoblastoma in a 29-month-old boy (case 12). A, Transverse contrast-
enhanced T1-weighted fat-suppressed spin-echo MR image shows a retinal detachment 
(arrow), with diffuse retinal thickening and enhancement due to retinoblastoma in 
the affected right eye. Compared with AES of the normal left eye, a strong abnormal 
enhancement is shown in the right eye. B, Histopathologic specimen of the iris, AC, and 
C, with details of the anterior iris surface (inset). The anatomic anterior surface of the iris 
(arrowheads ) is covered by a prominent vascular membrane of newly formed capillaries 
(short arrow) (IA, Pe’er stage 3). Some vessels are present directly beneath the anatomic 
anterior iris surface (long arrow) (H&E, original magnification 20 objective). C, IA at the 
anterior iris surface (arrow) is confirmed on additional CD31 staining (arrow) ( 40 objective). 
D and E, VEGF expression in the iris is particularly present in the anterior part of the iris 
(arrow ), and Flt-1 expression shows a widespread staining of the iris stroma (asterisk).
Histopathologic Findings
Retinoblastomawas located anterior to the equator in 4 (10%)
eyes, and tumor growth from posterior to anterior beyond the
equator was observed in 14 (33%) eyes. The mean amount of
tumor necrosis was 26.7%. Minimal choroidal inflammation
was observed in 9 (21%) eyes; and tumor invasion, in 9 (21%)
eyes. Massive choroidal invasion or scleral invasion, both im-
portantmetastatic risk factors, did not occur in our study pop-
ulation. The extent of optic nerve invasion was prelaminar in
17 (41%) eyes and postlaminar in 3 (7% eyes. ES invasion
was found histopathologically in 1 (2%) eye. IA was classified
as stage 0 in 28 (67%) eyes, stage 1 in 9 (21%) eyes, stage 2 in 4
Fig 3. Unilateral retinoblastoma in a 29-mo th-old boy (case 12). A, Transverse contrast-e hanced T1-weighted fat-suppressed spin-echo MR image shows a retinal detachment (arrow),
with diffuse retinal thickening and enhancement due to retinoblastoma in the affected right eye. Compared with AES of the normal left eye, a strong abnormal enhancement is shown
in the right eye. B, Histopathologic specimen of the iris, AC, and C, with details of the anterior iris surface (inset). The anatomic anterior surface of the iris (arrowheads ) is covered by
a prominent vascular membrane of newly formed capillaries (short arrow) (IA, Pe’er stage 3). Some v ssels are pres nt dir ctly beneath the anatomic anterior iris surface (long arrow) (H&E,
original magnification 20 objective). C, IA at the anterior iris surface (arrow) is confirmed on additional CD31 staining (arrow) (40 objective). D and E, VEGF expression in the iris is
particularly present in the anterior part of the iris (arrow ), and Flt-1 expression shows a widespread staining of the iris stroma (asterisk).
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A shallow AC as detected on MR imaging (P = .02), and tumor volume (P = .002) as 
well as histopathologic optic nerve invasion (P < 0.0001) and mean iris surface vessel 
count (P < 0.0001) (Fig 3B) all yielded a statistically significant positive association with 
AES enhancement. Choroidal inflammation (P = .02) showed a significant correlation 
with normal AES enhancement. A shallow anterior chamber as detected during clinical 
examination (P = .07) and histopathologic IA (Pe’er classification) (P = .06) (Fig 3B) 
showed a trend toward an association with AES enhancement. In multivariate ordinal 
regression, tumor volume (P = .02), optic nerve invasion (P = .04), mean iris surface-
vessel count (P = .05), and choroidal inflammation (P = .002) remained significant. 
Table 1. Distribution of Contrast Enhancement in the AES in relation to clinical findings in 42 
eyes with retinoblastoma*
Variable Normal (n = 13) Moderate (n = 15) Strong (n = 14) P Value
Tumor recurrence 1.00
    Yes 0 (0) 1 (7) 0(0)
    No 13 (100) 14 (93) 14 (100)
Intraocular pressure .61
    Unknown 9 (69) 7 (47) 4 (29)
    Mean ± SD (mmHg) 11.8 ± 5.7 24.1 ± 9.6 19.0 ± 10.3
    Range (mmHg) 7-20 11-36 10-37
Vitreous seeding .17
    Yes 3 (23) 8 (57) 7 (54)
    No 10(77) 6(43) 6(46)
Subretinal seeding .31
    Yes 6(46) 5(36) 3(23)
    No 7(54) 9(64) 10(77)
Anterior chamber seeding 1.00
    Yes 0(0) 1(7) 0(0)
    No 13(100) 14(93) 14(100)
Anterior chamber depth .07
    Shallow 0(0) 3(20) 4(29)
    Normal 13(100) 12(80) 10(71)
Pseudohypopyon 1.00
    Yes 0(0) 1(7) 0(0)
    No 13(100) 14(93) 14(100)
Hyperemia .20
    Yes 0(0) 4(27) 3(21)
    No 13(100) 11(73) 11(79)
Iris angiogenesis .20
    Yes 0(0) 0(0) 2(14)
    No 13(100) 15(100) 12(86)
* Unless otherwise indicated, data are the number of eyes, and number in parentheses are 
percentages.
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Table 2. Distribution of contrast enhancement in the AES in relation to MR imaging findings 
in 42 eyes with retinoblastoma* 
Variable Normal
(n = 13)
Moderate
(n = 15)
Strong
(n = 14)
P Value
Retinal detachment .17
    Total detachment 2(15) 6(40) 6(43)
    Some amount of 
    detachment
7(54) 4(27) 6(43)
    No detachment 4(31) 5(33) 2(14)
Anterior chamber depth .02
    Shallow 1(8) 4(27) 7(50)
    Normal 12(92) 11(73) 7(50)
Tumor volume† .002
    Mean ± SD (mm3) 932.8 ± 561.3 1492.7 ± 617.4 1514.4 ± 388.7
    Range (mm3) 221.5-1845.0 523.6-2463.5 910.5-2106.8
    Very small 5(38) 1(7) 0(0)
    Small 5(38) 6(40) 5(36)
    Medium 3(23) 3(20) 7(50)
    Large 0(0) 5(33) 2(14)
* Unless otherwise indicated, data are the number of eyes, and number in parentheses are 
percentages. Percentages may not add up to 100% because of rounding. † Log-transformed.
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Table 3. Distribution of contrast enhancement in the AES in relation to histopathologic
findings in 42 eyes with retinoblastoma*
Variable Normal (n = 13) Moderate (n = 15) Strong (n = 14) P Value
Tumor location .88
    Anterior to equator 2(15) 1(7) 1(7)
    Posterior to equator 8(62) 8(53) 8(57)
    Combination 3(23) 6(40) 5(36)
Necrosis .56
    Mean ± SD 24.6 ± 20.0 34.0 ± 21.2 20.7 ± 11.9 
    Range 5-60 5-70 10-50
Choroidal inflammation .02
    Yes 5(39) 4(27) 0(0)
    No 8(62) 11(73) 14(100)
Choroidal invasion .17
    Massive 0 (0) 0(0) 0(0)
    Minimal 4(31) 4(27) 1(7)
    No 9(69) 11(73) 13(93)
Scleral invasion 1.00
    Yes 0 (0) 0(0) 0 (0)
    No 13(100) 15(100) 14(100)
AES invasion 1.00
    Yes 0(0) 1(7) 0(0)
    No 13(100) 14(93) 14(100)
Optic nerve invasion < .0001
    Postlaminar 0(0) 1(7) 2(14)
    Prelaminar 2(15) 5(33) 10(71)
    No 11(85) 9(60) 2(14)
Iris angiogenesis .06
    Stage 3 0(0) 0(0) 1(7)
    Stage 2 0(0) 3(20) 1(7)
    Stage 1 1(8) 4(27) 4(29)
    Stage 0 12(92) 8(53) 8(57)
Iris vessel count /5 HPF .18
    Mean ± SD 75.8 ± 11.9 83.9 ± 14.6 83.2 ± 14.6 
    Range 56-93 47-102 66-124
Iris surface vessel
count /5 HPF
< .0001†
    Mean ± SD 3.7 ± 2.8 9.5 ± 6.6 12.8 ± 9.5
    Range 0-9 1-26 1-32
* Unless otherwise indicated, data are the number of eyes, and number in parentheses are 
percentages. 
† Square-root transformed for statistical analysis, because of skewed distribution.
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Table 4. Immunohistochemical findings in 14 eyes with retinoblastoma
Patient No./ AES VEGF Flt-1 CD-31
Age(Mo)/Sex Enhancement Iris Surface Iris Stroma Iris Surface Iris Stroma *  IA †
1/2/M normal strong weak weak weak 1
2/25/F normal weak negative negative negative 0
3/4/M normal strong weak weak weak 0
4/12/M normal negative negative negative negative 0
5/31/M normal strong weak negative weak 0
6/26/F moderate weak negative negative weak 0
7/16/F moderate strong weak strong weak 3
8/2/F moderate strong weak negative weak 0
9/2/M moderate strong strong negative weak 0
10/36/M strong weak negative negative weak 1
11/20/F strong negative negative negative weak 2
12/29/M strong weak negative negative weak 3
13/6/M strong strong weak strong strong 2
14/3/M strong strong weak negative weak 1
Note. AES = Anterior Eye Segment; *Significant correlation between AES-enhancement 
and the data in this row (r=.555; P=.04)
†Significant correlation between AES-enhancement and the data in this row (r=.665; 
P=.009) IA according to the Pe’er classification [12]
Correlation of AeS enhancement and immunohistochemical findings
Immunohistochemical findings are summarized in Table 4. IA as detected with CD31 
immunoreactivity was classified as Pe’er stage 0 in 7 (50%) eyes, 1 in 3 (21%) eyes, 2 in 
2 (14%) eyes, and 3 in 2 (14%) eyes (Fig 3C). Only 1 (20%) eye showed early-stage IA in 
the absence of abnormal AES enhancement, and 1 (25%) eye showed extensive IA in 
the group of moderate AES enhancement. Furthermore, a strong AES enhancement 
was associated with some degree of IA in all 5 eyes. IA as detected with CD31 
immunoreactivity yielded a statistically significant positive correlation with AES 
enhancement (r = 0.665; P = .009) (Figs 4 and 5). 
The iris showed VEGF immunoreactivity in all 14 eyes, with 12 (86%) eyes showing 
anterior iris surface staining (Fig 3D) and 8 (57%) eyes showing iris stroma staining. 
No significant associations between AES enhancement and VEGF expression in the iris 
were found. Iris stroma showed Flt-1 staining in 12 (86%) eyes, whereas the anterior iris 
surface was negative in 10 (71%) eyes. The correlation between Flt-1 staining in the iris 
stroma and AES enhancement was significant (r = 0.555; P = .04) (Fig 3E). 
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figure 4. Unilateral 
retinoblastoma in a 6-month-
old boy (case 13). A, Transverse 
contrast-enhanced T1-weighted 
fat-suppressed spin-echo MR 
image shows a large enhancing 
tumor mass in the left eye 
combined with a strong abnormal 
enhancement of the AES (arrow). 
B, Histopathologic specimen 
shows detail of the iris. Marked 
increase of blood vessels directly 
beneath the anatomic anterior iris 
surface (arrowheads) is present in 
this part of the iris (H&E, original 
magnification 40 objective). C, 
CD31 staining shows a layer of 
fine capillaries (arrow) covering 
the anatomic anterior iris surface 
(IA, Pe’er stage 2) (original 
magnification 40 objective).
figure 5. Unilateral retinoblastoma 
in a 2-month-old boy (case 5). A, 
Transverse contrast-enhanced 
T1-weighted fat-suppressed 
spin-echo MR image shows a 
large enhancing tumor mass in 
the left eye. Symmetric normal 
enhancement of the AES of both 
eyes is shown. B, CD31 staining 
shows the absence of vessels 
outside the anterior iris surface 
(no IA, Pe’er stage 0) (original 
magnification 40 objective). 
C, Histopathologic specimen 
shows details of the iris 
with a normal aspect of the 
anterior surface (H&E, original 
magnification 40 objective). 
icance with immunohistochemical analysis, probably because
CD31 antibody staining is supposed to be more sensitive for
the detection of vessels thanH&E staining,27 providing amore
accurate discrimination of IA subgroups.
Clinically, retinoblastoma-associated IA, for which enucle-
ation is usually performed, especially in patients with unilat-
eral disease, is considered a bad prognostic factor for globe
salvage and vision. However, routine ophthalmoscopy has a
Fig 4. Unilateral retinoblastoma in a 6-month-old boy (case 13). A, Transverse contrast-enhanced T1-weighted fat-suppressed spin-echo MR image shows a large enhancing tumor mass
in the left eye combined with a strong abnormal enhancement of the AES (arrow). B, Histopathologic specimen shows detail of the iris. Marked increase of blood vessels directly beneath
the anatomic anterior iris surface (arrowheads) is present in this part of the iris (H&E, original magnification 40 objective). C, CD31 staining shows a layer of fine capillaries (arrow)
covering the anatomic anterior iris surface (IA, Pe’er stage 2) (original magnification 40 objective).
Table 4: Immunohistochemical findings in 14 eyes with retinoblastoma
Case No./Sex/
Age (mo)
AES VEGF Flt-1 CD31
Enhancement Iris Surface Iris Stroma Iris Surface Iris Stromaa IAb
1/M/2 Normal Strong Weak Weak Weak 1
2/F/25 Normal Weak Negative Negative Negative 0
3/M/4 Normal Strong Weak Weak Weak 0
4/M/12 Normal Negative Negative Negative Negative 0
5/M/31 Normal Strong Weak Negative Weak 0
6/F/26 Moderate Weak Negative Negative Weak 0
7/F/16 Moderate Strong Weak Strong Weak 3
8/F/2 Moderate Strong Weak Negative Weak 0
9/M/2 Moderate Strong Strong Negative Weak 0
10/M/36 Strong Weak Negative Negative Weak 1
11/F/20 Strong Negative Negative Negative Weak 2
12/M/29 Strong Weak Negative Negative Weak 3
13/M/6 Strong Strong Weak Strong Strong 2
14/M/3 Strong Strong Weak Negative Weak 1
a Significant correlation between AES enhancement and the data in this column (r  .555; P  .04)
b Significant correlation between AES enhancement and the data in this column (r  .665; P  .009). IA according to the Pe’er classification.12
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low sensitivity for detecting early or subtle stages of IA, a find-
ing confirmed in our study (2 eyes with IA detected clinically,
compared with 14 eyes detected histopathologically).18,28 The
degree of AES enhancement might be a valuable diagnostic
parameter in the choice between enucleation and conservative
treatment strategies. Normal AES enhancement seems to be
an indication for considering globe salvage rather than enu-
cleation. Abnormal AES enhancement, especially in eyes
showing a strong enhancement, represents a sign of IA and
could be considered an additional argument in favor of
enucleation.
Tumors with increased angiogenesis have a greater poten-
tial for tumor progression, invasion of surrounding struc-
tures, and metastasis.9,10 In our study, patients with an ad-
vanced stage of disease, indicated by a large tumor volume or
the presence of optic nerve invasion, showed a higher degree of
AES enhancement, compared with those with early-stage dis-
ease. All eyes containing large tumors showed some degree of
abnormal AES enhancement, whereas this finding was un-
common in very small and small tumors.
Optic nerve invasion beyond the lamina cribrosa is one of
the most important risk factors for extraocular relapse; and as
observed before,18 an abnormal AES enhancement should
prompt a radiologist to be suspicious of optic nerve invasion.
In the absence of abnormal AES enhancement, there was no
tumor invasion of the optic nerve to a postlaminar degree.
Hypoxic conditions in retinoblastoma, secondary to the
overgrowth of its vasculature, cause tumor necrosis and en-
hance angiogenic activity in the posterior segment as well as
the AES, with the induction of IA and BOB disruption as a
consequence. Pe’er et al12 found a strong association between
higher stages of IA in eyes containing tumors with greater
amounts of necrosis. Our study material showed no differ-
ences between the amounts of necrosis in the various AES
enhancement groups. Theoretically, retinal hypoxia second-
ary to retinal detachment may also cause BOB disruption and
IA. Although retinal detachment was a frequent finding in our
study population (74%), with a substantial amount of total
detachments, we failed to demonstrate a significant associa-
tion with AES enhancement.
A shallow AC was clinically demonstrated in 7 patients,
whereas evaluation of MR imaging depicted it in 12 patients.
In univariate statistical analysis, AES enhancement correlated
statistically significantly only with a shallow AC as detected on
MR imaging. Possibly,MR imaging ismore sensitive in detect-
ing minor anterior displacement of the lens-iris diaphragm,
because this parameter can be judged on transverse cross-sec-
tional images.
Inflammation and angiogenesis are linked processes, regu-
lated by inflammatory cytokines and VEGF.25,29 An increased
uveal enhancement, including the AES, was reported as a sign
of choroidal inflammation.6 Surprisingly, we found a signifi-
cant inverse correlation between AES enhancement and cho-
roidal inflammation. Angiogenesis and inflammation are
multistep processes influenced by an imbalance between pos-
itive and negative regulators produced by both tumor cells and
Fig 5. Unilateral retinoblastoma in a 2-month-old boy (case 5). A, Transverse contrast-enhanced T1-weighted fat-suppressed spin-echo MR image shows a large enhancing tumor mass
in the left eye. Symmetric normal enhancement of the AES of both eyes is shown. B, Histopathologic specimen shows details of the iris with a normal aspect of the anterior surface (H&E,
original magnification 40 objective). C, CD31 staining shows the absence of vessels outside the anterior iris surface (no IA, Pe’er stage 0) (original magnification 40 objective).
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DISCUSSION
Three previous studies draw attention to abnormal AES enhancement, which is 
present in a substantial number of MR images of eyes harboring retinoblastoma 
(6,8,18). Authors of these studies correlated AES enhancement with clinical and 
histopathologic findings. De Graaf et al (6) reported the clinical presence of IA, 
hyperemia, or inflammation as possible explanations for AES enhancement. 
Galluzzi et al (18) published a series of 16 eyes and found a correlation between 
histopathologic optic nerve and/or choroid invasion and AES enhancement on MR 
imaging; however, no correlation between clinical or histopathologic presence of IA 
and AES enhancement could be detected. On the other hand, Brisse et al (8) could 
not confirm this correlation between AES enhancement and optic nerve invasion in 10 
eyes. To our knowledge, the present investigation is the most comprehensive study so 
far in the search for an explanation for variable AES enhancement in retinoblastoma, 
which confirmed the role of IA in vivo. Additionally, our study indicates that abnormal 
AES enhancement in retinoblastoma is also related to tumor volume and optic nerve 
invasion. 
In healthy human eyes, the uveal tract enhances after intravenous administration of 
gadolinium contrast material, with the choroid and ciliary body enhancing slightly 
more than the iris. In the literature (21,22), there is evidence for an anterior diffusional 
pathway that causes diffusion of proteins (and gadolinium) from the choroid into the 
AC. This diffusion goes from the ciliary body vessels, via the ciliary body stroma, into 
the root of the iris and finally into the AC. A gradual signal-intensity increase in the AC, 
as a result of diffusion of gadolinium into the AC is physiologic (anterior diffusional 
pathway). However, this physiologic diffusion is much slower than the enhancement 
described earlier. First, this enhancement becomes detectable at the AC angle 
12 minutes after injection and moves slightly toward the AC center (30 minutes), 
reaching a peak in 74 minutes (21,22). However, in our patients, the MR images were 
obtained shortly after contrast material injection and showed an early signal-intensity 
increase in the AC of 69% of affected eyes. This early enhancement has been attributed 
to leakage of contrast material into the extravascular space through regions of BOB 
disruption (18,23). In newly formed capillaries during IA, the BOB is poorly developed 
from the outset and becomes further compromised under hypoxic conditions, with 
VEGF as an important mediator. 
Tumor hypoxia initiates compensatory mechanisms that prevent cell death, including 
up-regulation of proangiogenic factors, such as VEGF, which are highly expressed 
in areas of novel vasculature in eyes containing retinoblastoma (12–14). We found a 
positive iris VEGF staining in most of the eyes, being more frequent at the anterior iris 
surface than in the iris stroma. However, no significant correlation between iris VEGF 
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expression and AES enhancement could be detected. This could be explained by the 
fact that the study population did not include very early stages of retinoblastoma, 
because these patients are currently treated with eye-preserving strategies. A 
significant percentage of retinoblastoma eyes succumbing to enucleation demonstrate 
a high level of VEGF expression (12–14). Different angiogenic mechanisms might 
be differentially important in various stages of tumor progression, and some data 
suggest that VEGF may be especially important in the initial stages (24). Two human 
tyrosine kinases, Flt-1 and KDR, have been shown to function as specific receptors for 
VEGF-related angiogenesis (25). In the present investigation, only Flt-1 was analyzed 
because the expression of Flt-1, but not that of KDR, is directly up-regulated by hypoxia 
(26). Flt-1 expression is up-regulated by hypoxia via a HIF-1-dependent mechanism, 
and the expression is also potentiated by VEGF (26). Hypoxia-induced up-regulation 
of Flt-1 could provide a mechanism by which local sensitivity to VEGF is enhanced, 
with increased angiogenesis and vascular permeability as a consequence. In the iris, 
a positive Flt-1 staining at the level of the iris stroma yielded a significant correlation 
with AES enhancement, which is a bit surprising because a receptor is expected to 
bind to cells. We assume that cellular protrusions are the basis for this staining, though 
staining of a soluble form of Flt-1 in the stroma cannot be excluded. 
The degree of AES enhancement correlated significantly with vascular proliferation on 
the inner as well as on the outer surface of the anatomic anterior iris border. The mean 
number of iris vessels located directly beneath the anterior surface was higher in the 
abnormal AES enhancement groups than in the group with normal AES enhancement. 
Furthermore, increased AES enhancement showed a similar relationship with the 
histopathologic stage of IA on the outer surface. This relationship showed a borderline 
significance for the entire study group but reached statistical significance with 
immunohistochemical analysis, probably because CD31 antibody staining is supposed 
to be more sensitive for the detection of vessels than H&E staining (27) providing a 
more accurate discrimination of IA subgroups. 
Clinically, retinoblastoma-associated IA, for which enucleation is usually performed, 
especially in patients with unilateral disease, is considered a bad prognostic factor 
for globe salvage and vision. However, routine ophthalmoscopy has a low sensitivity 
for detecting early or subtle stages of IA, a finding confirmed in our study (2 eyes 
with IA detected clinically, compared with 14 eyes detected histopathologically) 
(18,28). The degree of AES enhancement might be a valuable diagnostic parameter 
in the choice between enucleation and conservative treatment strategies. Normal 
AES enhancement seems to be an indication for considering globe salvage rather 
than enucleation. Abnormal AES enhancement, especially in eyes showing a strong 
enhancement, represents a sign of IA and could be considered an additional argument 
in favor of enucleation. 
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Tumors with increased angiogenesis have a greater potential for tumor progression, 
invasion of surrounding structures, and metastasis (9,10). In our study, patients with 
an advanced stage of disease, indicated by a large tumor volume or the presence of 
optic nerve invasion, showed a higher degree of AES enhancement, compared with 
those with early-stage disease. All eyes containing large tumors showed some degree 
of abnormal AES enhancement, whereas this finding was uncommon in very small and 
small tumors. 
Optic nerve invasion beyond the lamina cribrosa is one of the most important risk 
factors for extraocular relapse; and as observed before (18) an abnormal AES 
enhancement should prompt a radiologist to be suspicious of optic nerve invasion. In 
the absence of abnormal AES enhancement, there was no tumor invasion of the optic 
nerve to a postlaminar degree. 
Hypoxic conditions in retinoblastoma, secondary to the overgrowth of its vasculature, 
cause tumor necrosis and enhance angiogenic activity in the posterior segment as well 
as the AES, with the induction of IA and BOB disruption as a consequence. Pe’er et al 
(12) found a strong association between higher stages of IA in eyes containing tumors 
with greater amounts of necrosis. Our study material showed no differences between 
the amounts of necrosis in the various AES enhancement groups. Theoretically, retinal 
hypoxia secondary to retinal detachment may also cause BOB disruption and IA. 
Although retinal detachment was a frequent finding in our study population (74%), 
with a substantial amount of total detachments, we failed to demonstrate a significant 
association with AES enhancement. 
A shallow AC was clinically demonstrated in 7 patients, whereas evaluation of MR 
imaging depicted it in 12 patients. In univariate statistical analysis, AES enhancement 
correlated statistically significantly only with a shallow AC as detected on MR imaging. 
Possibly, MR imaging is more sensitive in detecting minor anterior displacement of 
the lens-iris diaphragm, because this parameter can be judged on transverse cross-
sectional images. 
Inflammation and angiogenesis are linked processes, regulated by inflammatory 
cytokines and VEGF (25,29). An increased uveal enhancement, including the AES, was 
reported as a sign of choroidal inflammation (6). Surprisingly, we found a significant 
inverse correlation between AES enhancement and choroidal inflammation. 
Angiogenesis and inflammation are multistep processes influenced by an imbalance 
between positive and negative regulators produced by both tumor cells and normal 
cells. Regulatory proteins other than VEGF, which show mutually opposing functions 
of stimulating angiogenesis and inhibiting inflammation, might play an additional role 
(30,31) Furthermore, the AES is not always involved in posterior uveitis; therefore, 
differences in the extent and severity of uveal contrast enhancement depend on the 
severity of BOB breakdown in the AES (32). 
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Limitations to this study are primarily related to the retrospective design. Currently, 
the use of orbital surface coils is recommended for retinoblastoma imaging to increase 
spatial resolution and signal–to-noise ratio (5,7). Future research on retinoblastoma-
associated BOB impairment and quantification of leakage across the endothelium 
should be performed with dynamic contrast-enhanced MR imaging, which is widely 
used for tumor imaging (33). Contrast-enhanced MR imaging seems to be a useful tool 
for noninvasive detection of retinoblastoma-related angiogenesis and could define a 
subgroup of patients who would potentially profit from vascular targeting drugs in 
the future (11,34). 
In conclusion, the degree of abnormal AES enhancement on MR imaging in 
retinoblastoma reflects angiogenesis in the iris. AES enhancement is also a hallmark 
of advanced retinoblastoma because its degree correlates with tumor volume and 
optic nerve invasion. 
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